EP2314691A3 - Funktionale und hyperfunktionale siRNA - Google Patents
Funktionale und hyperfunktionale siRNA Download PDFInfo
- Publication number
- EP2314691A3 EP2314691A3 EP10013098A EP10013098A EP2314691A3 EP 2314691 A3 EP2314691 A3 EP 2314691A3 EP 10013098 A EP10013098 A EP 10013098A EP 10013098 A EP10013098 A EP 10013098A EP 2314691 A3 EP2314691 A3 EP 2314691A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- fuctional
- hyperfunctional sirna
- gene silencing
- silencing
- sirna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y502/00—Cis-trans-isomerases (5.2)
- C12Y502/01—Cis-trans-Isomerases (5.2.1)
- C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42613702P | 2002-11-14 | 2002-11-14 | |
US50205003P | 2003-09-10 | 2003-09-10 | |
EP03786798A EP1560931B1 (de) | 2002-11-14 | 2003-11-14 | Funktionelle und hyperfunktionelle sirna |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03786798.3 Division | 2003-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2314691A2 EP2314691A2 (de) | 2011-04-27 |
EP2314691A3 true EP2314691A3 (de) | 2012-01-18 |
Family
ID=32329096
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10013099A Withdrawn EP2305812A3 (de) | 2002-11-14 | 2003-11-14 | Funktionale und hyperfunktionale siRNA |
EP10013098A Withdrawn EP2314691A3 (de) | 2002-11-14 | 2003-11-14 | Funktionale und hyperfunktionale siRNA |
EP10003382A Expired - Lifetime EP2213738B1 (de) | 2002-11-14 | 2003-11-14 | siRNA moleküle gegen Bcl-2 |
EP10012132.6A Expired - Lifetime EP2284266B1 (de) | 2002-11-14 | 2003-11-14 | siRNA Molekül gegen tp53 |
EP03786798A Expired - Lifetime EP1560931B1 (de) | 2002-11-14 | 2003-11-14 | Funktionelle und hyperfunktionelle sirna |
EP10013100A Withdrawn EP2305813A3 (de) | 2002-11-14 | 2003-11-14 | Funktionale und hyperfunktionale siRNA |
EP10013081A Withdrawn EP2278005A3 (de) | 2002-11-14 | 2003-11-14 | Funktionelle und hyperfunktionelle Sirna |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10013099A Withdrawn EP2305812A3 (de) | 2002-11-14 | 2003-11-14 | Funktionale und hyperfunktionale siRNA |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10003382A Expired - Lifetime EP2213738B1 (de) | 2002-11-14 | 2003-11-14 | siRNA moleküle gegen Bcl-2 |
EP10012132.6A Expired - Lifetime EP2284266B1 (de) | 2002-11-14 | 2003-11-14 | siRNA Molekül gegen tp53 |
EP03786798A Expired - Lifetime EP1560931B1 (de) | 2002-11-14 | 2003-11-14 | Funktionelle und hyperfunktionelle sirna |
EP10013100A Withdrawn EP2305813A3 (de) | 2002-11-14 | 2003-11-14 | Funktionale und hyperfunktionale siRNA |
EP10013081A Withdrawn EP2278005A3 (de) | 2002-11-14 | 2003-11-14 | Funktionelle und hyperfunktionelle Sirna |
Country Status (9)
Country | Link |
---|---|
US (52) | US8090542B2 (de) |
EP (7) | EP2305812A3 (de) |
JP (2) | JP2006507841A (de) |
AT (1) | ATE517992T1 (de) |
AU (1) | AU2003295600A1 (de) |
DK (1) | DK2284266T3 (de) |
ES (1) | ES2440284T3 (de) |
PT (1) | PT2284266E (de) |
WO (1) | WO2004045543A2 (de) |
Families Citing this family (1342)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20050053976A1 (en) * | 1996-06-06 | 2005-03-10 | Baker Brenda F. | Chimeric oligomeric compounds and their use in gene modulation |
US6841539B1 (en) * | 1998-05-21 | 2005-01-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
ES2571230T3 (es) * | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US20040157327A1 (en) * | 1999-10-22 | 2004-08-12 | Wyeth | Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
HU230458B1 (hu) | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
EP1390383B1 (de) * | 2001-05-11 | 2012-02-29 | Isis Pharmaceuticals, Inc. | Antisense-permeationsverstärker |
WO2008030239A1 (en) * | 2006-09-05 | 2008-03-13 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20070173473A1 (en) * | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
US20050119212A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA) |
US20050164968A1 (en) * | 2001-05-18 | 2005-07-28 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA) |
US20050196767A1 (en) * | 2001-05-18 | 2005-09-08 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA) |
US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
US20030144221A1 (en) * | 2001-07-17 | 2003-07-31 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL2-associated X protein expression |
US7425545B2 (en) * | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US20050043256A1 (en) * | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
AU2002330724A1 (en) * | 2001-08-16 | 2003-03-10 | Bar Ilan University | Diagnosis, prevention and treatment of cancer |
DE10154163A1 (de) | 2001-11-03 | 2003-05-22 | Advanced Med Tech | Vorrichtung zum Aufrichten und Stabilisieren der Wirbelsäule |
US20060009409A1 (en) * | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
WO2003064625A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
US20030166282A1 (en) * | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
US7405292B2 (en) * | 2002-02-19 | 2008-07-29 | The Children's Hospital Of Philadelphia | Cellular genes regulated by HIV-1 infection and methods of use thereof |
US7662952B2 (en) * | 2002-02-20 | 2010-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA) |
US8067575B2 (en) * | 2002-02-20 | 2011-11-29 | Merck, Sharp & Dohme Corp. | RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA) |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
MXPA04010282A (es) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20040248094A1 (en) * | 2002-06-12 | 2004-12-09 | Ford Lance P. | Methods and compositions relating to labeled RNA molecules that reduce gene expression |
US7582058B1 (en) * | 2002-06-26 | 2009-09-01 | Nuvasive, Inc. | Surgical access system and related methods |
US6793678B2 (en) | 2002-06-27 | 2004-09-21 | Depuy Acromed, Inc. | Prosthetic intervertebral motion disc having dampening |
EP2100565A1 (de) | 2002-07-19 | 2009-09-16 | Interventional Spine, Inc. | Vorrichtung zur Wirbelsäulenfixierung |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
DE60326961D1 (de) * | 2002-07-26 | 2009-05-14 | Novartis Vaccines & Diagnostic | Modifizierte kleine irns moleküle und methoden zu deren anwendung |
US20080274989A1 (en) | 2002-08-05 | 2008-11-06 | University Of Iowa Research Foundation | Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof |
WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
KR101212512B1 (ko) * | 2002-08-21 | 2012-12-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
EP2277551B1 (de) | 2002-09-06 | 2013-05-08 | Cerulean Pharma Inc. | Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel |
EP1549767A4 (de) | 2002-09-26 | 2006-06-07 | Amgen Inc | Modulation der expression von forkhead-box o1a |
US20060160759A1 (en) * | 2002-09-28 | 2006-07-20 | Jianzhu Chen | Influenza therapeutic |
US20050259483A1 (en) * | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
US7892793B2 (en) * | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
US9827263B2 (en) | 2002-11-05 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
AU2003295472A1 (en) * | 2002-11-13 | 2004-06-03 | Metabolex, Inc. | A pancreatic islet transcription factor and uses thereof |
US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
US20080268457A1 (en) * | 2002-11-14 | 2008-10-30 | Dharmacon, Inc. | siRNA targeting forkhead box P3 (FOXP3) |
US9771586B2 (en) | 2002-11-14 | 2017-09-26 | Thermo Fisher Scientific Inc. | RNAi targeting ZNF205 |
US10011836B2 (en) | 2002-11-14 | 2018-07-03 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US7691998B2 (en) * | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US20100113307A1 (en) * | 2002-11-14 | 2010-05-06 | Dharmacon, Inc. | siRNA targeting vascular endothelial growth factor (VEGF) |
US9879266B2 (en) | 2002-11-14 | 2018-01-30 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7619081B2 (en) * | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
US7977471B2 (en) * | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
JP2006507841A (ja) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
US8198427B1 (en) | 2002-11-14 | 2012-06-12 | Dharmacon, Inc. | SiRNA targeting catenin, beta-1 (CTNNB1) |
US9839649B2 (en) | 2002-11-14 | 2017-12-12 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9719094B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting SEC61G |
US9228186B2 (en) * | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US9719092B2 (en) | 2002-11-14 | 2017-08-01 | Thermo Fisher Scientific Inc. | RNAi targeting CNTD2 |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
US7635770B2 (en) * | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US20090227780A1 (en) * | 2002-11-14 | 2009-09-10 | Dharmacon, Inc. | siRNA targeting connexin 43 |
US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
WO2004048566A1 (ja) * | 2002-11-22 | 2004-06-10 | Bio-Think Tank Co., Ltd. | Rna干渉の標的塩基配列検索方法、rna干渉を生じさせるポリヌクレオチドの塩基配列設計方法、2本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム |
US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US7618948B2 (en) | 2002-11-26 | 2009-11-17 | Medtronic, Inc. | Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA |
US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20060257851A1 (en) * | 2002-11-26 | 2006-11-16 | Itzhak Bentwich | Bioinformatically detectable group of novel viral regulatory genes and uses thereof |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
JP3792655B2 (ja) * | 2003-01-20 | 2006-07-05 | 日本電気株式会社 | 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途 |
US7732591B2 (en) * | 2003-11-25 | 2010-06-08 | Medtronic, Inc. | Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna |
US7994149B2 (en) | 2003-02-03 | 2011-08-09 | Medtronic, Inc. | Method for treatment of Huntington's disease through intracranial delivery of sirna |
WO2004071453A2 (en) | 2003-02-13 | 2004-08-26 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of pouchitis |
WO2004076664A2 (en) * | 2003-02-21 | 2004-09-10 | University Of South Florida | Vectors for regulating gene expression |
KR20050098954A (ko) * | 2003-03-05 | 2005-10-12 | 세네스코 테크놀로지스 인코포레이티드 | 이아이에프-5에이1의 발현을 억제하기 위한 안티센스올리고뉴클레오타이드 또는 에스아이알엔에이의 이용 |
AU2004220525B2 (en) * | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
US20040185559A1 (en) * | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
WO2004100977A1 (en) * | 2003-03-25 | 2004-11-25 | The Board Of Trustees Of The University Of Illinois | Inhibition of tumor cell proliferation by foxm1b inhibitors |
EP1469070A1 (de) * | 2003-04-15 | 2004-10-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Livinspezifische SiRNAs zur Behandlung von therapie-resistente Tumoren |
AU2004233043A1 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
WO2004105774A1 (ja) * | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | オリゴ核酸担持複合体、当該複合体を含有する医薬組成物 |
US20080020990A1 (en) * | 2003-05-30 | 2008-01-24 | Nippon Shinyaku Co., Ltd. | Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same |
US8309704B2 (en) | 2003-06-02 | 2012-11-13 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
DK1633767T3 (en) * | 2003-06-02 | 2019-03-25 | Univ Massachusetts | METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING |
US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US7595306B2 (en) * | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
WO2005004794A2 (en) * | 2003-06-09 | 2005-01-20 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
EP1646357A4 (de) * | 2003-06-27 | 2007-01-10 | Diadexus Inc | Pro104 antikörper-zusammensetzungen und anwendungsverfahren |
US20060280725A1 (en) * | 2003-07-02 | 2006-12-14 | Barrie Bode | Compositions and methods of treating and diagnosing hepatoma |
FR2857013B1 (fr) * | 2003-07-02 | 2005-09-30 | Commissariat Energie Atomique | Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications |
CN101961497A (zh) * | 2003-07-03 | 2011-02-02 | 宾夕法尼亚大学理事会 | 对Syk激酶表达的抑制 |
US7888497B2 (en) * | 2003-08-13 | 2011-02-15 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
JP2007502284A (ja) * | 2003-08-13 | 2007-02-08 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | siRNAによるTGFベータII型受容体発現のサイレンシング |
US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
AU2004264481B2 (en) * | 2003-08-18 | 2009-12-10 | Japan Health Sciences Foundation | Improved siRNA molecule and method of inhibiting gene expression with the use of the same |
KR101242260B1 (ko) * | 2003-09-11 | 2013-03-13 | 휴비트 제노믹스 가부시키가이샤 | 경화를 초래하는 증식성 질환의 검출방법 및 키트, 경화를초래하는 증식성 질환의 예방 및/또는 치료제, 그리고경화를 초래하는 증식성 질환의 예방 및/또는 치료에유효한 물질을 동정하는 방법 및 키트 |
US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
DK2821085T3 (da) * | 2003-09-12 | 2020-08-03 | Univ Massachusetts | Rna-interferens til behandling af "gain-of-function"-forstyrrelser |
US8680063B2 (en) | 2003-09-12 | 2014-03-25 | University Of Massachusetts | RNA interference for the treatment of gain-of-function disorders |
EP1668130A2 (de) | 2003-09-18 | 2006-06-14 | Isis Pharmaceuticals, Inc. | Modulation der eif4e-expression |
US8722637B2 (en) * | 2003-09-22 | 2014-05-13 | The Board Of Trustees Of The University Of Illinois | Methods and compositions of IG20 and DENN-SV splice variants |
CN1890382A (zh) * | 2003-09-24 | 2007-01-03 | 肿瘤疗法科学股份有限公司 | 检测、诊断和治疗肝细胞癌(hcc)的方法 |
AR041407A1 (es) * | 2003-09-26 | 2005-05-18 | Nestor Alberto Kerner | Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento |
EP1687410A4 (de) | 2003-10-07 | 2008-04-09 | Isis Pharmaceuticals Inc | Für das nieren-targeting optimierte antisense-oligonukleotide |
JP4486928B2 (ja) * | 2003-10-09 | 2010-06-23 | タカラバイオ株式会社 | ヒトFlt3の機能を抑制するための組成物 |
WO2005042719A2 (en) * | 2003-10-30 | 2005-05-12 | The Cbr Institute For Biomedical Research, Inc. | Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents |
US20050191653A1 (en) * | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
CA2548150A1 (en) | 2003-12-04 | 2005-06-23 | University Of South Florida | Polynucleotides for reducing respiratory syncytial virus gene expression |
SE0303397D0 (sv) * | 2003-12-17 | 2003-12-17 | Index Pharmaceuticals Ab | Compounds and method for RNA interference |
US20060134787A1 (en) | 2004-12-22 | 2006-06-22 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA |
EP1715896A4 (de) * | 2004-01-12 | 2009-01-07 | Lorus Therapeutics Inc | Antisense-oligonucleotide gegen ribonucleotid-reductase r2 und ihre verwendungen in kombinationstherapien zur behandlung von krebs |
US7642066B2 (en) * | 2004-01-15 | 2010-01-05 | Washington University | High throughput pharmaceutical screening using drosophila |
EP1726313A4 (de) * | 2004-01-16 | 2008-04-09 | Takeda Pharmaceutical | Arzneimittel zur prävention und behandlung von arteriosklerose |
US20050164271A1 (en) * | 2004-01-20 | 2005-07-28 | Sanjay Bhanot | Modulation of glucocorticoid receptor expression |
US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US20050203043A1 (en) * | 2004-01-23 | 2005-09-15 | Dharmacon, Inc. | Identification of toxic nucleotide sequences |
US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
AU2005214904B2 (en) | 2004-02-13 | 2011-07-21 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
GB0404209D0 (en) * | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
JP2007527240A (ja) * | 2004-03-01 | 2007-09-27 | マサチューセッツ インスティテュート オブ テクノロジー | アレルギー性鼻炎および喘息のためのRNAiベースの治療 |
DE102004010547A1 (de) * | 2004-03-03 | 2005-11-17 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz |
ES2423060T3 (es) * | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
MXPA06010667A (es) * | 2004-03-19 | 2007-07-04 | Penn State Res Found | Metodos combinatorios y composiciones para el tratamiento de melanoma. |
JP4938451B2 (ja) * | 2004-03-23 | 2012-05-23 | オンコセラピー・サイエンス株式会社 | 非小細胞肺癌の診断のための方法 |
JP2005312428A (ja) * | 2004-03-31 | 2005-11-10 | Keio Gijuku | Skp−2発現抑制を利用した癌の治療 |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US8088902B2 (en) * | 2004-04-05 | 2012-01-03 | The Rockefeller University | DNA virus microRNA and methods for inhibiting same |
US7416842B2 (en) * | 2004-04-05 | 2008-08-26 | The Rockefeller University | DNA virus microRNA |
WO2005097817A2 (en) | 2004-04-05 | 2005-10-20 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
EP2520652B1 (de) | 2004-04-09 | 2015-06-10 | Genecare Research Institute Co., Ltd | Krebszellenspezifische Apoptoseinduktoren, die auf mit Chromosomenstabilisierung in Zusammenhang stehende Gene abzielen |
US7365058B2 (en) | 2004-04-13 | 2008-04-29 | The Rockefeller University | MicroRNA and methods for inhibiting same |
WO2005117938A2 (en) * | 2004-04-13 | 2005-12-15 | Regents Of The University Of Minnesota | Methods of treating ocular conditions |
US20050261233A1 (en) * | 2004-04-21 | 2005-11-24 | Sanjay Bhanot | Modulation of glucose-6-phosphatase translocase expression |
CA2562673A1 (en) * | 2004-04-22 | 2005-11-03 | Yissum Research Development Company Of The Hebrew University Of Jerusal Em | Universal target sequences for sirna gene silencing |
CA2562833A1 (en) * | 2004-04-27 | 2005-11-03 | Galapagos N.V. | Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts |
JP4584986B2 (ja) | 2004-04-27 | 2010-11-24 | アルニラム ファーマスーティカルズ インコーポレイテッド | 2−アリールプロピル部分を含む1本鎖及び2本鎖オリゴヌクレオチド |
EP1750776A2 (de) | 2004-04-30 | 2007-02-14 | Alnylam Pharmaceuticals Inc. | Oligonukleotide mit c5-modifiziertem pyrimidin |
US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
US7605250B2 (en) * | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
IL179285A (en) * | 2004-05-14 | 2011-04-28 | Rosetta Genomics Ltd | Micrornas and uses thereof |
WO2005111213A1 (ja) * | 2004-05-18 | 2005-11-24 | Kurume University | Myc標的遺伝子mimitin |
US8101350B1 (en) * | 2004-05-24 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Modulation of exportin 5 expression |
US7563885B1 (en) * | 2004-05-24 | 2009-07-21 | Isis Pharmaceuticals, Inc. | Modulation of Tudor-SN expression |
US20100152280A1 (en) * | 2004-05-24 | 2010-06-17 | Isis Pharmaceuticals, Inc. | Modulation of sid-1 expression |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
US7575863B2 (en) * | 2004-05-28 | 2009-08-18 | Applied Biosystems, Llc | Methods, compositions, and kits comprising linker probes for quantifying polynucleotides |
US20060015264A1 (en) * | 2004-06-02 | 2006-01-19 | Mcshea Andrew | Interfering stem-loop sequences and method for identifying |
EP1765415A4 (de) * | 2004-06-03 | 2010-03-24 | Isis Pharmaceuticals Inc | Oligomere verbindungen zur erleichterung der risc-beladung |
US8394947B2 (en) * | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
EP1602926A1 (de) | 2004-06-04 | 2005-12-07 | University of Geneva | Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus |
US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
US20060156421A1 (en) * | 2004-06-18 | 2006-07-13 | Cagan Ross L | High throughput screening methods for anti-metastatic compounds |
EP2298896A1 (de) * | 2004-06-22 | 2011-03-23 | The Board of Trustees of the University of Illinois | Verfahren zur Inhibierung von Tumorzellwachstum mit FOXM1 siRNS |
US20060051815A1 (en) * | 2004-06-25 | 2006-03-09 | The J. David Gladstone Institutes | Methods of treating smooth muscle cell disorders |
SI1766010T1 (sl) | 2004-06-28 | 2011-06-30 | Univ Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo |
WO2006088490A2 (en) | 2004-06-30 | 2006-08-24 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a non-phosphate backbone linkage |
US20060004398A1 (en) * | 2004-07-02 | 2006-01-05 | Binder Lawrence J Jr | Sequential dilator system |
JP2006031308A (ja) * | 2004-07-15 | 2006-02-02 | Mitsubishi Space Software Kk | 核酸配列設計装置、核酸配列設計方法、核酸配列設計プログラム、機能阻害効果算出装置、機能阻害効果算出方法、機能阻害効果算出プログラム、機能阻害影響度算出装置、機能阻害影響度算出方法および機能阻害影響度算出プログラム。 |
WO2006093526A2 (en) * | 2004-07-21 | 2006-09-08 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a modified or non-natural nucleobase |
CA2574086A1 (en) * | 2004-07-21 | 2006-02-23 | Medtronic, Inc. | Medical devices and methods for reducing localized fibrosis |
US7514548B2 (en) * | 2004-08-02 | 2009-04-07 | University Of Iowa Research Foundation | Methods of inhibiting COX-2 |
AU2005330637B2 (en) | 2004-08-04 | 2012-09-20 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
US20060223147A1 (en) * | 2004-08-05 | 2006-10-05 | Kyowa Hakko Kogyo Co., Ltd., | Process for producing glycoprotein composition |
AU2005277508B2 (en) | 2004-08-16 | 2011-04-14 | Quark Pharmaceuticals, Inc | Therapeutic uses of inhibitors of RTP801 |
WO2006017932A1 (en) * | 2004-08-18 | 2006-02-23 | Genesense Technologies Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
US20110313024A1 (en) * | 2004-08-20 | 2011-12-22 | Leonid Beigelman | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
DK1781787T3 (en) * | 2004-08-23 | 2017-07-31 | Sylentis Sau | TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS |
CN100395335C (zh) * | 2004-08-24 | 2008-06-18 | 暨南大学 | 抑制bcl-2基因表达的siRNA双链 |
CN1324136C (zh) * | 2004-08-24 | 2007-07-04 | 暨南大学 | 抑制bc1-2基因表达的siRNA双链及其应用 |
CN100410373C (zh) * | 2004-08-24 | 2008-08-13 | 暨南大学 | 抑制bcl-2基因表达的siRNA双链 |
AU2005278918B2 (en) * | 2004-08-31 | 2010-07-29 | Sylentis S.A.U. | Methods and compositions to inhibit P2X7 receptor expression |
WO2006032039A2 (en) | 2004-09-17 | 2006-03-23 | University Of Massachusetts | Compositions and their uses for lysosomal enzyme deficiencies |
GB0420977D0 (en) * | 2004-09-21 | 2004-10-20 | Keymed Medicals & Ind Equip | An instrument for use in a medical simulator |
AU2005286663A1 (en) * | 2004-09-23 | 2006-03-30 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
NZ554214A (en) | 2004-09-24 | 2009-10-30 | Alnylam Pharmaceuticals Inc | Rnai modulation of apob and uses thereof |
JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
CN101291948B (zh) * | 2004-09-28 | 2012-05-30 | 夸克医药公司 | 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法 |
WO2006039253A2 (en) * | 2004-09-29 | 2006-04-13 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
EP1796732B1 (de) * | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modifizierte, kleine, interferierende rna-moleküle und verwendungsverfahren dafür |
US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
US7825229B2 (en) * | 2005-03-25 | 2010-11-02 | Rosetta Genomics Ltd. | Lung cancer-related nucleic acids |
US20090186353A1 (en) * | 2004-10-04 | 2009-07-23 | Rosetta Genomics Ltd. | Cancer-related nucleic acids |
CA2582464A1 (en) * | 2004-10-13 | 2006-04-27 | Sanjay Bhanot | Antisense modulation of ptp1b expression |
US8080420B2 (en) | 2004-10-22 | 2011-12-20 | University Of Central Florida Research Foundation, Inc. | Methods and products for biasing cellular development |
US20060110440A1 (en) * | 2004-10-22 | 2006-05-25 | Kiminobu Sugaya | Method and system for biasing cellular development |
US7790878B2 (en) * | 2004-10-22 | 2010-09-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
WO2006053315A2 (en) * | 2004-11-12 | 2006-05-18 | Massachusetts Institute Of Technology | Methods and compositions for treating cellular proliferative diseases |
US8440610B2 (en) * | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
AU2005306533B2 (en) * | 2004-11-17 | 2012-05-31 | Arbutus Biopharma Corporation | siRNA silencing of apolipoprotein B |
WO2006054625A1 (ja) * | 2004-11-19 | 2006-05-26 | Genecare Research Institute Co., Ltd. | 癌細胞特異的細胞増殖抑制剤 |
US7923206B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Method of determining a cellular response to a biological agent |
US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
ATE539758T1 (de) * | 2004-11-24 | 2012-01-15 | Alnylam Pharmaceuticals Inc | Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen |
US8003780B2 (en) * | 2004-11-24 | 2011-08-23 | Neomics Co., Ltd. | AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2 |
US9944713B2 (en) | 2004-11-24 | 2018-04-17 | Medicinal Bioconvergence Research Center | Antibody specific to the AIMP2-DX2 |
US20060121040A1 (en) * | 2004-12-08 | 2006-06-08 | Wisconsin Alumni Research Foundation | Compositions and methods for treating neuroendocrine tumors |
WO2006062369A1 (en) | 2004-12-08 | 2006-06-15 | Bioneer Corporation | Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna |
EP1819346A4 (de) * | 2004-12-09 | 2009-07-15 | Centocor Inc | Oxytocin-rezeptorantagonisten und deren verwendung zur behandlung von lungenkrankheiten |
AU2005313883B2 (en) * | 2004-12-09 | 2011-03-31 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
EP1824872B1 (de) * | 2004-12-14 | 2012-02-08 | Alnylam Pharmaceuticals Inc. | Rnai-modulation von mll-af4 und verwendungen dafür |
US7332591B2 (en) * | 2004-12-21 | 2008-02-19 | The University Of Iowa Research Foundation | Bardet-Biedl susceptibility gene and uses thereof |
DE602005027747D1 (de) * | 2004-12-22 | 2011-06-09 | Alnylam Pharmaceuticals Inc | Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen |
TWI401316B (zh) * | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用 |
WO2006071884A2 (en) * | 2004-12-27 | 2006-07-06 | The Regents Of The University Of Michigan | Oligonucleotide based therapeutics |
KR101169668B1 (ko) * | 2005-01-07 | 2012-08-07 | 알닐람 파마슈티칼스 인코포레이티드 | RSV의 RNAi 조절 및 이를 위한 약제학적 조성물 |
DE102005003788A1 (de) | 2005-01-19 | 2006-07-20 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | siRNA-Moleküle zur Behandlung von Blutgefäßen |
CA2594919A1 (en) * | 2005-01-24 | 2006-08-03 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of the nogo-l or nogo-r gene and uses thereof |
US7879992B2 (en) * | 2005-01-31 | 2011-02-01 | Isis Pharmaceuticals, Inc. | Modification of MyD88 splicing using modified oligonucleotides |
TW200639252A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
JP2008544742A (ja) | 2005-02-25 | 2008-12-11 | アイシス ファーマシューティカルズ, インコーポレーテッド | IL4R−αに対する組成物およびその使用 |
AU2006219666B2 (en) * | 2005-03-02 | 2011-01-27 | National Institute Of Immunology | Inhibition of SPAG9 expression with siRNAs |
US20070185044A1 (en) * | 2005-03-08 | 2007-08-09 | Dobie Kenneth W | Modulation of ace2 expression |
EP1856259A1 (de) * | 2005-03-11 | 2007-11-21 | Alcon Inc. | Rnai-vermittelte hemmung von frizzled-verwandtem protein-1 zur behandlung von glaukomen |
GB0505081D0 (en) * | 2005-03-14 | 2005-04-20 | Genomica Sau | Downregulation of interleukin-12 expression by means of rnai technology |
EP1877556B1 (de) * | 2005-03-25 | 2011-09-14 | Medtronic, Inc. | Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung |
JP4131271B2 (ja) * | 2005-03-30 | 2008-08-13 | ソニー株式会社 | 情報処理装置および方法、並びにプログラム |
ES2381201T3 (es) * | 2005-03-31 | 2012-05-24 | Calando Pharmaceuticals, Inc. | Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos |
US8299041B2 (en) * | 2005-04-08 | 2012-10-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to acetyl-CoA carboxylases |
US20070213293A1 (en) * | 2005-04-08 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
US20090117539A1 (en) * | 2005-04-12 | 2009-05-07 | Larry Gilbertson | DNA sequences for gene suppression |
JP2008537752A (ja) | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法 |
JP4982757B2 (ja) * | 2005-04-15 | 2012-07-25 | 国立大学法人鳥取大学 | hTERT発現調節遺伝子 |
US20090203055A1 (en) * | 2005-04-18 | 2009-08-13 | Massachusetts Institute Of Technology | Compositions and methods for RNA interference with sialidase expression and uses thereof |
US20060253068A1 (en) * | 2005-04-20 | 2006-11-09 | Van Bilsen Paul | Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart |
EP1714970A1 (de) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Anwendung von Inhibitoren von Enzymen der RNAse-A Genfamilie zur Stabilisierung von Oligonukleotiden mit RNA interferierender Aktivität |
EP2631293A3 (de) | 2005-04-29 | 2013-11-20 | The Rockefeller University | Menschliche Mikro-RNAs und Verfahren zur Hemmung davon |
EP1885854B1 (de) * | 2005-05-06 | 2012-10-17 | Medtronic, Inc. | Verfahren und sequenzen zur unterdrückung der expression des huntington-gens in primaten |
US7902352B2 (en) * | 2005-05-06 | 2011-03-08 | Medtronic, Inc. | Isolated nucleic acid duplex for reducing huntington gene expression |
KR20060119412A (ko) * | 2005-05-20 | 2006-11-24 | 아주대학교산학협력단 | IL-6 발현 억제를 위한 siRNA 및 이를 함유하는조성물 |
ATE538798T1 (de) * | 2005-05-24 | 2012-01-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase |
EP1728514A1 (de) * | 2005-06-03 | 2006-12-06 | Immunotech S.A. | Verwendungen von Oligonukleotiden welche mesenchymale Stammzellen Proliferation verursachen |
CA2609206A1 (en) * | 2005-06-06 | 2006-12-14 | Gen-Probe Incorporated | Compositions, methods and kits for determining the presence of chlamydophila pneumoniae in a test sample |
WO2006131925A2 (en) * | 2005-06-10 | 2006-12-14 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
EP1734118A1 (de) * | 2005-06-15 | 2006-12-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Genom-weites RNAi-Screening zur Identifizierung von Genen die das JAK/STAT Pathway modulieren |
FI20050640A0 (fi) * | 2005-06-16 | 2005-06-16 | Faron Pharmaceuticals Oy | Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon |
WO2007002390A2 (en) * | 2005-06-23 | 2007-01-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing |
US7737265B2 (en) * | 2005-06-27 | 2010-06-15 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of HIF-1 and therapeutic uses thereof |
US20080280843A1 (en) * | 2006-05-24 | 2008-11-13 | Van Bilsen Paul | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US9133517B2 (en) | 2005-06-28 | 2015-09-15 | Medtronics, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin |
WO2007014075A2 (en) * | 2005-07-21 | 2007-02-01 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of the rho-a gene in research models |
US20090155241A1 (en) * | 2005-07-22 | 2009-06-18 | Japanese Foundation For Cancer Research | Prophylactic/therapeutic agent for cancer |
EP2295602B1 (de) * | 2005-07-27 | 2012-07-11 | Oncotherapy Science, Inc. | Verfahren zur Prognose von Krebsarten |
US20070026436A1 (en) * | 2005-07-28 | 2007-02-01 | University Of Massachusetts | Glucose transport-related genes, polypeptides, and methods of use thereof |
US20070105803A1 (en) | 2005-08-18 | 2007-05-10 | Muthiah Manoharan | Methods and compositions for treating neurological disease |
ATE532878T1 (de) * | 2005-08-24 | 2011-11-15 | Life Technologies Corp | Verfahren zur quantifizierung von sirnas, mirnas und polymorphen mirnas |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
EP2281876A3 (de) * | 2005-09-16 | 2012-04-11 | deVGen N.V. | Verfahren zur Kontrolle von Schädligen durch Verwendung von RNAi-Technologie |
EA200800868A1 (ru) * | 2005-09-19 | 2008-10-30 | ДЖОНСОН ЭНД ДЖОНСОН ФАРМАСЬЮТИКАЛ РИСЕРЧ ЭНД ДИВЕЛОПМЕНТ, Эл. Эл. Си. | Модуляция экспрессии глюкокортикоидного рецептора |
US20080311552A1 (en) * | 2005-09-20 | 2008-12-18 | London Health Sciences Centre Research, Inc. | Use of Sirnas in Organ Storage/Reperfusion Solutions |
US20120164730A1 (en) * | 2005-10-11 | 2012-06-28 | Ben-Gurion University Of The Negev Research And Development Authority Ltd. | Compositions for silencing the expression of vdac1 and uses thereof |
CA2625891A1 (en) | 2005-10-14 | 2007-04-26 | Carlton D. Donald | Inhibition of pax2 by defb1 induction as a therapy for cancer |
GB0521351D0 (en) * | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
WO2007047913A2 (en) * | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
US20090136502A1 (en) * | 2005-10-24 | 2009-05-28 | Toshimitsu Arai | Preventives/Remedies for Cancer |
GB0521716D0 (en) * | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
US7723314B1 (en) * | 2005-10-28 | 2010-05-25 | Transderm, Inc. | Methods and compositions for treating pachyonychia congenita |
WO2007051077A2 (en) * | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
US7320965B2 (en) | 2005-10-28 | 2008-01-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Huntingtin gene |
WO2007053803A2 (en) * | 2005-10-31 | 2007-05-10 | Centocor, Inc. | Antagonist of teb4 and methods of use |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
CA2626584A1 (en) * | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
WO2007056331A2 (en) | 2005-11-09 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
US8066730B2 (en) * | 2005-11-14 | 2011-11-29 | Scapa Flow, Llc | Medical dilator system or dilator device |
US7919603B2 (en) * | 2005-12-19 | 2011-04-05 | New York University | Heat shock RNA |
US8067558B2 (en) | 2005-12-19 | 2011-11-29 | New York University | Constitutively active fragments of eukaryotic heat shock RNA |
WO2007076366A2 (en) * | 2005-12-20 | 2007-07-05 | Isis Pharmaceuticals, Inc | Double stranded nucleic acid molecules targeted to il-4 receptor alpha |
US8258287B2 (en) | 2005-12-21 | 2012-09-04 | Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) | Interfering RNAs targeting the morbillivirus nucleoprotein gene |
MX2008008302A (es) * | 2005-12-22 | 2009-01-21 | Exegenics Inc | Composiciones y metodos para regular el sistema de complemento. |
AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
US8673873B1 (en) | 2005-12-28 | 2014-03-18 | Alcon Research, Ltd. | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
TW200731980A (en) * | 2005-12-29 | 2007-09-01 | Alcon Mfg Ltd | RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis |
US7444453B2 (en) * | 2006-01-03 | 2008-10-28 | International Business Machines Corporation | Address translation device |
EP2368912B1 (de) | 2006-01-05 | 2017-05-03 | Children's Medical Center Corporation | Regulatoren von NFAT |
US20090060921A1 (en) * | 2006-01-17 | 2009-03-05 | Biolex Therapeutics, Inc. | Glycan-optimized anti-cd20 antibodies |
AU2007205935B2 (en) * | 2006-01-17 | 2013-07-11 | Synthon Biopharmaceuticals B.V. | Compositions and methods for humanization and optimization of N-glycans in plants |
WO2007084954A2 (en) * | 2006-01-19 | 2007-07-26 | The Board Of Trustees Of The University Of Illinois | Selective inhibition of ig20 splice variants to treat cancers |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
NL2000439C2 (nl) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
WO2007089584A2 (en) * | 2006-01-26 | 2007-08-09 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
US8229398B2 (en) * | 2006-01-30 | 2012-07-24 | Qualcomm Incorporated | GSM authentication in a CDMA network |
US20090221435A1 (en) * | 2006-02-08 | 2009-09-03 | Dharmacon, Inc. | Microarray for detecting and quantifying microrna |
CN105385679B (zh) * | 2006-02-13 | 2020-05-26 | 孟山都技术有限公司 | 选择和稳定dsRNA构建体 |
JP4961549B2 (ja) * | 2006-02-16 | 2012-06-27 | 国立大学法人愛媛大学 | アンドロゲン受容体遺伝子に特異的なsiRNA |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
FI20060246A0 (fi) | 2006-03-16 | 2006-03-16 | Jukka Westermarck | Uusi kasvua stimuloiva proteiini ja sen käyttö |
US7846908B2 (en) * | 2006-03-16 | 2010-12-07 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of TGF-beta and therapeutic uses thereof |
BRPI0709147A2 (pt) * | 2006-03-24 | 2011-06-28 | Novartis Ag | composições de dsrna e métodos para tratamento de infecção por hpv |
US7718629B2 (en) | 2006-03-31 | 2010-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
WO2007120883A2 (en) * | 2006-04-12 | 2007-10-25 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
WO2007121156A2 (en) * | 2006-04-13 | 2007-10-25 | Alcon Research, Ltd | Rnai-mediated inhibition of histamine receptor h1-related conditions |
TW201336514A (zh) | 2006-04-13 | 2013-09-16 | Alcon Res Ltd | RNA干擾(RNAi)所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用(二) |
WO2007123391A1 (en) * | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
KR20090015073A (ko) * | 2006-04-21 | 2009-02-11 | 인터벤셔널 스파인, 인코포레이티드 | 척추 고정을 위한 방법 및 기구 |
US7691824B2 (en) * | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
US8158598B2 (en) * | 2006-05-05 | 2012-04-17 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to PTPR alpha |
CN103554205A (zh) * | 2006-05-05 | 2014-02-05 | Isis制药公司 | 调节gccr的表达的化合物和方法 |
TWI322690B (en) * | 2006-05-11 | 2010-04-01 | Flysun Dev Co Ltd | Short interference ribonucleic acids for treating allergic dieases |
JP5570806B2 (ja) * | 2006-05-11 | 2014-08-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Pcsk9遺伝子の発現を阻害するための組成物および方法 |
US8243715B2 (en) * | 2006-05-15 | 2012-08-14 | Oracle Israel Ltd. | Delivering sip-based call services to circuit-switched terminals |
WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
US7812150B2 (en) * | 2006-05-19 | 2010-10-12 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of Aha and therapeutic uses thereof |
WO2007136758A2 (en) * | 2006-05-19 | 2007-11-29 | Board Of Regents, The University Of Texas System | Sirna inhibition of p13k p85, p110, and akt2 and methods of use |
EP1857548A1 (de) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Mittel und Verfahren zur Induktion von Exon-skipping |
WO2007137239A2 (en) * | 2006-05-19 | 2007-11-29 | The Scripps Research Institute | Treatment of protein misfolding |
CN101448943B (zh) | 2006-05-19 | 2013-07-17 | 爱尔康研究有限公司 | 肿瘤坏死因子α相关状况的RNAi介导的抑制 |
AU2012201409B2 (en) * | 2006-05-19 | 2014-06-12 | Arrowhead Research Corporation | RNAi-Mediated inhibition of tumor necrosis factor alpha-related conditions |
US7888498B2 (en) * | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US9273356B2 (en) | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
US8430813B2 (en) | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
AR061168A1 (es) * | 2006-06-02 | 2008-08-06 | Alcon Mfg Ltd | Inhibicion mediada por arni de blancos relacionados con factor 1 derivado de celulas de estroma para el tratamiento de enfermedades relacionadas con neovascularizacion |
EP2026843A4 (de) * | 2006-06-09 | 2011-06-22 | Quark Pharmaceuticals Inc | Therapeutische verwendungen von rtp801l |
WO2007142336A1 (ja) * | 2006-06-09 | 2007-12-13 | Kabushiki Kaisha Yakult Honsha | ヒトがん細胞の不死化に関わる遺伝子およびその利用 |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
ES2390499T3 (es) * | 2006-06-12 | 2012-11-13 | Opko Pharmaceuticals, Llc | Composiciones y métodos para la inhibición de la angiogénesis por sirna |
KR100794705B1 (ko) * | 2006-06-13 | 2008-01-14 | (주)바이오니아 | 선택적 스플라이싱을 고려한 siRNA를 이용하여 표적mRNA의 발현을 억제하는 방법 |
GB0612342D0 (en) | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
WO2008005769A2 (en) * | 2006-06-30 | 2008-01-10 | Immusol, Incorporated | Methods of inhibiting hcv replication |
US8124752B2 (en) * | 2006-07-10 | 2012-02-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the MYC gene |
JP4756271B2 (ja) * | 2006-07-18 | 2011-08-24 | 独立行政法人産業技術総合研究所 | ガン細胞の老化、アポトーシス誘導剤 |
EP1884569A1 (de) | 2006-07-31 | 2008-02-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sensibilisierung von Krebszellen für eine Therapie unter der Verwendung von siNA gerichtet gegen Gene aus der 1p und 19q chromosomalen Region |
US8138160B2 (en) | 2006-08-03 | 2012-03-20 | Warsaw Orthopedic, Inc. | Reagents, methods and systems to suppress pro-inflammatory cytokines |
WO2008019351A2 (en) | 2006-08-04 | 2008-02-14 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to diacylglycerol acyltransferase 1 |
CA2660052A1 (en) * | 2006-08-04 | 2008-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of jnk proteins |
WO2008017473A2 (en) | 2006-08-08 | 2008-02-14 | Gunther Hartmann | Structure and use of 5' phosphate oligonucleotides |
US20080039415A1 (en) * | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
PT2049664E (pt) * | 2006-08-11 | 2012-01-03 | Prosensa Technologies Bv | Oligonucleotídeos de cadeia simples complementares dos elementos repetitivos para tratar perturbações genéticas associadas à instabilidade das repetições do adn |
WO2008029790A1 (fr) * | 2006-09-04 | 2008-03-13 | Kyowa Hakko Kirin Co., Ltd. | Nouvel acide nucléique |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
KR20090083338A (ko) | 2006-09-18 | 2009-08-03 | 알닐람 파마슈티칼스 인코포레이티드 | SCAP의 RNAi 조절 및 이들의 치료적 용도 |
WO2008035692A1 (fr) * | 2006-09-19 | 2008-03-27 | Jcr Pharmaceuticals Co., Ltd. | Marqueur d'identification de cellule cancéreuse et inhibiteur de prolifération de cellule cancéreuse |
AR055648A1 (es) * | 2006-09-21 | 2007-08-29 | Gen Med Sa | Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos |
AU2007299629C1 (en) | 2006-09-21 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the HAMP gene |
CA2663601C (en) | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
US9074205B2 (en) * | 2006-10-18 | 2015-07-07 | Marina Biotech, Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
WO2008063760A2 (en) * | 2006-10-18 | 2008-05-29 | The University Of Texas M.D. Anderson Cancer Center | Methods for treating cancer targeting transglutaminase |
JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のsiRNAおよびその使用方法 |
US9375440B2 (en) * | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
AU2006350507A1 (en) * | 2006-11-09 | 2008-05-15 | Unibioscreen S.A. | Targeting of alpha-1 or alpha-3 subunit of Na+, K+-ATPase in the treatment of proliferative diseases |
US8304399B2 (en) * | 2006-11-09 | 2012-11-06 | The Board Of Regents Of The University Of Texas System | Hedgehog signaling pathway proteins and uses thereof |
WO2008059491A1 (en) * | 2006-11-13 | 2008-05-22 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using sirna molecules directed against cd24 |
US7988668B2 (en) * | 2006-11-21 | 2011-08-02 | Medtronic, Inc. | Microsyringe for pre-packaged delivery of pharmaceuticals |
US8034921B2 (en) * | 2006-11-21 | 2011-10-11 | Alnylam Pharmaceuticals, Inc. | IRNA agents targeting CCR5 expressing cells and uses thereof |
US7819842B2 (en) | 2006-11-21 | 2010-10-26 | Medtronic, Inc. | Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites |
US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
MX2009005527A (es) * | 2006-11-27 | 2009-06-08 | Isis Pharmaceuticals Inc | Metodos para el tratamiento de hipercolesterolemia. |
US20080171719A1 (en) * | 2006-11-28 | 2008-07-17 | Alcon Manufacturing, Ltd. | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS |
WO2008070863A2 (en) | 2006-12-07 | 2008-06-12 | Interventional Spine, Inc. | Intervertebral implant |
US8979931B2 (en) | 2006-12-08 | 2015-03-17 | DePuy Synthes Products, LLC | Nucleus replacement device and method |
US20100099746A1 (en) * | 2006-12-18 | 2010-04-22 | Kyowa Hakko Kirin Co., Ltd. | Novel nucleic acid |
CN101563460A (zh) * | 2006-12-22 | 2009-10-21 | 弗·哈夫曼-拉罗切有限公司 | 选择方法 |
US8476243B2 (en) | 2006-12-29 | 2013-07-02 | Transderm, Inc. | Methods and compositions for treating keratin hyperproliferative disorders |
US7754698B2 (en) * | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
CA2925983A1 (en) | 2007-01-16 | 2008-07-24 | The University Of Queensland | Method of inducing an immune response |
JP2010516625A (ja) | 2007-01-24 | 2010-05-20 | インサート セラピューティクス, インコーポレイテッド | 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート |
WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
TW200900420A (en) | 2007-02-02 | 2009-01-01 | Amgen Inc | Hepcidin, hepcidin antagonists and methods of use |
US20080188433A1 (en) * | 2007-02-07 | 2008-08-07 | Academia Sinica | Methods of diagnosis of spinal muscular atrophy and treatments thereof |
US20090163431A1 (en) * | 2007-02-14 | 2009-06-25 | Ontherex Llc | Compositions and methods for modulation of pdx-1 |
WO2008106102A2 (en) * | 2007-02-26 | 2008-09-04 | Quark Pharmaceuticals, Inc. | Inhibitors of rtp801 and their use in disease treatment |
US20100292301A1 (en) * | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
US20080293136A1 (en) * | 2007-03-02 | 2008-11-27 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting akt gene expression and uses thereof |
US20090018099A1 (en) * | 2007-03-02 | 2009-01-15 | Hitto Kaufmann | Protein production |
US20100055783A1 (en) * | 2007-03-02 | 2010-03-04 | Mdrna, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
CA2679244A1 (en) * | 2007-03-02 | 2009-03-05 | Mdrna, Inc. | Nucleic acid compounds for inhibiting myc gene expression and uses thereof |
US20080287383A1 (en) * | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
EP2522730A1 (de) * | 2007-03-02 | 2012-11-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verbesserung der Herstellung von Proteinen |
JP2010519913A (ja) * | 2007-03-02 | 2010-06-10 | エムディーアールエヌエー,インコーポレイテッド | Wnt遺伝子の発現を抑制するための核酸化合物およびその使用 |
WO2008109362A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf gene expression and uses thereof |
WO2008109449A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna Inc. | Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof |
WO2008109357A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting apob gene expression and uses thereof |
JP2010519908A (ja) * | 2007-03-02 | 2010-06-10 | エムディーアールエヌエー,インコーポレイテッド | Hif1a遺伝子の発現を抑制するための核酸化合物およびその使用 |
US20100105134A1 (en) * | 2007-03-02 | 2010-04-29 | Mdrna, Inc. | Nucleic acid compounds for inhibiting gene expression and uses thereof |
CA2679867A1 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
US20100112687A1 (en) * | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
US20100292302A1 (en) * | 2007-03-08 | 2010-11-18 | Mak Tak W | Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity |
EP2546651A1 (de) | 2007-03-14 | 2013-01-16 | Bionsil S.r.l. | Modulatorverbindungen der Arzneimittelresistenz in Epitheltumorzellen |
JP5103621B2 (ja) * | 2007-03-20 | 2012-12-19 | 国立大学法人愛媛大学 | ADAT1遺伝子に特異的なsiRNA |
US7812002B2 (en) * | 2007-03-21 | 2010-10-12 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer |
JP2010522245A (ja) | 2007-03-24 | 2010-07-01 | ゲンザイム コーポレイション | ヒトアポリポタンパク質bと相補的なアンチセンスオリゴヌクレオチドの投与 |
PE20090064A1 (es) * | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
US7759320B2 (en) | 2007-03-29 | 2010-07-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the Ebola |
GB0707069D0 (en) * | 2007-04-12 | 2007-05-23 | Medical Res Council | Methods and uses |
WO2008124927A1 (en) * | 2007-04-13 | 2008-10-23 | Vincent Research & Consulting Inc. | Sirna against thymidylate synthase and uses thereof in cancer treatment regimens |
KR20100024399A (ko) * | 2007-05-01 | 2010-03-05 | 엔즌 파마슈티칼스, 인코포레이티드 | 베타-카테닌의 조절용 rna 길항제 화합물 |
WO2008143774A2 (en) * | 2007-05-01 | 2008-11-27 | University Of Massachusetts | Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy |
ES2581480T3 (es) * | 2007-05-04 | 2016-09-06 | Index Pharmaceuticals Ab | Compuestos inhibidores de crecimiento tumoral y métodos de uso de los mismos |
US20100286238A1 (en) * | 2007-05-15 | 2010-11-11 | Rivory Laurent Pierre | Suppression of viruses involved in respiratory infection or disease |
DE202007007322U1 (de) * | 2007-05-23 | 2008-10-02 | Baumgart, Rainer, Prof. Dr.med., Dipl.-Ing. | Instrumentensatz zur minimal invasiven Vorbereitung einer Knochennagelung |
WO2008147837A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds, non-naturally occurring micro-rnas, and methods for optimizing non-naturally occurring micro-rnas |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
WO2008148304A1 (fr) * | 2007-05-31 | 2008-12-11 | Xiamen University | Cible d'interférence arn pour traiter le sida |
US8278043B2 (en) * | 2007-06-05 | 2012-10-02 | Melica Hb | Methods and materials related to grey alleles |
US20090054366A1 (en) * | 2007-06-15 | 2009-02-26 | Reliance Life Sciences Pvt. Ltd. | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY |
US20100273854A1 (en) * | 2007-06-15 | 2010-10-28 | Hagar Kalinski | Compositions and methods for inhibiting nadph oxidase expression |
AU2012203782B2 (en) * | 2007-06-15 | 2012-12-20 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
AR066984A1 (es) * | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
US8900307B2 (en) | 2007-06-26 | 2014-12-02 | DePuy Synthes Products, LLC | Highly lordosed fusion cage |
CA2691166A1 (en) * | 2007-06-27 | 2008-12-31 | Liu Dongxu | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
PT2170403E (pt) | 2007-06-27 | 2014-07-17 | Quark Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes pró-apoptóticos |
US8043343B2 (en) | 2007-06-28 | 2011-10-25 | Zimmer Spine, Inc. | Stabilization system and method |
US8198256B2 (en) * | 2007-07-03 | 2012-06-12 | Kyorin Pharmaceutical Co., Ltd. | Treatment of influenza |
EP2319926B1 (de) | 2007-07-05 | 2016-08-31 | Arrowhead Research Corporation | DSRNA zur Behandlung viraler Infektionen |
CA2693048C (en) * | 2007-07-12 | 2016-10-18 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
WO2009008725A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
EP2017340A1 (de) * | 2007-07-16 | 2009-01-21 | Qiagen GmbH | Positive Kontrollen für expressionsmodulierende Experimente |
AR067786A1 (es) * | 2007-08-03 | 2009-10-21 | Alcon Mfg Ltd | Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma |
US20090036396A1 (en) | 2007-08-03 | 2009-02-05 | Alcon Research, Ltd. | RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESIS |
WO2009021150A2 (en) * | 2007-08-08 | 2009-02-12 | California Pacific Medical Center | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
US8263571B2 (en) * | 2007-08-10 | 2012-09-11 | Vendevia Group, Llc | Gene silencing of the brother of the regulator of imprinted sites (BORIS) |
EP2185702A4 (de) * | 2007-08-21 | 2011-05-04 | Scott And White Memorial Hospital And Scott Sherwood And Brindley Foundation | Verfahren und zusammensetzungen posttranskriptionelle genausschaltung |
EP2190985A4 (de) * | 2007-08-24 | 2010-12-15 | Oncotherapy Science Inc | Mit krebs assoziierte gene cdca5, epha7, stk31 und wdhd1 |
CN105018492B (zh) | 2007-08-27 | 2018-08-24 | 北京强新生物科技有限公司 | 不对称干扰rna的组合物及其用途 |
CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
US20100286241A1 (en) * | 2007-09-18 | 2010-11-11 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
DK2548962T3 (en) | 2007-09-19 | 2016-04-11 | Applied Biosystems Llc | Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof |
CA2701128A1 (en) * | 2007-10-01 | 2009-04-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
EP2231168A4 (de) * | 2007-10-03 | 2012-01-04 | Quark Pharmaceuticals Inc | Neuartige sirna strukturen |
KR20100080529A (ko) | 2007-10-05 | 2010-07-08 | 신세스 게엠바하 | 팽창 시스템 및 이를 이용한 방법 |
EP2209894B1 (de) * | 2007-10-12 | 2015-06-03 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Verfahren zur öffnung fester verbindungen |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
CA2704049A1 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2222283A2 (de) * | 2007-10-29 | 2010-09-01 | University of Massachusetts | Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
EP2220230A2 (de) * | 2007-11-09 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Modulation der expression von faktor 9 |
RU2010119775A (ru) | 2007-11-09 | 2011-12-27 | Айсис Фармасьютикалс,Инк. (Us) | Модулирование экспрессии фактора 7 |
EP2848688A1 (de) | 2007-12-10 | 2015-03-18 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression |
US20100204305A1 (en) * | 2007-12-11 | 2010-08-12 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
WO2009074990A2 (en) * | 2007-12-12 | 2009-06-18 | Quark Pharmaceuticals, Inc. | Rtp801l sirna compounds and methods of use thereof |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
AU2008334948B2 (en) | 2007-12-13 | 2014-11-20 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
WO2009079399A2 (en) * | 2007-12-14 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
US20110044978A1 (en) | 2007-12-14 | 2011-02-24 | Amgen Inc. | Method for treating bone fracture |
KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 RNAi 기구를 포화시키지않는 신규한 siRNA 구조 및 그 용도 |
MX2010006925A (es) * | 2007-12-20 | 2011-05-02 | Angiochem Inc | Conjugados de polipeptido-acido nucleico y sus usos. |
EP2077335A1 (de) * | 2007-12-22 | 2009-07-08 | Universitätsklinikum Schleswig-Holstein | EXO1-Promoter-Polymorphismus im Zusammenhang mit außergewöhnlich hoher Lebenserwartung beim Menschen |
KR100942807B1 (ko) * | 2007-12-26 | 2010-02-18 | 재단법인서울대학교산학협력재단 | 폐암의 예방 또는 치료용 유전자 치료제 및 약제 조성물 |
CA2710713C (en) * | 2007-12-27 | 2017-09-19 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
EP2075333A1 (de) * | 2007-12-28 | 2009-07-01 | Qiagen GmbH | Positive Kontrollen für expressionsmodulierende Experimente |
EP2242854A4 (de) * | 2008-01-15 | 2012-08-15 | Quark Pharmaceuticals Inc | Sirna-verbindungen und verfahren zur verwendung davon |
CA2710142A1 (en) | 2008-01-17 | 2009-07-23 | Beat Lechmann | An expandable intervertebral implant and associated method of manufacturing the same |
US20100297750A1 (en) * | 2008-01-24 | 2010-11-25 | Toru Natsume | Polynucleotide or analogue thereof, and gene expression regulation method using the polynucleotide or the analogue thereof |
KR100980098B1 (ko) * | 2008-01-30 | 2010-09-03 | 한국과학기술연구원 | 음이온 채널을 통한 신경전달물질의 방출 조절 |
JP2011511004A (ja) * | 2008-01-31 | 2011-04-07 | アルナイラム ファーマシューティカルズ インコーポレイテッド | PCSK9遺伝子を標的とするdsRNAを送達するための最適化された方法 |
NZ587178A (en) * | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
CN104975020B (zh) | 2008-02-11 | 2020-01-17 | 菲奥医药公司 | 经修饰的RNAi多核苷酸及其用途 |
WO2009137128A2 (en) * | 2008-02-12 | 2009-11-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd45 gene |
WO2009103067A2 (en) * | 2008-02-14 | 2009-08-20 | The Children's Hospital Of Philadelphia | Compositions and methods to treat asthma |
KR100870314B1 (ko) * | 2008-02-19 | 2008-11-25 | 고려대학교 산학협력단 | 암 치료용 핵산 의약 조성물 |
DE112009000372A5 (de) * | 2008-02-20 | 2011-01-27 | Technische Universität Dresden | Verwendung von Substanzen zur Sensibilisierung von Tumorzellen gegen Bestrahlung und/oder Chemotherapie |
CN105267233B (zh) | 2008-03-05 | 2019-07-26 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因表达的组合物和方法 |
KR101123130B1 (ko) * | 2008-03-17 | 2012-03-30 | 연세대학교 산학협력단 | Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제 |
CA2718765A1 (en) * | 2008-03-20 | 2009-09-24 | Quark Pharmaceuticals, Inc. | Novel sirna compounds for inhibiting rtp801 |
EP2105145A1 (de) * | 2008-03-27 | 2009-09-30 | ETH Zürich | Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide |
WO2009122639A1 (ja) * | 2008-03-31 | 2009-10-08 | Sugimoto Yoshikazu | Abcトランスポーター蛋白質発現抑制剤 |
ES2605618T3 (es) * | 2008-03-31 | 2017-03-15 | National Institute Of Advanced Industrial Science And Technology | ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN |
US7902166B2 (en) * | 2008-04-03 | 2011-03-08 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
TWI348916B (en) * | 2008-04-03 | 2011-09-21 | Univ Nat Taiwan | A novel treatment tool for cancer: rna interference of bcas2 |
US8198255B2 (en) * | 2008-05-16 | 2012-06-12 | The Board Of Regents Of The University Of Oklahoma | SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1 |
US8936941B2 (en) | 2008-04-03 | 2015-01-20 | The Board Of Regents Of The University Of Oklahoma | Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof |
US7956044B1 (en) | 2008-04-03 | 2011-06-07 | The Board Of Regents Of The University Of Oklahoma | Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same |
AU2009232355A1 (en) * | 2008-04-04 | 2009-10-08 | Calando Pharmaceuticals, Inc. | Compositions and use of EPAS1 inhibitors |
BRPI0910325A8 (pt) | 2008-04-05 | 2019-01-29 | Synthes Gmbh | implante intervertebral expansível |
CA2720887A1 (en) * | 2008-04-09 | 2009-10-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Inhibitors of stim1 for the treatment of cardiovascular disorders |
EP2285385A4 (de) * | 2008-04-15 | 2013-01-16 | Quark Pharmaceuticals Inc | siRNA-VERBINDUNGEN ZUR NRF2-HEMMUNG |
EP2770057A1 (de) * | 2008-04-15 | 2014-08-27 | Protiva Biotherapeutics Inc. | Stilllegung von CSN5-Genexpression mittels interferierender RNA |
US7875711B2 (en) * | 2008-04-17 | 2011-01-25 | Alnylam Pharamaceuticals, Inc. | Compositions and methods for inhibiting expression of XBP-1 gene |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
ES2721148T3 (es) * | 2008-04-18 | 2019-07-29 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso |
JP5462862B2 (ja) | 2008-04-22 | 2014-04-02 | サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィク | メラニン形成を阻害するためのKif13A阻害剤およびAP−1阻害剤の使用 |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
EP2119783A1 (de) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel |
AU2009246134B2 (en) * | 2008-05-16 | 2016-03-03 | The Children's Hospital Of Philadelphia | Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes |
US9663585B2 (en) | 2008-05-16 | 2017-05-30 | The Board Of Regents Of The University Of Oklahoma | Anti-DCLK1 monoclonal antibodies and methods of production and use thereof |
JP5689413B2 (ja) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 平滑末端を有する5’三リン酸オリゴヌクレオチドおよびその使用 |
WO2009143390A2 (en) | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of rbp4 |
WO2009143391A2 (en) * | 2008-05-22 | 2009-11-26 | Isis Pharmaceuticals, Inc | Methods for modulation expression of creb |
ES2361099B1 (es) | 2008-05-26 | 2012-05-08 | Rudolf Morgenstern Lopez | "prótesis intervertebral" |
WO2009148137A1 (ja) * | 2008-06-04 | 2009-12-10 | 協和発酵キリン株式会社 | 肥満細胞の脱顆粒を制御する核酸 |
WO2009147684A2 (en) | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
US20110092575A1 (en) * | 2008-06-06 | 2011-04-21 | Assignment for Published Patent Application Gene Techno Science Co., Ltd. | Sirna of human osteopontin |
WO2009147246A1 (en) * | 2008-06-06 | 2009-12-10 | Medizinische Universität Graz | Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors |
WO2009150156A1 (en) * | 2008-06-13 | 2009-12-17 | Riboxx Gmbh | Method for enzymatic synthesis of chemically modified rna |
US20090312194A1 (en) * | 2008-06-13 | 2009-12-17 | Oregon Health & Science University | Selection of personalized cancer therapy regimens using interfering rna functional screening |
TWI455944B (zh) * | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
EP2310507A4 (de) * | 2008-07-08 | 2013-03-20 | David Gladstone Inst | Verfahren und zusammensetzungen zur angiogenesemodulierung |
ES2566008T3 (es) * | 2008-07-10 | 2016-04-08 | Regenesance B.V. | Antagonistas de complementos y usos de los mismos |
EP2310021A4 (de) * | 2008-07-10 | 2012-06-27 | Merck Sharp & Dohme | Verfahren zur verwendung von zusammensetzungen mit mir-192 und/oder mir-215 zur behandlung von krebs |
US20110184046A1 (en) * | 2008-07-11 | 2011-07-28 | Dinah Wen-Yee Sah | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes |
EP2313506A1 (de) * | 2008-07-11 | 2011-04-27 | Medizinische Universität Innsbruck | Antagonisten von nr2f6 zur verstärkung der immunantwort |
US8309791B2 (en) * | 2008-07-16 | 2012-11-13 | Recombinectics, Inc. | Method for producing a transgenic pig using a hyper-methylated transposon |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
WO2010008069A1 (ja) * | 2008-07-18 | 2010-01-21 | 国立大学法人名古屋大学 | 細胞増殖阻害剤 |
CN101632833B (zh) * | 2008-07-25 | 2013-11-06 | 上海市计划生育科学研究所 | 一种前列腺癌相关的基因及其用途 |
US8901095B2 (en) * | 2008-07-29 | 2014-12-02 | The Board Of Regents Of The University Of Texas System | Selective inhibition of polyglutamine protein expression |
EP2323667A4 (de) * | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen |
US8669102B2 (en) | 2008-08-14 | 2014-03-11 | Isis Pharmaceuticals, Inc. | Modulation of prion expression |
US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
NZ591416A (en) | 2008-08-25 | 2012-11-30 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US20130324478A1 (en) * | 2008-09-08 | 2013-12-05 | Laurence Faure | Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration |
EP3133170B1 (de) | 2008-09-10 | 2020-03-18 | Rutgers, the State University of New Jersey | Abbildung einzelner mrna-moleküle mithilfe mehrerer individuell markierter sonden |
PT2334794T (pt) | 2008-09-15 | 2017-02-15 | Harvard College | Modulação de bcl11a para tratamento de hemoglobinopatias |
JP2010068723A (ja) * | 2008-09-16 | 2010-04-02 | Tokyo Medical & Dental Univ | アレルギー疾患の治療のための核酸医薬 |
EP2949752B1 (de) | 2008-09-22 | 2017-12-20 | RXi Pharmaceuticals Corporation | Selbstfreisetzende rnai-verbindungen von reduzierter grösse |
JP5529142B2 (ja) | 2008-09-25 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法 |
EP2344638A1 (de) | 2008-10-06 | 2011-07-20 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der expression einer rna aus west-nile-virus |
CA2739788A1 (en) * | 2008-10-07 | 2010-04-15 | President And Fellows Of Harvard College | Telomerase inhibitors that bind to the cr4-cr5 domain of the rna component of human telomerase and methods of use thereof |
CN102245636A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | 用于药物递送的依托泊苷和多柔比星结合物 |
SI2379084T1 (en) | 2008-10-15 | 2018-04-30 | Ionis Pharmaceuticals, Inc. | Modulation of factor expression 11 |
BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
CA2743828C (en) * | 2008-10-15 | 2018-09-04 | Promising Future, Llc | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells |
EA020312B1 (ru) * | 2008-10-20 | 2014-10-30 | Элнилэм Фармасьютикалз, Инк. | Композиции и способы для ингибирования экспрессии транстиретина |
AU2015249072C1 (en) * | 2008-10-20 | 2022-10-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
US20100168205A1 (en) * | 2008-10-23 | 2010-07-01 | Alnylam Pharmaceuticals, Inc. | Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules |
CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
EP2350656B1 (de) * | 2008-10-30 | 2015-01-07 | The Translational Genomics Research Institute | Verfahren und Kits zur Identifikation invasiver Glioblastome |
US9095592B2 (en) * | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
US20100267803A1 (en) * | 2008-11-07 | 2010-10-21 | The Research Foundation Of State University Of New York | Regulators Of Fat Metabolism As Anti-Cancer Targets |
US20100120787A1 (en) * | 2008-11-13 | 2010-05-13 | Modgene, Llc | Modification of amyloid-beta load in non-brain tissue |
US9074211B2 (en) * | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
AU2009316853A1 (en) | 2008-11-21 | 2010-05-27 | Isis Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
CA2744987C (en) | 2008-12-02 | 2018-01-16 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
WO2010064851A2 (ko) * | 2008-12-02 | 2010-06-10 | 울산대학교 산학협력단 | 종간 교차활성을 지닌 mTOR을 표적으로 하는 siRNA, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물 |
MX2011005918A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen. |
WO2010065662A2 (en) * | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
EP2361306A1 (de) | 2008-12-04 | 2011-08-31 | OPKO Ophthalmics, LLC | Zusammensetzungen und verfahren zur selektiven hemmung proangiogener vegf-isoformen |
AU2009322043A1 (en) | 2008-12-05 | 2011-07-07 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
US20110144687A1 (en) * | 2009-12-10 | 2011-06-16 | Kleiner Jeffrey | Lateral Based Retractor System |
AU2009324534B2 (en) | 2008-12-10 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | GNAQ targeted dsRNA compositions and methods for inhibiting expression |
WO2010068978A1 (en) * | 2008-12-17 | 2010-06-24 | Commonwealth Scientific Industrial Research Organisation | Methods of modulating the sex of avians |
AU2009336191B2 (en) * | 2008-12-18 | 2017-08-24 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
CA2745775A1 (en) * | 2008-12-18 | 2010-07-15 | Centre National De La Recherche Scientifique - Cnrs- | Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof |
US11408003B2 (en) | 2008-12-18 | 2022-08-09 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
WO2010078536A1 (en) * | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
JPWO2010079819A1 (ja) * | 2009-01-08 | 2012-06-28 | 塩野義製薬株式会社 | 肥満または糖尿病治療用医薬組成物 |
US9127273B2 (en) * | 2009-01-13 | 2015-09-08 | The Board Of Regents Of The University Of Texas System | UNC-45A splice variants based cancer diagnostics and therapeutics |
WO2010093263A1 (en) * | 2009-02-03 | 2010-08-19 | Solilrna Biosciences Limited | Compositions and methods for the treatment and prevention of neoplastic disorders |
MX2011007776A (es) * | 2009-02-03 | 2011-08-12 | Hoffmann La Roche | Compsiciones y metodos para inhibir la expresion de genes ptp1b. |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
WO2010091396A2 (en) * | 2009-02-09 | 2010-08-12 | Archemix Corp. | Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics |
WO2010093788A2 (en) * | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
CA2752237C (en) * | 2009-02-12 | 2020-03-24 | Opko Curna, Llc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2010091878A2 (en) * | 2009-02-13 | 2010-08-19 | Silence Therapeutics Ag | Means for inhibiting the expression of opa1 |
CN102333869A (zh) * | 2009-02-24 | 2012-01-25 | 里博克斯艾克斯有限公司 | 小干扰rna的改进设计 |
GB2468477A (en) * | 2009-03-02 | 2010-09-15 | Mina Therapeutics Ltd | Double stranded RNA molecule comprising siRNA and miRNA precursors |
ES2845644T3 (es) * | 2009-03-04 | 2021-07-27 | Curna Inc | Tratamiento de enfermedades relacionadas con sirtuina1 (SIRT1) mediante inhibición del transcrito del antisentido natural a sirtuina 1 |
JPWO2010101249A1 (ja) | 2009-03-06 | 2012-09-10 | 国立大学法人三重大学 | T細胞の機能増強方法 |
EP2406376A1 (de) * | 2009-03-12 | 2012-01-18 | Alnylam Pharmaceuticals, Inc. | Lipidformulierte zusammensetzungen und verfahren zur hemmung der expression von eg5- und vegf-genen |
CA2755409C (en) * | 2009-03-16 | 2019-04-30 | Joseph Collard | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
US9107933B2 (en) | 2009-03-16 | 2015-08-18 | Isis Pharmaceuticals, Inc. | Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III |
AU2010226604A1 (en) * | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
WO2010107958A1 (en) * | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
WO2010111198A1 (en) | 2009-03-23 | 2010-09-30 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
WO2010111490A2 (en) * | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2411516A1 (de) * | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von ask1 (apoptose-signalregulierende kinase 1) unter verwendung von sina (short interfering nucleic acid) |
US20120004281A1 (en) * | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
US9526620B2 (en) | 2009-03-30 | 2016-12-27 | DePuy Synthes Products, Inc. | Zero profile spinal fusion cage |
EP2414520A2 (de) | 2009-03-31 | 2012-02-08 | Altair Therapeutics, Inc. | Verfahren zur modulation einer immunantwort auf eine virusinfektion |
ES2599153T3 (es) * | 2009-03-31 | 2017-01-31 | Delta-Fly Pharma, Inc. | Molécula de ARNi para la timidilato sintasa y uso de la misma |
WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
CN103555722B (zh) * | 2009-04-03 | 2016-08-31 | 戴瑟纳制药公司 | 利用不对称双链rna特异性抑制kras的方法和组合物 |
EP2238937B1 (de) * | 2009-04-07 | 2012-08-22 | Biedermann Technologies GmbH & Co. KG | Werkzeug zur Verwendung mit einem Knochenanker, insbesondere für die Wirbelsäulenchirurgie |
EP2421562B1 (de) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Behandlung von ovarialkarzinom mit einem an ein angiopep-2-analogon konjugierten antitumorwirkstoff |
AU2010239779A1 (en) | 2009-04-24 | 2011-11-17 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
US8349808B2 (en) * | 2009-05-05 | 2013-01-08 | Medical Diagnostic Laboratories, Llc | Identification of a novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity |
EP2427557B1 (de) | 2009-05-05 | 2015-03-18 | Boehringer Ingelheim International GmbH | Cho/cert-zelllinien |
CN103223177B (zh) * | 2009-05-06 | 2016-08-10 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
GB0908467D0 (en) * | 2009-05-15 | 2009-06-24 | Univ Gent | Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression |
WO2011005363A2 (en) * | 2009-05-18 | 2011-01-13 | Ensysce Biosciences, Inc. | Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
US8895527B2 (en) * | 2009-05-22 | 2014-11-25 | Curna, Inc. | Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
WO2010136417A1 (en) * | 2009-05-25 | 2010-12-02 | Università Degli Studi Di Roma "La Sapienza" | miR-31 IN DUCHENNE MUSCULAR DYSTROPHY THERAPY |
CN102449615B (zh) * | 2009-05-27 | 2014-11-26 | 甲骨文以色列有限公司 | 为基于事件的网络提供基于会话的服务 |
GB2471065A (en) * | 2009-06-10 | 2010-12-22 | Univ Sheffield | Modulator of claspin for treatment of cell proliferative disorder |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
NZ597504A (en) * | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
CN106983768B (zh) | 2009-06-17 | 2023-04-07 | 冷泉港实验室 | 用于在对象中调节smn2剪接的组合物和方法 |
WO2010151674A2 (en) * | 2009-06-26 | 2010-12-29 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
IL292615B2 (en) | 2009-07-01 | 2023-11-01 | Protiva Biotherapeutics Inc | Nucleic acid-lipid particles, preparations containing them and their uses |
CN102596993A (zh) | 2009-07-02 | 2012-07-18 | 安吉奥开米公司 | 多聚体肽结合物以及其应用 |
BR112012000828A8 (pt) | 2009-07-06 | 2017-10-10 | Ontorii Inc | Novas pró-drogas de ácido nucleico e métodos de uso das mesmas |
US8603814B2 (en) * | 2009-07-20 | 2013-12-10 | Rutgers The State University Of New Jersey | Method of inhibiting nonsense-mediated mRNA decay |
US9849146B2 (en) | 2009-07-20 | 2017-12-26 | Rutgers, The State University Of New Jersey | Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A |
KR101801407B1 (ko) * | 2009-07-24 | 2017-11-24 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료 |
WO2011019763A2 (en) * | 2009-08-10 | 2011-02-17 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for the treatment of krabbe and other neurodegenerative diseases |
WO2011019815A2 (en) * | 2009-08-11 | 2011-02-17 | Curna, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
EP3381937A3 (de) | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Verfahren zur modulierung der immunfunktion |
EP2810643A3 (de) | 2009-08-14 | 2015-03-11 | Alnylam Pharmaceuticals Inc. | Zusammensetzungen aus Lipidformulierung und Verfahren zur Hemmung der Expression eines Gens aus dem Ebola-Virus |
US8598327B2 (en) * | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
JP5943836B2 (ja) * | 2009-08-21 | 2016-07-05 | カッパーアールエヌエー,インコーポレイテッド | ‘hsp70相互作用タンパク質c末端’(chip)に対する天然アンチセンス転写産物の阻害によるchip関連疾患の治療 |
US9114197B1 (en) | 2014-06-11 | 2015-08-25 | Silver Bullett Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
WO2011031548A2 (en) | 2009-08-27 | 2011-03-17 | Silver Bullet Therapeutics, Inc. | Bone implants for the treatment of infection |
US8927004B1 (en) | 2014-06-11 | 2015-01-06 | Silver Bullet Therapeutics, Inc. | Bioabsorbable substrates and systems that controllably release antimicrobial metal ions |
US9821094B2 (en) | 2014-06-11 | 2017-11-21 | Silver Bullet Therapeutics, Inc. | Coatings for the controllable release of antimicrobial metal ions |
US10265435B2 (en) | 2009-08-27 | 2019-04-23 | Silver Bullet Therapeutics, Inc. | Bone implant and systems and coatings for the controllable release of antimicrobial metal ions |
US20120171213A1 (en) * | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
KR101774526B1 (ko) | 2009-09-11 | 2017-09-04 | 아이오니스 파마수티컬즈, 인코포레이티드 | 헌팅틴 발현의 조절 |
CN102639115A (zh) | 2009-09-15 | 2012-08-15 | 阿尔尼拉姆医药品有限公司 | 脂质配制的组合物及抑制eg5和vegf基因的表达的方法 |
WO2011038031A1 (en) | 2009-09-22 | 2011-03-31 | Alnylam Pharmaceuticals, Inc. | Dual targeting sirna agents |
EP2480668A2 (de) * | 2009-09-23 | 2012-08-01 | Protiva Biotherapeutics Inc. | Zusammensetzungen und verfahren zur ausschaltung von in krebs exprimierten genen |
CN102028947B (zh) * | 2009-09-29 | 2014-02-05 | 苏州瑞博生物技术有限公司 | Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途 |
BR112012007137A2 (pt) | 2009-09-30 | 2015-09-15 | Harvard College | metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia |
US8394778B1 (en) | 2009-10-08 | 2013-03-12 | Immune Disease Institute, Inc. | Regulators of NFAT and/or store-operated calcium entry |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
US20110104154A1 (en) * | 2009-10-30 | 2011-05-05 | Alcon Research, Ltd. | Single nucleotide polymorphisms and genes associated with age-related macular degeneration |
EP2496238A4 (de) | 2009-11-03 | 2013-10-02 | Alnylam Pharmaceuticals Inc | Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der transthyretinexpression |
US20120277144A1 (en) * | 2009-11-04 | 2012-11-01 | Henricus Johannes Duckers | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
CN101708328A (zh) * | 2009-11-06 | 2010-05-19 | 上海市免疫学研究所 | Cyr61蛋白在制药中的应用 |
US9799416B2 (en) * | 2009-11-06 | 2017-10-24 | Terrapower, Llc | Methods and systems for migrating fuel assemblies in a nuclear fission reactor |
WO2011057171A1 (en) | 2009-11-08 | 2011-05-12 | Quark Pharmaceuticals, Inc. | METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM |
PL2499249T3 (pl) | 2009-11-12 | 2019-03-29 | Univ Western Australia | Cząsteczki antysensowne i sposoby leczenia patologii |
EP2322927A1 (de) * | 2009-11-16 | 2011-05-18 | Deutsches Krebsforschungszentrum | Verbindungen zum Hemmen der CD95-Signalisierung bei der Behandlung von Pankreaskrebs |
ES2759003T3 (es) | 2009-11-26 | 2020-05-07 | Quark Pharmaceuticals Inc | Compuestos de ARNip que comprenden sustituciones terminales |
KR101168726B1 (ko) | 2009-11-30 | 2012-07-30 | 한국생명공학연구원 | 암 치료용 약학 조성물 |
US8710209B2 (en) | 2009-12-09 | 2014-04-29 | Nitto Denko Corporation | Modulation of HSP47 expression |
US9393129B2 (en) | 2009-12-10 | 2016-07-19 | DePuy Synthes Products, Inc. | Bellows-like expandable interbody fusion cage |
AU2014280918B2 (en) * | 2009-12-18 | 2016-11-17 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat HSF1-related diseases |
EP3000885B1 (de) | 2009-12-18 | 2018-07-25 | Arrowhead Pharmaceuticals, Inc. | Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen |
GB0922332D0 (en) * | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
EP2515947B1 (de) * | 2009-12-23 | 2021-10-06 | CuRNA, Inc. | Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2 |
DK2516648T3 (en) * | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
JP6141018B2 (ja) | 2009-12-24 | 2017-06-07 | バイオマリン テクノロジーズ ベー.フェー. | 炎症性障害を治療するための分子 |
WO2011084193A1 (en) | 2010-01-07 | 2011-07-14 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
AU2011203986C1 (en) | 2010-01-08 | 2015-03-05 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
ES2664866T3 (es) * | 2010-01-11 | 2018-04-23 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg |
WO2011088148A1 (en) * | 2010-01-12 | 2011-07-21 | Isis Pharmaceuticals, Inc. | Modulation of transforming growth factor-beta 1 expression |
US9198983B2 (en) * | 2010-01-25 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Mylip/Idol gene |
CA2789005A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
EP3208347B1 (de) | 2010-02-08 | 2019-08-14 | Ionis Pharmaceuticals, Inc. | Selektive reduktion von allelvarianten |
WO2011106689A1 (en) * | 2010-02-26 | 2011-09-01 | Isis Pharmaceuticals, Inc. | Modulation of smad3 expression |
US20130047297A1 (en) | 2010-03-08 | 2013-02-21 | Robert D. Sammons | Polynucleotide molecules for gene regulation in plants |
EP3578183B1 (de) | 2010-03-24 | 2021-09-08 | Phio Pharmaceuticals Corp. | Rna-interferenz bei augenerkrankungen |
RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
WO2011119887A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Rna interference in dermal and fibrotic indications |
US8853182B2 (en) * | 2010-03-26 | 2014-10-07 | The University Of Tokyo | Cell growth inhibitor and screening method thereof |
US8796240B2 (en) | 2010-03-26 | 2014-08-05 | The University Of Tokyo | Cell growth inhibitor and screening method thereof |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
AU2015268740B2 (en) * | 2010-04-06 | 2017-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
EP4385568A2 (de) * | 2010-04-06 | 2024-06-19 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression |
CN102985544A (zh) * | 2010-04-23 | 2013-03-20 | 诺瓦提斯公司 | 治疗β-ENaC-相关疾病的有机组合物 |
WO2011139917A1 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
KR20130101442A (ko) * | 2010-05-03 | 2013-09-13 | 큐알엔에이, 인크. | 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료 |
WO2011140365A1 (en) * | 2010-05-05 | 2011-11-10 | Auburn University | Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid |
WO2011146938A1 (en) * | 2010-05-21 | 2011-11-24 | NanoOncology, Inc. | Reagents and methods for treating cancer |
CA2801066C (en) * | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
RU2016118528A (ru) * | 2010-06-23 | 2018-10-31 | Курна, Инк. | Лечение заболеваний, связанных с альфа-субъединицей потенциалзависимого натриевого канала (scna), путем ингибирования природного антисмыслового транскрипта гена scna |
US8979860B2 (en) | 2010-06-24 | 2015-03-17 | DePuy Synthes Products. LLC | Enhanced cage insertion device |
US9282979B2 (en) | 2010-06-24 | 2016-03-15 | DePuy Synthes Products, Inc. | Instruments and methods for non-parallel disc space preparation |
WO2012003175A1 (en) | 2010-06-29 | 2012-01-05 | Synthes Usa, Llc | Distractible intervertebral implant |
FR2962041B1 (fr) * | 2010-07-01 | 2012-07-27 | Genethon | Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies |
CA2804210A1 (en) * | 2010-07-06 | 2012-01-12 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna |
CN106434648A (zh) | 2010-07-19 | 2017-02-22 | F·C·贝内特 | 肌强直性营养障碍蛋白激酶(dmpk)表达的调节 |
BR112013001918A2 (pt) | 2010-07-28 | 2016-05-24 | Alcon Res Ltd | sirna direcionado para vegfa e métodos para tratamento in vivo |
US8455304B2 (en) | 2010-07-30 | 2013-06-04 | Atmel Corporation | Routable array metal integrated circuit package fabricated using partial etching process |
WO2012023288A1 (en) * | 2010-08-20 | 2012-02-23 | Oncotherapy Science, Inc. | Fam161a as a target gene for cancer therapy and diagnosis |
US9233997B2 (en) * | 2010-08-26 | 2016-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) |
EP3118316A1 (de) | 2010-09-02 | 2017-01-18 | Université de Mons | Zur behandlung von fazioskapulohumeraler muskeldystrophie nützliche wirkstoffe |
RU2710717C2 (ru) | 2010-09-09 | 2020-01-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1ВВ |
US20140141015A1 (en) * | 2010-09-20 | 2014-05-22 | Douglas Lake | QSOX1 as an Anti-Neoplastic Drug Target |
US8946186B2 (en) * | 2010-09-20 | 2015-02-03 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University | QSOX1 as an anti-neoplastic drug target |
US8217163B2 (en) * | 2010-09-20 | 2012-07-10 | Biomics Biotechnologies Co., Ltd. | Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas |
WO2012039137A2 (en) * | 2010-09-22 | 2012-03-29 | National University Corporation Hokkaido University | A nucleic acid having an anti-metabolic syndrome effect |
WO2012039448A1 (ja) | 2010-09-24 | 2012-03-29 | 株式会社キラルジェン | 不斉補助基 |
EP2623600A4 (de) * | 2010-09-30 | 2014-11-26 | Lsip Llc | Hemmer der expression dominant mutierter gene |
US20120083035A1 (en) | 2010-09-30 | 2012-04-05 | Dharmacon, Inc. | Modified Cell Lines for Increasing Lentiviral Titers |
WO2012044620A2 (en) * | 2010-09-30 | 2012-04-05 | Nitto Denko Corporation | Modulation of timp1 and timp2 expression |
WO2012048316A2 (en) * | 2010-10-08 | 2012-04-12 | Immune Disease Institute, Inc. | Regulators of nfat and/or store-operated calcium entry |
US9402732B2 (en) | 2010-10-11 | 2016-08-02 | DePuy Synthes Products, Inc. | Expandable interspinous process spacer implant |
CA2818662C (en) | 2010-10-22 | 2021-07-06 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid molecule inducing rna interference, and uses thereof |
CA2815116A1 (en) | 2010-10-27 | 2012-05-03 | Devgen Nv | Down-regulating gene expression in insect pests |
WO2012056441A1 (en) * | 2010-10-28 | 2012-05-03 | Nanodoc Ltd. | Compositions and methods for specific cleavage of exogenous rna in a cell |
JP2013545736A (ja) * | 2010-10-29 | 2013-12-26 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Pcsk9遺伝子の阻害のための組成物および方法 |
WO2012064758A2 (en) | 2010-11-08 | 2012-05-18 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
EP2637608B1 (de) | 2010-11-12 | 2016-03-02 | Silver Bullet Therapeutics Inc. | Knochenimplantat und systeme zur kontrollierten freisetzung von silber |
JP6336755B2 (ja) | 2010-11-12 | 2018-06-06 | ザ ジェネラル ホスピタル コーポレイション | ポリコームに関連する非コードrna |
US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
JP6126009B2 (ja) | 2010-11-17 | 2017-05-10 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | α−シヌクレイン発現の調節 |
KR102010598B1 (ko) * | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료 |
WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
WO2012078536A2 (en) * | 2010-12-06 | 2012-06-14 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
EP2648763A4 (de) * | 2010-12-10 | 2014-05-14 | Alnylam Pharmaceuticals Inc | Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a |
US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
EP2652135A1 (de) * | 2010-12-17 | 2013-10-23 | Université Pierre et Marie Curie (Paris 6) | Abcg1-gen als marker und zielgen zur behandlung von adipositas |
ES2710109T3 (es) * | 2010-12-17 | 2019-04-23 | Inst Nat Sante Rech Med | Acidos nucleicos que se dirigen a TCTP para su uso en el tratamiento de cánceres quimiorresistentes u hormonorresistentes |
US9644042B2 (en) | 2010-12-17 | 2017-05-09 | Carnegie Mellon University | Electrochemically mediated atom transfer radical polymerization |
WO2012094115A1 (en) * | 2010-12-17 | 2012-07-12 | Arrowhead Research Corporation | Compositions and methods for inhibiting expression of flt3 genes |
WO2012083363A1 (en) * | 2010-12-22 | 2012-06-28 | Murdoch Childrens Research Institute | A method of treatment |
AU2011353283A1 (en) * | 2010-12-30 | 2013-07-18 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of Hif1alpha expression and anticancer composition containing the same |
AU2012209074A1 (en) | 2011-01-25 | 2013-07-11 | Almac Diagnostics Limited | Colon cancer gene expression signatures and methods of use |
US20120197320A1 (en) * | 2011-01-28 | 2012-08-02 | Laser Spine Surgical Center, LLC | Foraminoplasty Device |
WO2012106175A1 (en) * | 2011-02-02 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma |
PL2670411T3 (pl) | 2011-02-02 | 2019-09-30 | Excaliard Pharmaceuticals, Inc. | Związki antysensowne ukierunkowane na czynnik wzrostu tkanki łącznej (ctgf) do leczenia bliznowców lub blizn przerostowych |
US8394129B2 (en) * | 2011-03-10 | 2013-03-12 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US8518087B2 (en) * | 2011-03-10 | 2013-08-27 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
WO2012122645A1 (en) * | 2011-03-11 | 2012-09-20 | Sarissa Inc. | Methods of treating cancer by inhibition of dna repair proteins |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
KR102481317B1 (ko) | 2011-03-29 | 2022-12-26 | 알닐람 파마슈티칼스 인코포레이티드 | Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법 |
US8816056B2 (en) | 2011-04-01 | 2014-08-26 | Isis Pharmaceuticals, Inc. | Modulation of signal transducer and activator of transcription 3 (STAT3)expression |
CN103547588B (zh) | 2011-04-13 | 2016-06-29 | Isis制药公司 | Ptp1b表达的反义调节 |
US10941399B2 (en) * | 2011-04-14 | 2021-03-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction |
SG10201604074TA (en) | 2011-04-21 | 2016-07-28 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
TW201243330A (en) * | 2011-04-22 | 2012-11-01 | Univ Nat Cheng Kung | Method for analyzing sectretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis |
EP2717883B1 (de) | 2011-05-02 | 2017-03-22 | Stichting VUmc | Schutz gegen barrier endotheliale dysfunktion durch inhibition von abl-gen assoziiert tyrosinkinase (arg) |
AU2012268619B2 (en) * | 2011-06-06 | 2017-08-17 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of isocitrate dehydrogenase (IDH1) gene expression |
CN103620036B (zh) * | 2011-06-09 | 2016-12-21 | 库尔纳公司 | 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病 |
US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
US9315811B2 (en) | 2011-06-10 | 2016-04-19 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
EP2721156B1 (de) | 2011-06-16 | 2016-12-21 | Ionis Pharmaceuticals, Inc. | Antisense-modulierung der expression des fibroblastenwachstumsfaktor-rezeptors 4 |
JP5993002B2 (ja) * | 2011-06-21 | 2016-09-14 | ミナ セラピューティクス リミテッド | アルブミン産生及び細胞増殖 |
WO2012177949A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP2723861A4 (de) * | 2011-06-21 | 2014-12-10 | Alnylam Pharmaceuticals Inc | Zusammensetzungen und verfahren zur hemmung des hepcidin-antimikrobiellen peptids (hamp) oder der damit zusammenhängenden genexpression |
US9315813B2 (en) | 2011-06-21 | 2016-04-19 | Alnylam Pharmaceuticals, Inc | Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes |
ES2923573T3 (es) | 2011-06-21 | 2022-09-28 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas |
FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Turun Yliopisto | Yhdistelmähoito |
WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
US9322021B2 (en) | 2011-06-29 | 2016-04-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
ES2907620T3 (es) | 2011-07-18 | 2022-04-25 | Univ Kentucky Res Found | Protección de células de la degeneración inducida por ARN Alu e inhibidores para proteger células |
US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
EP2739735A2 (de) * | 2011-08-01 | 2014-06-11 | Alnylam Pharmaceuticals, Inc. | Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten |
EP2742136B1 (de) | 2011-08-11 | 2017-09-27 | Ionis Pharmaceuticals, Inc. | Gapmerverbindungen mit 5'-modifizierten desoxyribonukleotiden im gap und verwendungen davon |
WO2013028756A1 (en) | 2011-08-22 | 2013-02-28 | Carnegie Mellon University | Atom transfer radical polymerization under biologically compatible conditions |
KR101275264B1 (ko) * | 2011-08-24 | 2013-06-17 | 포항공과대학교 산학협력단 | 샤프로닌 단백질의 조절 물질 탐색 방법 |
EP3640332A1 (de) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-konjugat-komplexe und deren verwendung |
US9617538B2 (en) * | 2011-08-29 | 2017-04-11 | Niigata University Of Pharmacy And Applied Life Science | Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells |
WO2013030778A2 (en) | 2011-09-02 | 2013-03-07 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
FI20115876A0 (fi) | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Yhdistelmähoito |
WO2013036879A1 (en) * | 2011-09-08 | 2013-03-14 | Gradalis, Inc. | Compositions and methods for treating prostate cancer |
MX343072B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para controlar malezas. |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
AU2012308686B2 (en) | 2011-09-13 | 2018-05-10 | Monsanto Technology Llc | Methods and compositions for weed control |
CA2848689A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control targeting pds |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
UA116092C2 (uk) * | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
MX362812B (es) | 2011-09-13 | 2019-02-13 | Monsanto Technology Llc | Metodos y composiciones para el control de malezas. |
JP6018068B2 (ja) * | 2011-09-14 | 2016-11-02 | 日本化薬株式会社 | 細胞の増殖抑制方法、nek10バリアント遺伝子に対するrna干渉作用を有する核酸分子、及び抗癌剤 |
US11058708B2 (en) * | 2011-09-19 | 2021-07-13 | Sweyshen Chen | RNA interference of galectin-3 expression and methods of use thereof |
AU2012312433B2 (en) | 2011-09-20 | 2017-07-06 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCGR expression |
US9453261B2 (en) * | 2011-09-20 | 2016-09-27 | The George Washington University | Alternative splicing variants of genes associated with prostate cancer risk and survival |
US9481895B2 (en) | 2011-09-23 | 2016-11-01 | Ge Healthcare Dharmacon, Inc. | Introduction of modular vector elements during production of a lentivirus |
WO2013048345A1 (en) * | 2011-09-28 | 2013-04-04 | Agency For Science, Technology And Research | Methods and pharmaceutical compositions for treating cancer |
JP2013079210A (ja) * | 2011-10-04 | 2013-05-02 | Nagoya City Univ | 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法 |
US9382534B2 (en) | 2011-10-05 | 2016-07-05 | Ge Healthcare Dharmacon, Inc. | Optimization of vectors for effective delivery and expression of genetic content |
BR112014009790A2 (pt) | 2011-10-25 | 2018-05-15 | Isis Pharmaceuticals Inc | composto para modulação antisense da expressão de gccr, seu uso e composição |
US9622779B2 (en) | 2011-10-27 | 2017-04-18 | DePuy Synthes Products, Inc. | Method and devices for a sub-splenius / supra-levator scapulae surgical access technique |
US9773091B2 (en) | 2011-10-31 | 2017-09-26 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
CN102373206B (zh) * | 2011-10-31 | 2013-02-27 | 暨南大学 | 靶向抑制PPP2R5C基因表达和肿瘤T细胞增殖的PPP2R5C-siRNA799及其应用 |
WO2013067001A1 (en) * | 2011-10-31 | 2013-05-10 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
WO2013067179A2 (en) | 2011-11-01 | 2013-05-10 | Synthes Usa, Llc | Dilation system |
ES2761343T3 (es) | 2011-11-07 | 2020-05-19 | Ionis Pharmaceuticals Inc | Modulación de la expresión de TMPRSS6 |
WO2013071022A1 (en) | 2011-11-10 | 2013-05-16 | Shire Human Genetic Therapies, Inc. | Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof |
US9006199B2 (en) * | 2011-11-14 | 2015-04-14 | Silenseed Ltd. | Methods and compositions for treating prostate cancer |
JP6093775B2 (ja) * | 2011-11-17 | 2017-03-08 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 自動認識治療用r/dnaキメラナノ粒子(np) |
KR102095699B1 (ko) | 2011-11-18 | 2020-04-02 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법 |
WO2013075233A1 (en) * | 2011-11-21 | 2013-05-30 | The Royal Institution For The Advancement Of Learning / Mcgill University | Method for treating brain cancer |
US9546367B2 (en) * | 2011-12-07 | 2017-01-17 | Jenny Chee Ning Chang | siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer |
CA2860676A1 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
US9707235B1 (en) | 2012-01-13 | 2017-07-18 | University Of Kentucky Research Foundation | Protection of cells from degeneration and treatment of geographic atrophy |
CA2862628C (en) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
EP2814455B1 (de) | 2012-02-13 | 2017-07-19 | Unilever N.V. | Hautaufhellende zusammensetzung |
KR102384791B1 (ko) | 2012-02-24 | 2022-04-08 | 아뷰터스 바이오파마 코포레이션 | 트리알킬 양이온성 지질 및 그의 사용 방법 |
US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
WO2013138668A1 (en) * | 2012-03-16 | 2013-09-19 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of mcl1 by double-stranded rna |
US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
ES2742284T3 (es) | 2012-03-28 | 2020-02-13 | Somalogic Inc | Aptámeros contra PDGF y VEGF y su utilización en el tratamiento de afecciones mediadas por PDGF y VEGF |
KR20140139512A (ko) * | 2012-03-29 | 2014-12-05 | 고쿠리쓰다이가쿠호진 규슈다이가쿠 | 페리오스틴 유전자의 발현 억제 핵산 분자, 페리오스틴 유전자의 발현 억제 방법 및 그 용도 |
WO2013149191A1 (en) * | 2012-03-29 | 2013-10-03 | The Trustees Of Columbia University In The City Of New York | Methods for regulating hair growth disorders |
WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
WO2013151058A1 (ja) * | 2012-04-03 | 2013-10-10 | 独立行政法人国立成育医療研究センター | miR-140の発現を制御するDNA及び該DNAを利用した薬剤のスクリーニング方法 |
US9133461B2 (en) * | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US9265490B2 (en) | 2012-04-16 | 2016-02-23 | DePuy Synthes Products, Inc. | Detachable dilator blade |
WO2013158046A1 (en) * | 2012-04-20 | 2013-10-24 | Agency For Science, Technology And Research | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies |
US10407677B2 (en) * | 2012-04-26 | 2019-09-10 | Intana Bioscience Gmbh | High complexity siRNA pools |
US9127274B2 (en) * | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
TWI480043B (zh) * | 2012-05-01 | 2015-04-11 | Univ Kaohsiung Medical | 用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物 |
MX2014013367A (es) * | 2012-05-02 | 2014-12-08 | Novartis Ag | Composiciones organicas para tratar enfermedades relacionadas con kras. |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
EA201492123A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии семейства генов smn |
CA2873779A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating mecp2 expression |
AU2013262699A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating ATP2A2 expression |
AP2014008100A0 (en) | 2012-05-16 | 2014-12-31 | Gen Hospital Corp | Compositions and methods for modulating hemoglobingene family expression |
CA2873797A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating utrn expression |
US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
KR101567576B1 (ko) | 2012-05-22 | 2015-11-10 | 올릭스 주식회사 | 세포 내 관통능을 가지고 rna 간섭을 유도하는 핵산 분자 및 그 용도 |
EP2852606B1 (de) | 2012-05-22 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation der durch verstärker-rns vermittelten genexpression |
IN2014MN02404A (de) | 2012-05-24 | 2015-08-21 | Seeds Ltd Ab | |
US9828602B2 (en) * | 2012-06-01 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
WO2013181666A2 (en) | 2012-06-01 | 2013-12-05 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
US9201916B2 (en) * | 2012-06-13 | 2015-12-01 | Infosys Limited | Method, system, and computer-readable medium for providing a scalable bio-informatics sequence search on cloud |
CN102703451B (zh) * | 2012-06-21 | 2013-04-17 | 浙江省医学科学院 | 一种抑制Bcl2基因表达的表达盒及含有该表达盒的载体 |
CN102703452B (zh) * | 2012-06-21 | 2013-06-05 | 浙江省医学科学院 | 一种抑制Bcl2基因表达的siRNA双链及其应用 |
AR091512A1 (es) * | 2012-06-22 | 2015-02-11 | Syngenta Participations Ag | Control biologico de plagas de coleopteros |
CA2877905A1 (en) | 2012-06-25 | 2014-01-03 | Isis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
ES2627500T3 (es) | 2012-07-13 | 2017-07-28 | Turun Yliopisto | Terapia de combinación |
KR20220139425A (ko) | 2012-07-13 | 2022-10-14 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
CN103540655A (zh) * | 2012-07-16 | 2014-01-29 | 复旦大学 | Mk5基因在筛选抗肝癌药物中的应用 |
WO2014018098A1 (en) | 2012-07-26 | 2014-01-30 | DePuy Synthes Products, LLC | Expandable implant |
JP6327713B2 (ja) * | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
WO2014022655A1 (en) * | 2012-08-01 | 2014-02-06 | The Trustees Of Columbia University In The City Of New York | Methods for regulating hair growth disorders |
KR101520383B1 (ko) | 2012-08-02 | 2015-05-15 | 에이비온 주식회사 | Hpv 감염과 관련된 암의 치료용 조성물 |
CA2874864C (en) | 2012-08-14 | 2023-02-21 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US20140067069A1 (en) | 2012-08-30 | 2014-03-06 | Interventional Spine, Inc. | Artificial disc |
CA2883356A1 (en) * | 2012-08-30 | 2014-03-06 | Turun Yliopisto | Method of selecting individualized brain cancer therapy |
EP3441467A3 (de) * | 2012-08-31 | 2019-04-24 | The General Hospital Corporation | Biotinkomplexe zur behandlung und diagnose von morbus alzheimer |
US20140066595A1 (en) * | 2012-09-04 | 2014-03-06 | Thermo Fisher Scientific Biosciences Inc. | Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom |
GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
IN2015DN02699A (de) | 2012-09-05 | 2015-09-04 | Sylentis Sau | |
US9932578B2 (en) | 2012-09-12 | 2018-04-03 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to P53 and methods of use thereof |
NZ615098A (en) * | 2012-09-13 | 2015-05-29 | Seminis Vegetable Seeds Inc | Genetic markers for myb28 |
US9480855B2 (en) | 2012-09-26 | 2016-11-01 | DePuy Synthes Products, Inc. | NIR/red light for lateral neuroprotection |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
ES2907254T3 (es) | 2012-10-11 | 2022-04-22 | Ionis Pharmaceuticals Inc | Un compuesto antisentido modificado para su uso en el tratamiento de la enfermedad de Kennedy |
US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
DK2906696T4 (da) | 2012-10-15 | 2023-02-27 | Ionis Pharmaceuticals Inc | Fremgangsmåder til modulering af c9orf72-ekspression |
WO2014062736A1 (en) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
RU2730677C2 (ru) | 2012-10-15 | 2020-08-24 | Ионис Фармасьютикалз, Инк. | Соединение для модуляции экспрессии гена c9orf72 и его применение |
WO2014060392A1 (en) * | 2012-10-16 | 2014-04-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders |
US10206911B2 (en) | 2012-10-26 | 2019-02-19 | Memorial Sloan-Kettering Cancer Center | Androgen receptor variants and methods for making and using |
WO2014076703A1 (en) * | 2012-11-14 | 2014-05-22 | Silenseed Ltd. | Methods and compositions for treating cancer |
WO2014077693A1 (en) * | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
CA2892860C (en) | 2012-11-27 | 2023-01-03 | Children's Medical Center Corporation | Targeting bcl11a distal regulatory elements for fetal hemoglobin reinduction |
HUE035887T2 (en) | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
CA2893824A1 (en) * | 2012-12-14 | 2014-06-19 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of ckap5 by double-stranded rna |
US9198674B2 (en) * | 2012-12-14 | 2015-12-01 | Warsaw Orthopedic, Inc. | Surgical instrument and method |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
CN105358695B (zh) | 2013-01-01 | 2019-07-12 | A.B.种子有限公司 | 将dsRNA引入植物种子以调节基因表达的方法 |
WO2014110291A1 (en) | 2013-01-09 | 2014-07-17 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
WO2014113431A2 (en) * | 2013-01-15 | 2014-07-24 | Tufts Medical Center | Methods and compositions for targeting immunoglobulins |
KR101409445B1 (ko) * | 2013-01-17 | 2014-06-24 | 한국과학기술연구원 | OTUB1 발현을 저해하는 siRNA 및 이를 포함하는 약제학적 조성물 |
KR101480523B1 (ko) * | 2013-02-07 | 2015-01-08 | 고려대학교 산학협력단 | 세포 내 rpS3 발현 억제를 위한 siRNA |
BR112015019515A8 (pt) | 2013-02-14 | 2017-10-03 | Isis Pharmaceuticals Inc | Modulação da expressão de apolipoproteí-na c-iii (apociii) em populações deficientes de lipopro-teína lipase (lpld) |
DE102013003869B4 (de) * | 2013-02-27 | 2016-11-24 | Friedrich-Schiller-Universität Jena | Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung |
CA2902393C (en) | 2013-02-28 | 2022-11-01 | Arrowhead Research Corporation | Organic compositions to treat epas1-related diseases |
US9717601B2 (en) | 2013-02-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
US9522070B2 (en) | 2013-03-07 | 2016-12-20 | Interventional Spine, Inc. | Intervertebral implant |
US9277928B2 (en) | 2013-03-11 | 2016-03-08 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
US9265789B2 (en) * | 2013-03-12 | 2016-02-23 | The Medical College Of Wisconsin, Inc. | Targeting CLPTM1L by RNA interference for treatment and prevention of cancer |
CA2905027A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
EP2967082A4 (de) | 2013-03-13 | 2016-11-02 | Monsanto Technology Llc | Verfahren und zusammensetzungen zur unkrautbekämpfung |
WO2014153118A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
ES2807379T3 (es) | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Composiciones y métodos para regular la expresión de Tau |
US9993353B2 (en) | 2013-03-14 | 2018-06-12 | DePuy Synthes Products, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
SI2970974T1 (sl) * | 2013-03-14 | 2017-12-29 | Alnylam Pharmaceuticals, Inc. | Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe |
EA202090946A3 (ru) | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии |
US9480574B2 (en) | 2013-03-14 | 2016-11-01 | Benvenue Medical, Inc. | Spinal fusion implants and devices and methods for deploying such implants |
WO2014140856A2 (en) | 2013-03-15 | 2014-09-18 | Graham Lord | Mir-142 and antagonists thereof for treating disease |
EP3662912A1 (de) | 2013-03-15 | 2020-06-10 | Sarepta Therapeutics, Inc. | Verbesserte eteplirsen dosierungen zur behandlung von duchenne muskeldystrophie |
SG11201507141SA (en) * | 2013-03-15 | 2015-10-29 | Techulon Inc | Antisense molecules for treatment of staphylococcus aureus infection |
US11342048B2 (en) | 2013-03-15 | 2022-05-24 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
US9132174B2 (en) | 2013-03-15 | 2015-09-15 | Anchored Rsk3 Inhibitors, Llc | Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3) |
WO2014144799A2 (en) | 2013-03-15 | 2014-09-18 | New York University | siRNA TARGETING HSR1 |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
US9418203B2 (en) | 2013-03-15 | 2016-08-16 | Cypher Genomics, Inc. | Systems and methods for genomic variant annotation |
US10235496B2 (en) | 2013-03-15 | 2019-03-19 | The Scripps Research Institute | Systems and methods for genomic annotation and distributed variant interpretation |
WO2014148529A1 (ja) * | 2013-03-21 | 2014-09-25 | 学校法人埼玉医科大学 | 二本鎖核酸分子、dna、ベクター、癌細胞増殖抑制剤、及び医薬 |
CN103205400B (zh) * | 2013-04-19 | 2014-09-17 | 青岛大学医学院附属医院 | 含有人泛素特异性蛋白酶基因USP39-shRNA的重组慢病毒及其应用 |
US9264644B2 (en) * | 2013-04-25 | 2016-02-16 | Forza Silicon Corporation | Analog-to-digital conversion for image sensor with non-destructive read pixel |
EP2992009B1 (de) | 2013-05-01 | 2020-06-24 | Ionis Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur modulation der apolipoprotein(a)-expression |
EP2991686A4 (de) | 2013-05-03 | 2017-04-05 | President and Fellows of Harvard College | Fremd-dna-überwachungsprotein |
IL293657A (en) | 2013-05-22 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Preparations of tmprss6 irna and methods of using them |
CN113018307A (zh) | 2013-05-22 | 2021-06-25 | 阿尔尼拉姆医药品有限公司 | SERPINA1 iRNA组合物及其使用方法 |
WO2014187964A2 (en) * | 2013-05-23 | 2014-11-27 | University Of Bremen | Novel treatment of metabolic diseases |
WO2014189996A1 (en) * | 2013-05-24 | 2014-11-27 | Nikolai Khodarev | Anti-tumor therapy |
JP2016524621A (ja) | 2013-06-03 | 2016-08-18 | バル−イラン ユニバーシティ | ウィスコットアルドリッチ症候群タンパク質を変調するリポソーム |
EP3888640A1 (de) * | 2013-06-05 | 2021-10-06 | AgeX Therapeutics, Inc. | Zusammensetzungen und verfahren zur induzierten geweberegeneration in säugerspezies |
US9522028B2 (en) | 2013-07-03 | 2016-12-20 | Interventional Spine, Inc. | Method and apparatus for sacroiliac joint fixation |
US9512430B2 (en) | 2013-07-03 | 2016-12-06 | Wisconsin Alumni Research Foundation | Compositions and methods to promote erythropoiesis |
JP2016528887A (ja) | 2013-07-03 | 2016-09-23 | ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. | 二本鎖RNAによるα−1アンチトリプシンの特異的阻害のための方法及び組成物 |
KR102306656B1 (ko) * | 2013-07-03 | 2021-09-29 | 삼성전자주식회사 | 항 c-Met 항체를 이용하는 암의 병용 치료 |
KR20150006743A (ko) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
KR20150006742A (ko) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
JP2016528897A (ja) * | 2013-08-16 | 2016-09-23 | ラナ セラピューティクス インコーポレイテッド | Rnaを調節するための組成物および方法 |
US10144928B2 (en) | 2013-08-23 | 2018-12-04 | Quark Pharmaceuticals, Inc. | Double stranded oligonucleotide compounds comprising positional modifications |
US9670492B2 (en) | 2013-08-28 | 2017-06-06 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (PKK) expression |
EP3041861B1 (de) * | 2013-09-05 | 2019-03-27 | Inis Biotech LLC | Sparc (sekretiertes protein, sauer und reich an cystein), ein neues ziel zur behandlung und prävention von akuter leberinsuffizienz |
CN111235149B (zh) * | 2013-09-05 | 2024-04-16 | 萨罗塔治疗公司(美国) | 酸性α-葡糖苷酶中反义诱导的外显子2纳入 |
US9695424B2 (en) | 2013-09-09 | 2017-07-04 | Somalogic, Inc. | PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders |
LT3043827T (lt) * | 2013-09-13 | 2019-08-12 | Ionis Pharmaceuticals, Inc. | Komplemento faktoriaus b moduliatoriai |
EP2853596A1 (de) * | 2013-09-30 | 2015-04-01 | IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) | Proteinphosphatasehemmer |
EP3052626A1 (de) * | 2013-10-02 | 2016-08-10 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur hemmung der lect2-genexpression |
EP3739049A1 (de) * | 2013-10-02 | 2020-11-18 | Albert Einstein College of Medicine | Verfahren und zusammensetzungen zur hemmung von metastasen, zur behandlung von fibrose und zur wundheilungsförderung |
PL3052628T3 (pl) * | 2013-10-04 | 2020-08-24 | Alnylam Pharmaceuticals, Inc. | Kompozycje i sposoby hamowania ekspresji genu ALAS1 |
SG11201602597YA (en) | 2013-10-11 | 2016-05-30 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
EP2865758A1 (de) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des ORAI1-Gens |
EP2865757A1 (de) * | 2013-10-22 | 2015-04-29 | Sylentis, S.A.U. | siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des PDK1-Gens |
MX2016005778A (es) | 2013-11-04 | 2016-12-20 | Monsanto Technology Llc | Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos. |
JP6672156B2 (ja) | 2013-11-11 | 2020-03-25 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸(siNA)の全身性送達 |
KR102507624B1 (ko) | 2013-11-22 | 2023-03-09 | 미나 테라퓨틱스 리미티드 | C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법 |
EP3079707A4 (de) | 2013-12-02 | 2017-10-18 | RXi Pharmaceuticals Corporation | Immuntherapie für krebs |
AU2014360314B2 (en) | 2013-12-06 | 2018-04-26 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
EP3087183B1 (de) | 2013-12-24 | 2020-08-26 | Ionis Pharmaceuticals, Inc. | Modulation einer angiopoietin-3-ähnlichen expression |
WO2015100436A1 (en) | 2013-12-27 | 2015-07-02 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna |
AU2015206585A1 (en) | 2014-01-15 | 2016-07-21 | Monsanto Technology Llc | Methods and compositions for weed control using EPSPS polynucleotides |
WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
EP3095461A4 (de) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator |
PT3094728T (pt) | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Desenho quiral |
CN104805085A (zh) * | 2014-01-29 | 2015-07-29 | 江苏命码生物科技有限公司 | 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用 |
JP6594902B2 (ja) | 2014-02-11 | 2019-10-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | ケトヘキソキナーゼ(KHK)iRNA組成物及びその使用方法 |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
KR101425140B1 (ko) * | 2014-02-19 | 2014-08-13 | 한국과학기술원 | Lin28a 메틸화 억제제를 포함하는 줄기세포 전능화 조절용 조성물 및 lin28a 메틸화 억제제의 스크리닝 방법 |
CN106132436B (zh) | 2014-02-21 | 2021-06-15 | Ibc药品公司 | 通过诱导对trop-2表达细胞的免疫应答的疾病疗法 |
CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
US10011837B2 (en) | 2014-03-04 | 2018-07-03 | Sylentis Sau | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions |
CN104894223B (zh) * | 2014-03-07 | 2019-03-26 | 上海吉凯基因化学技术有限公司 | 人copb2基因的用途及其相关药物 |
WO2015137459A1 (ja) * | 2014-03-13 | 2015-09-17 | 協和発酵キリン株式会社 | Irf5の発現を抑制する核酸 |
WO2015143078A1 (en) * | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
ES2890677T3 (es) | 2014-03-19 | 2022-01-21 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresión de ataxina 2 |
DK3119887T3 (da) * | 2014-03-20 | 2019-05-20 | Oommen Varghese | Forbedrede korte interfererende ribonukleinsyremolekyler |
WO2015153800A2 (en) | 2014-04-01 | 2015-10-08 | Isis Pharmaceuticals, Inc. | Compositions for modulating sod-1 expression |
EP3125676A4 (de) | 2014-04-01 | 2018-02-14 | Monsanto Technology LLC | Zusammensetzungen und verfahren zur bekämpfung von insektenbefall |
CN112159807A (zh) * | 2014-04-04 | 2021-01-01 | 柏业公司 | 新颖的双链寡rna和包含它的用于预防或治疗纤维化或呼吸系统疾病的药物组合物 |
ES2932304T3 (es) | 2014-04-17 | 2023-01-17 | Biogen Ma Inc | Composiciones y métodos para la modulación del empalme de SMN2 en un sujeto |
WO2015164750A2 (en) | 2014-04-25 | 2015-10-29 | Children's Medical Center Corporation | Compositions and methods to treating hemoglobinopathies |
CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
EP3137091B1 (de) | 2014-05-01 | 2020-12-02 | Ionis Pharmaceuticals, Inc. | Konjugate von antisens-oligonukleotiden und deren verwendung zur modulation der pkk-expression |
ES2745825T3 (es) * | 2014-05-01 | 2020-03-03 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor B del complemento |
WO2015168589A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
CN110903337A (zh) | 2014-05-01 | 2020-03-24 | Ionis制药公司 | 用于调节生长激素受体表达的组合物和方法 |
JP6795492B2 (ja) * | 2014-05-23 | 2020-12-02 | ウニヴェルシタ デッリ ストゥディ デラクイア | CLCN7(ADO2 CLCN7依存性)遺伝子変異によって引き起こされる常染色体優性大理石骨病2型(ADO2)療法のための短鎖干渉RNA(siRNA) |
KR20150137473A (ko) * | 2014-05-29 | 2015-12-09 | 한국과학기술연구원 | USP15의 발현을 저해하는 siRNA 및 이를 포함하는 약제학적 조성물 |
KR20170012366A (ko) | 2014-06-04 | 2017-02-02 | 교와 핫꼬 기린 가부시키가이샤 | CKAP5 유전자 발현 억제 RNAi 의약 조성물 |
US9452242B2 (en) | 2014-06-11 | 2016-09-27 | Silver Bullet Therapeutics, Inc. | Enhancement of antimicrobial silver, silver coatings, or silver platings |
TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
CA2953347A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
WO2015200539A1 (en) | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
US10314605B2 (en) | 2014-07-08 | 2019-06-11 | Benvenue Medical, Inc. | Apparatus and methods for disrupting intervertebral disc tissue |
EP3174982A4 (de) | 2014-07-29 | 2018-06-20 | Monsanto Technology LLC | Zusammensetzungen und verfahren zur bekämpfung von insektenbefall |
AU2015301221B2 (en) | 2014-08-04 | 2020-07-02 | MiRagen Therapeutics, Inc. | Inhibitors of MYH7B and uses thereof |
US9980737B2 (en) | 2014-08-04 | 2018-05-29 | Medos International Sarl | Flexible transport auger |
US20170137820A1 (en) * | 2014-08-06 | 2017-05-18 | Bavarian Nordic A/S | Agonists and antagonists of toll-like receptor (tlr) 13 |
GB2547586A (en) * | 2014-08-20 | 2017-08-23 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof(In the PCT request) |
KR102631505B1 (ko) | 2014-08-29 | 2024-02-01 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법 |
CA2959386C (en) * | 2014-08-29 | 2024-06-04 | Lee Adam Wheeler | Methods and compositions for the treatment of cancer |
US10731163B2 (en) * | 2014-09-02 | 2020-08-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Oligonucleotide targeted to the A20-3′ untranslated region |
US10900039B2 (en) * | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
WO2016040167A1 (en) * | 2014-09-08 | 2016-03-17 | Brandon Higgs | Compositions and methods for detecting and treating small cell lung cancer |
US10264959B2 (en) | 2014-09-09 | 2019-04-23 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US9924979B2 (en) | 2014-09-09 | 2018-03-27 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
US10111712B2 (en) | 2014-09-09 | 2018-10-30 | Medos International Sarl | Proximal-end securement of a minimally invasive working channel |
WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
KR20170058979A (ko) * | 2014-09-18 | 2017-05-29 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 헌팅턴병 일배체형에 대한 대립 유전자-특이적 치료 |
US9777279B2 (en) * | 2014-09-24 | 2017-10-03 | University Of Cincinnati | Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles |
JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
WO2016061487A1 (en) * | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
KR101646609B1 (ko) * | 2014-10-24 | 2016-08-08 | 한국원자력의학원 | 후두암 또는 후두암의 방사선 저항성의 진단을 위한 조성물 및 진단 방법 |
WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
US10302644B2 (en) * | 2014-11-04 | 2019-05-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating multiple myeloma |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
WO2016077566A1 (en) * | 2014-11-12 | 2016-05-19 | Research Institute At Nationwide Children's Hospital | Modulation of alternative mdm2 splicing |
US10287584B2 (en) * | 2014-11-12 | 2019-05-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of COMP |
US10364433B2 (en) | 2014-11-14 | 2019-07-30 | The Regents Of The University Of California | Modulation of AGPAT5 expression |
MX2017006216A (es) | 2014-11-14 | 2018-08-29 | Voyager Therapeutics Inc | Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela). |
EP3221451A1 (de) | 2014-11-17 | 2017-09-27 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein-c3 (apoc3)-irna-zusammensetzungen und verfahren zur verwendung davon |
WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
CN104450710B (zh) * | 2014-11-28 | 2018-06-05 | 广州市锐博生物科技有限公司 | 抑制myd88基因的寡聚核酸及其应用 |
US9714424B1 (en) * | 2014-12-16 | 2017-07-25 | Icahn School Of Medicine At Mount Sinai | RNAi inhibition of USP10 to treat ocular disorders |
MX2017007904A (es) * | 2014-12-23 | 2017-09-05 | Syngenta Participations Ag | Control biologico de plagas de coleopteros. |
WO2016105535A2 (en) * | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway |
ES2833028T3 (es) * | 2014-12-25 | 2021-06-14 | Guangzhou Ribobio Co Ltd | Composiciones y métodos para inhibir la expresión de ADAMTS-5 y ADAM17 |
US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
US10793855B2 (en) * | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
US9982070B2 (en) | 2015-01-12 | 2018-05-29 | Carnegie Mellon University | Aqueous ATRP in the presence of an activator regenerator |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
US9434947B2 (en) * | 2015-01-20 | 2016-09-06 | Oregon Health & Science University | Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome |
RU2723049C2 (ru) | 2015-01-22 | 2020-06-08 | Монсанто Текнолоджи Ллс | Композиции и способы борьбы с leptinotarsa |
US10022243B2 (en) | 2015-02-06 | 2018-07-17 | Benvenue Medical, Inc. | Graft material injector system and method |
US10758558B2 (en) | 2015-02-13 | 2020-09-01 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
EP3256587A2 (de) * | 2015-02-13 | 2017-12-20 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing-3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon |
US10036017B2 (en) | 2015-02-17 | 2018-07-31 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA |
US10525076B2 (en) * | 2015-02-20 | 2020-01-07 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting genes associated with cystic fibrosis |
US9840709B2 (en) * | 2015-02-20 | 2017-12-12 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting genes associated with cystic fibrosis |
WO2016137937A1 (en) * | 2015-02-24 | 2016-09-01 | Dcb-Usa Llc | Short interfering rna for treating cancer |
BR112017017178A2 (pt) | 2015-02-26 | 2018-04-03 | Ionis Pharmaceuticals Inc | moduladores específicos de alelo de rodopsina de p23h |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
US11426290B2 (en) | 2015-03-06 | 2022-08-30 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
US10227594B2 (en) | 2015-03-20 | 2019-03-12 | Conopco, Inc. | Antiperspirant composition |
EP3072969A1 (de) * | 2015-03-23 | 2016-09-28 | DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Oligonukleotidsequenzen mit abzielung auf den transkriptionsfaktor tsc22d4 zur behandlung von insulinresistenz |
EP3273974A4 (de) | 2015-03-26 | 2018-11-07 | Women and Infants Hospital of Rhode Island Inc. | Therapie für maligne erkrankungen |
US10786264B2 (en) | 2015-03-31 | 2020-09-29 | Medos International Sarl | Percutaneous disc clearing device |
EP3277844A4 (de) * | 2015-04-01 | 2018-11-07 | Institute Of Environmental Science And Research Limited | Verfahren und materialien zur detektion von rna-sequenzen |
LT3277814T (lt) * | 2015-04-03 | 2020-10-26 | University Of Massachusetts | Oligonukleotidų junginiai, skirti nukreipimui į hantingtino mrnr |
CN107429250B (zh) | 2015-04-03 | 2022-03-01 | Ionis制药公司 | 用于调节tmprss6表达的化合物和方法 |
HUE057431T2 (hu) | 2015-04-03 | 2022-05-28 | Univ Massachusetts | Oligonukleotid vegyületek preeklampszia és más angiogén rendellenességek kezelésére |
US20160319278A1 (en) * | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
CN115927335A (zh) | 2015-04-13 | 2023-04-07 | 阿尔尼拉姆医药品有限公司 | 类血管生成素3(ANGPTL3)iRNA组合物及其使用方法 |
SG11201708468YA (en) | 2015-04-16 | 2017-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
CN107530439B (zh) * | 2015-04-17 | 2021-06-18 | 詹尼斯费尔公司 | 用于治疗癌症的对人抗原R表达的siRNA抑制 |
EP3286318A2 (de) * | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna-zusammensetzungen und verfahren zur verwendung |
WO2016182917A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
US20180161368A1 (en) | 2015-05-29 | 2018-06-14 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
UY36703A (es) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | Composiciones y métodos para la administración de un polinucleótido en una planta |
CN108024517A (zh) | 2015-06-03 | 2018-05-11 | 孟山都技术公司 | 用于将核酸引入到植物中的方法和组合物 |
CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
WO2016209862A1 (en) * | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
US10874622B2 (en) | 2015-06-24 | 2020-12-29 | Board Of Regents, The University Of Texas System | Dual assembly nanoparticles |
US9833338B2 (en) * | 2015-06-30 | 2017-12-05 | Expanding Orthopedics Inc. | Tool for intervertebral cage |
EP3112466A1 (de) * | 2015-07-01 | 2017-01-04 | Samsung Electronics Co., Ltd. | Zusammensetzung zur verringerung des zellseneszenzwerts einschliesslich aktivitätsinhibitor mit hemmung der dcun1d3-aktivität oder expressionsinhibitor mit hemmung des dcun1d3-decodierungsgens und verwendung davon |
US9913727B2 (en) | 2015-07-02 | 2018-03-13 | Medos International Sarl | Expandable implant |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
JP6983752B2 (ja) | 2015-07-06 | 2021-12-17 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | スーパーオキシドディスムターゼ1(sod1)を標的とする核酸分子 |
WO2017011286A1 (en) * | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
AU2016294347B2 (en) | 2015-07-10 | 2022-07-28 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
TW201713769A (zh) * | 2015-07-13 | 2017-04-16 | Kyowa Hakko Kirin Co Ltd | 抑制β2GPI之表現之反義寡核苷酸 |
US20170051282A1 (en) * | 2015-07-23 | 2017-02-23 | Cold Spring Harbor Laboratory | Extracellular vesicle methods and compositions |
US20180216114A1 (en) * | 2015-07-27 | 2018-08-02 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
CA2989384A1 (en) | 2015-07-30 | 2017-02-02 | Bayer Cropscience Aktiengesellschaft | Methods and compositions for the control of rust fungi by inhibiting expression of the hxt1 gene |
SG10201912341SA (en) | 2015-07-31 | 2020-02-27 | Alnylam Pharmaceuticals Inc | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES |
CN105063048A (zh) * | 2015-08-13 | 2015-11-18 | 吉林大学 | 一种抑制Survivin基因表达的siRNA及其应用 |
EP3334746B1 (de) * | 2015-08-14 | 2021-11-24 | The University Of Sydney | Connexin-45-hemmung zur therapie |
CN106467914A (zh) * | 2015-08-18 | 2017-03-01 | 华东理工大学 | 靶向人TSPAN8基因的siRNA及其应用 |
WO2017029391A1 (en) * | 2015-08-20 | 2017-02-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New method for treating cancer |
CN114939124A (zh) | 2015-08-25 | 2022-08-26 | 阿尔尼拉姆医药品有限公司 | 治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物 |
JP7028764B2 (ja) | 2015-09-02 | 2022-03-02 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | プログラム細胞死1リガンド1(PD-L1)iRNA組成物およびその使用方法 |
US11439380B2 (en) | 2015-09-04 | 2022-09-13 | Medos International Sarl | Surgical instrument connectors and related methods |
CN113143355A (zh) | 2015-09-04 | 2021-07-23 | 美多斯国际有限公司 | 多护罩脊柱进入系统 |
US10987129B2 (en) | 2015-09-04 | 2021-04-27 | Medos International Sarl | Multi-shield spinal access system |
US11744447B2 (en) | 2015-09-04 | 2023-09-05 | Medos International | Surgical visualization systems and related methods |
US11672562B2 (en) | 2015-09-04 | 2023-06-13 | Medos International Sarl | Multi-shield spinal access system |
WO2017042239A1 (en) * | 2015-09-08 | 2017-03-16 | Sylentis Sau | siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene |
MA44908A (fr) * | 2015-09-08 | 2018-07-18 | Sylentis Sau | Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp |
GB201516685D0 (en) * | 2015-09-21 | 2015-11-04 | Varghese Oommen P And Oommen Oommen P | Nucleic acid molecules with enhanced activity |
WO2017053681A1 (en) | 2015-09-24 | 2017-03-30 | Wisconsin Alumni Research Foundation | Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof |
EP3353303B1 (de) | 2015-09-25 | 2023-08-02 | Ionis Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur modulation von ataxin 3-expression |
CN106554962B (zh) * | 2015-09-30 | 2021-06-04 | 中国科学院上海药物研究所 | 过表达gpr160的癌症的预防、诊断和治疗 |
WO2017062422A1 (en) | 2015-10-07 | 2017-04-13 | The Research Foundation For The State University Of New York | METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXβ REDUCTASE |
BR112018005223B1 (pt) | 2015-10-08 | 2022-08-09 | Ionis Pharmaceuticals, Inc | Compostos, uso dos mesmos, e composição farmacêutica |
WO2017066697A1 (en) * | 2015-10-14 | 2017-04-20 | Dou Qingping | Treatments and diagnostics for cancers |
WO2017066657A1 (en) * | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Nucleic acid based tia-1 inhibitors |
WO2017065369A1 (ko) * | 2015-10-15 | 2017-04-20 | 한국과학기술원 | Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제 |
KR101842679B1 (ko) * | 2015-10-15 | 2018-03-28 | 한국과학기술원 | Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제 |
WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
WO2017068791A1 (ja) * | 2015-10-23 | 2017-04-27 | レナセラピューティクス株式会社 | 少なくとも1つのバルジ構造を有する核酸複合体 |
WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
US20180320177A1 (en) | 2015-11-05 | 2018-11-08 | University Of Connecticut | Compositions and methods for the treatment of liver fibrosis |
WO2017079739A1 (en) | 2015-11-06 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | MODULATING APOLIPOPROTEIN (a) EXPRESSION |
IL289849B2 (en) | 2015-11-10 | 2024-01-01 | Nat Inst Biotechnology Negev Ltd | Means and methods for reducing the tumorigenicity of cancer stem cells |
CN108699556B (zh) | 2015-11-16 | 2023-02-17 | 奥利克斯医药有限公司 | 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性 |
EP3378482B1 (de) * | 2015-11-19 | 2024-02-21 | Public University Corporation Nagoya City University | Formulierung zur verabreichung eines antitumor-arzneimittel |
JP7008328B2 (ja) * | 2015-11-20 | 2022-01-25 | 国立大学法人九州大学 | 免疫制御剤 |
MX2018006527A (es) | 2015-11-30 | 2018-11-29 | Univ British Columbia | Inhibidores de oligonucleotidos antisentido (aso) del transportador de monocarboxilato4 (mct4) para su uso como agentes terapeuticos en el tratamiento de cancer. |
WO2017096395A1 (en) | 2015-12-04 | 2017-06-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
CN108601795A (zh) | 2015-12-07 | 2018-09-28 | 建新公司 | 用于治疗serpinc1相关病症的方法和组合物 |
JP2018536689A (ja) * | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法 |
ES2844899T3 (es) | 2015-12-10 | 2021-07-23 | Fibrogen Inc | Métodos para el tratamiento de enfermedades de las neuronas motoras |
BR112018008344A2 (pt) | 2015-12-13 | 2018-10-30 | Nitto Denko Corp | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, método para prevenir, tratar ou melhorar uma doença, e, uso de uma composição |
EP3181698A1 (de) | 2015-12-16 | 2017-06-21 | European Molecular Biology Laboratory (EMBL) | Microrna mir-142 als stammzellenmarker |
WO2017120365A1 (en) | 2016-01-05 | 2017-07-13 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
AU2017210726B2 (en) | 2016-01-31 | 2023-08-03 | University Of Massachusetts | Branched oligonucleotides |
CN108779464B (zh) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 |
WO2017134525A1 (en) * | 2016-02-02 | 2017-08-10 | Olix Pharmaceuticals, Inc. | TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1 |
US10299838B2 (en) | 2016-02-05 | 2019-05-28 | Medos International Sarl | Method and instruments for interbody fusion and posterior fixation through a single incision |
US10519442B2 (en) | 2016-02-11 | 2019-12-31 | City Of Hope | Twist signaling inhibitor compositions and methods of using the same |
CA3012332A1 (en) * | 2016-02-19 | 2017-08-24 | The Regents Of The University Of California | Short hairpin rna (shrna734) and use of same to positively select and eliminate genetically modified cells |
EP3426349A4 (de) | 2016-03-09 | 2020-01-01 | Ionis Pharmaceuticals, Inc. | Verfahren und zusammensetzungen zur hemmung der pmp22-expression |
US10577607B2 (en) | 2016-03-16 | 2020-03-03 | Ionis Pharmaceuticals, Inc. | Modulation of DYRK1B expression |
AU2017234678A1 (en) | 2016-03-16 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
CN105925576B (zh) * | 2016-03-24 | 2018-04-20 | 嘉兴市第一医院 | 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用 |
MA45340A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques du récepteur des androgènes et leurs utilisations |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
ES2640524B1 (es) * | 2016-04-01 | 2018-09-24 | Universidad Autónoma de Madrid | Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas |
CA3020487C (en) | 2016-04-11 | 2022-05-31 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor |
SG11201808981XA (en) * | 2016-04-14 | 2018-11-29 | Benitec Biopharma Ltd | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof |
EA201892366A1 (ru) | 2016-04-18 | 2019-03-29 | Сарепта Терапьютикс, Инк. | Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы |
CN107345230A (zh) * | 2016-05-05 | 2017-11-14 | 江苏命码生物科技有限公司 | 一种抑制K-RAS基因表达的siRNA及其前体和应用 |
CN105969771A (zh) * | 2016-05-30 | 2016-09-28 | 东北师范大学 | 靶向沉默FOXG1的shRNA |
US20230348911A1 (en) * | 2016-06-08 | 2023-11-02 | Aalborg Universitet | Antisense oligonucleotides for modulation of long noncoding rnas |
PT109454A (pt) * | 2016-06-14 | 2017-12-14 | Phyzat Biopharmaceuticals Lda | Ácidos nucleicos de interferência e composições que os compreendem |
WO2017218884A1 (en) | 2016-06-16 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of smn expression |
AU2017286811A1 (en) | 2016-06-17 | 2018-11-22 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
US11510788B2 (en) | 2016-06-28 | 2022-11-29 | Eit Emerging Implant Technologies Gmbh | Expandable, angularly adjustable intervertebral cages |
JP7019616B2 (ja) | 2016-06-28 | 2022-02-15 | イーアイティー・エマージング・インプラント・テクノロジーズ・ゲーエムベーハー | 関節運動式継手を備えた拡張可能かつ角度調節可能な椎間ケージ |
KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
CN107557363B (zh) * | 2016-06-30 | 2021-03-12 | 中国科学院分子细胞科学卓越创新中心 | 可诱导型siRNA表达载体及其制备和应用 |
WO2018009547A1 (en) * | 2016-07-05 | 2018-01-11 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Diagnosing col6-related disorders and methods for treating same |
WO2018013801A1 (en) * | 2016-07-13 | 2018-01-18 | Indiana University Research And Technology Corporation | Rnai insecticide materials and methods |
AR109207A1 (es) * | 2016-08-05 | 2018-11-07 | Syngenta Participations Ag | Control de plagas de coleópteros utilizando moléculas de arn |
CA3033368A1 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
UY37376A (es) | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
EP3512527A4 (de) | 2016-09-15 | 2020-05-20 | The Brigham and Women's Hospital, Inc. | Modulation von pcsk9 und ldlr durch drp1-hemmung |
MX2019003070A (es) | 2016-09-16 | 2019-10-14 | Bio Path Holdings Inc | Terapia de combinacion con oligonucleotidos antisentido liposomales. |
US10933081B2 (en) | 2016-09-21 | 2021-03-02 | Alnylam Pharmaceuticals, Inc. | Myostatin iRNA compositions and methods of use thereof |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
MA46649A (fr) | 2016-10-13 | 2019-08-21 | Juno Therapeutics Inc | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
WO2018078648A2 (en) * | 2016-10-25 | 2018-05-03 | Council Of Scientific & Industrial Research | Gold nanoparticle based formulation for use in cancer therapy |
US10537436B2 (en) | 2016-11-01 | 2020-01-21 | DePuy Synthes Products, Inc. | Curved expandable cage |
JOP20190104A1 (ar) * | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
US10646540B2 (en) | 2016-11-18 | 2020-05-12 | City Of Hope | Peptide inhibitors of twist |
TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法 |
CN106421790B (zh) * | 2016-11-25 | 2018-12-25 | 复旦大学附属金山医院 | Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用 |
US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
CN110249046A (zh) | 2016-12-05 | 2019-09-17 | 朱诺治疗学股份有限公司 | 用于过继细胞疗法的工程化细胞的产生 |
US10888433B2 (en) | 2016-12-14 | 2021-01-12 | DePuy Synthes Products, Inc. | Intervertebral implant inserter and related methods |
TW201827596A (zh) * | 2016-12-23 | 2018-08-01 | 日商協和醱酵麒麟有限公司 | 抑制補體b因子之表現之核酸 |
SG10202107429WA (en) | 2017-01-06 | 2021-08-30 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
JOP20180003B1 (ar) | 2017-01-10 | 2022-09-15 | Arrowhead Pharmaceuticals Inc | عوامل RNAi ألفا-1 مضادة للتريبسين (AAT)، وتركيبات تتضمن عوامل AAT RNAi، وطرق الاستخدام |
US11174325B2 (en) | 2017-01-12 | 2021-11-16 | Carnegie Mellon University | Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes |
EP3568480A1 (de) * | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense-oligonukleotide zur modulierung der nfkb2-expression |
CN110770343A (zh) | 2017-02-10 | 2020-02-07 | 成均馆大学校产学协力团 | 用于rna干扰的长双链rna |
CN106668863B (zh) * | 2017-02-21 | 2019-04-23 | 南方医科大学 | 靶向ktn1治疗皮肤鳞状细胞癌的药物 |
AU2018232367A1 (en) * | 2017-03-09 | 2019-10-03 | Kyowa Kirin Co., Ltd. | Nucleic acid capable of inhibiting expression of MASP2 |
US10758286B2 (en) | 2017-03-22 | 2020-09-01 | Benvenue Medical, Inc. | Minimal impact access system to disc space |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
WO2018185240A1 (en) * | 2017-04-05 | 2018-10-11 | Silence Therapeutics Gmbh | Products and compositions |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
CA3058018A1 (en) * | 2017-04-19 | 2018-10-25 | Bio-Path Holdings, Inc. | P-ethoxy nucleic acids for stat3 inhibition |
NO344051B1 (en) * | 2017-05-04 | 2019-08-26 | Patogen As | Novel virus in Fish and Method for detection |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
US10398563B2 (en) | 2017-05-08 | 2019-09-03 | Medos International Sarl | Expandable cage |
WO2018208972A1 (en) | 2017-05-09 | 2018-11-15 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (als) |
WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
US11466272B2 (en) * | 2017-05-31 | 2022-10-11 | Kyowa Kirin Co., Ltd. | Nucleic acid suppressing expression of APCS |
KR101940061B1 (ko) * | 2017-06-02 | 2019-01-21 | 김준 | 리보솜 단백질 S3에 대한 siRNA를 포함하는 암 세포 전이 억제용 약학 조성물 |
CN107177594B (zh) * | 2017-06-07 | 2020-03-03 | 浙江大学 | 特异性抑制CA7基因表达的siRNA及其重组载体和应用 |
US11344424B2 (en) | 2017-06-14 | 2022-05-31 | Medos International Sarl | Expandable intervertebral implant and related methods |
FR3067933B1 (fr) * | 2017-06-21 | 2020-07-17 | L'oreal | Modulateurs de l’opsine 3 dans la modulation de la pigmentation de la peau |
WO2019006337A2 (en) * | 2017-06-30 | 2019-01-03 | The Trustees Of Princeton University | GENETIC VARIANTS ASSOCIATED WITH HYPER-SOCIAL BEHAVIOR DIRECTED TO HUMAN BEING IN DOMESTIC DOGS |
US10940016B2 (en) | 2017-07-05 | 2021-03-09 | Medos International Sarl | Expandable intervertebral fusion cage |
CA3061752A1 (en) | 2017-07-06 | 2019-01-10 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of alpha-enac and methods of use |
JP7193874B2 (ja) * | 2017-07-06 | 2022-12-21 | マイケル エス. カピロフ, | 筋肉Aキナーゼアンカータンパク質(mAKAP)作用の阻害による心臓病の処置 |
JP7337044B2 (ja) | 2017-07-13 | 2023-09-01 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Hao1(ヒドロキシ酸オキシダーゼ1(グリコール酸オキシダーゼ))遺伝子発現の阻害方法 |
BR112020001059A2 (pt) | 2017-07-18 | 2020-07-14 | Calimmune, Inc. | composições e métodos para o tratamento de beta-hemoglobinopatias |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
EP3664817A4 (de) * | 2017-08-07 | 2021-09-22 | Phio Pharmaceuticals Corp. | Chemisch modifizierte oligonukleotide |
CN110020273B (zh) * | 2017-08-16 | 2021-06-29 | 北京京东尚科信息技术有限公司 | 用于生成热力图的方法、装置以及系统 |
EP3668984A4 (de) | 2017-08-18 | 2021-09-08 | Ionis Pharmaceuticals, Inc. | Modulation des notch-signalweges zur behandlung von atemwegserkrankungen |
US11944671B2 (en) * | 2017-09-06 | 2024-04-02 | Baylor College Of Medicine | Hippo pathway deficiency reverses systolic heart failure post-infarction |
US11155819B2 (en) | 2017-09-07 | 2021-10-26 | Beijing Tide Pharmaceutical Co., Ltd. | Double-stranded RNA molecule targeting CKIP-1 and use thereof |
CA3075205A1 (en) * | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Stabilized hnf4a sarna compositions and methods of use |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
US10597657B2 (en) | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
PE20201287A1 (es) | 2017-09-14 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
BR112020005230A2 (pt) | 2017-09-19 | 2020-09-24 | Alnylam Pharmaceuticals, Inc. | composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr) |
JP7397488B2 (ja) | 2017-09-22 | 2023-12-13 | ユニバーシティ オブ マサチューセッツ | Sod1二重発現ベクターおよびその使用 |
US11781136B2 (en) | 2017-09-28 | 2023-10-10 | Secarna Pharmaceuticals Gmbh & Co. Kg | Oligonucleotide inhibiting the expression of Chop |
US20200345756A1 (en) * | 2017-10-10 | 2020-11-05 | University Of Virginia Patent Foundation | Compositions and methods for treating age-related macular degeneration and geographic atrophy |
US10953034B2 (en) | 2017-10-16 | 2021-03-23 | Hoffmann-La Roche Inc. | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
CN111372593B (zh) | 2017-10-20 | 2024-03-19 | 戴瑟纳制药公司 | 治疗乙型肝炎感染的方法 |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
US20230201357A1 (en) * | 2017-11-08 | 2023-06-29 | Aptamer Diagnostic, Inc. | D-dimer-specific aptamers and methods of use in diagnostics, therapeutic and theranostic purposes |
TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
GB201718701D0 (en) * | 2017-11-13 | 2017-12-27 | Syngenta Participations Ag | Improvements in or relating to gene silencing |
CN109777800A (zh) * | 2017-11-15 | 2019-05-21 | 信雅生物科技(苏州)有限公司 | 一种能够特异性抑制ZBED1基因的siRNA的构建方法及其应用 |
EP3714054A1 (de) * | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung |
GB201719680D0 (en) * | 2017-11-27 | 2018-01-10 | Devgen Nv | Improvements in or relating to gene silencing |
CA3083968C (en) | 2017-12-01 | 2024-04-23 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
CN110945130B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
CA3083526A1 (en) | 2017-12-06 | 2019-06-13 | Andrew John Geall | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
JP2021505175A (ja) * | 2017-12-11 | 2021-02-18 | ロシュ イノベーション センター コペンハーゲン エーエス | Fndc3bの発現を調節するためのオリゴヌクレオチド |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
GB201800370D0 (en) * | 2018-01-10 | 2018-02-21 | Ucl Business Plc | Anionic nanocomplexes for nucleic acid delivery |
CN108387621B (zh) * | 2018-01-10 | 2019-11-26 | 暨南大学 | 镉离子核酸适配体及丝网印刷电极电化学生物传感器 |
EP3740575A1 (de) | 2018-01-15 | 2020-11-25 | Ionis Pharmaceuticals, Inc. | Modulatoren der dnm2-expression |
AU2019209324A1 (en) * | 2018-01-16 | 2020-07-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ALDH2 expression |
WO2019148083A1 (en) | 2018-01-29 | 2019-08-01 | Benvenue Medical, Inc. | Minimally invasive interbody fusion |
US20210363587A1 (en) * | 2018-02-07 | 2021-11-25 | St. Jude Children's Research Hospital | EPIGENETIC HISTONE REGULATION MEDIATED BY CXorf67 |
RU2020125769A (ru) | 2018-02-09 | 2022-03-10 | Дженентек, Инк. | Олигонуклеотиды для модуляции экспрессии tmem106b |
EP3759127A4 (de) | 2018-03-02 | 2022-03-30 | Ionis Pharmaceuticals, Inc. | Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins |
CA3092092A1 (en) * | 2018-03-02 | 2019-09-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gys2 expression |
MX2020009147A (es) | 2018-03-02 | 2020-09-28 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de irf4. |
US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
WO2019178575A1 (en) | 2018-03-16 | 2019-09-19 | Benvenue Medical, Inc. | Articulated instrumentation and methods of using the same |
CN112020556A (zh) * | 2018-03-21 | 2020-12-01 | 瑞泽恩制药公司 | 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法 |
EP3768694A4 (de) | 2018-03-22 | 2021-12-29 | Ionis Pharmaceuticals, Inc. | Verfahren zur modulierung der fmr1-expression |
CN112236131A (zh) * | 2018-03-29 | 2021-01-15 | 技术研究及发展基金有限公司 | 包含pten抑制剂的囊泡及其用途 |
WO2019200172A1 (en) | 2018-04-11 | 2019-10-17 | Ionis Pharmaceuticals, Inc. | Modulators of ezh2 expression |
EP3799604A4 (de) | 2018-05-09 | 2022-09-07 | Ionis Pharmaceuticals, Inc. | Verbindungen und verfahren zur verminderung der fxi-expression |
JP2021522800A (ja) | 2018-05-09 | 2021-09-02 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Atxn3発現を低減するための化合物及び方法 |
WO2019241648A1 (en) * | 2018-06-14 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing stmn2 expression |
NO344698B1 (en) * | 2018-06-15 | 2020-03-09 | Patogen As | Novel fish virus |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
CR20210179A (es) | 2018-07-03 | 2022-05-23 | Hoffmann La Roche | OLIGONUCLEÓTIDOS PARA MODULAR LA EXPRESIÓN DE TAU (Divisional 2021-0058) |
WO2020011653A1 (en) * | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
WO2020011744A2 (en) * | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers5 |
AU2019310097A1 (en) | 2018-07-25 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ATXN2 expression |
EP3598995A1 (de) * | 2018-07-26 | 2020-01-29 | Silence Therapeutics GmbH | Produkte und zusammensetzungen |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
SG11202101288TA (en) | 2018-08-10 | 2021-03-30 | Univ Massachusetts | Modified oligonucleotides targeting snps |
MX2021001056A (es) | 2018-08-13 | 2021-04-12 | Alnylam Pharmaceuticals Inc | Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas. |
WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
CN111500576B (zh) * | 2018-08-27 | 2021-07-27 | 山东农业大学 | siRNA在制备抑制高致病性猪繁殖与呼吸障碍综合症病毒感染的阻断剂中的应用 |
AU2019328577A1 (en) * | 2018-08-31 | 2021-03-11 | University Of Florida Research Foundation, Incorporated | Adeno-associated viral vectors for the treatment of best disease |
JP7376952B2 (ja) | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | siRNA複合体及びその調製方法と使用 |
JP7191301B2 (ja) * | 2018-10-02 | 2022-12-19 | 小胞体ストレス研究所株式会社 | 予後不良のがん細胞の増殖抑制剤 |
US11446156B2 (en) | 2018-10-25 | 2022-09-20 | Medos International Sarl | Expandable intervertebral implant, inserter instrument, and related methods |
EP3874044A1 (de) * | 2018-11-02 | 2021-09-08 | BioMarin Technologies B.V. | Bispezifische antisense-oligonukleotide für dystrophin-exon-skipping |
TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
EP3880821A4 (de) | 2018-11-15 | 2023-01-25 | Ionis Pharmaceuticals, Inc. | Modulatoren der irf5-expression |
US20220025367A1 (en) * | 2018-11-23 | 2022-01-27 | Sanofi | Novel rna compositions and methods for inhibiting angptl8 |
CN111228289A (zh) * | 2018-11-28 | 2020-06-05 | 中国科学院大连化学物理研究所 | Plin2抑制剂的应用和治疗肿瘤药物混合物 |
ES2766855A1 (es) * | 2018-12-14 | 2020-06-15 | Consejo Superior Investigacion | Rhoq como diana farmacéutica para trastornos neurológicos |
ES2766950A1 (es) * | 2018-12-14 | 2020-06-15 | Consejo Superior Investigacion | ARHGEF6 como diana farmacéutica para trastornos neurológicos |
CA3123619A1 (en) | 2018-12-21 | 2020-06-25 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibodies and uses thereof |
WO2020142693A1 (en) * | 2019-01-04 | 2020-07-09 | Empirico Inc. | Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcripts |
WO2020144295A1 (en) | 2019-01-10 | 2020-07-16 | Biontech Rna Pharmaceuticals Gmbh | Localized administration of rna molecules for therapy |
US20220088051A1 (en) * | 2019-01-15 | 2022-03-24 | Bioneer Corporation | Double-stranded oligonucleotide targeting dkk1 gene, construct including same, and hair loss prevention or hair growth composition containing same |
CN113614232A (zh) * | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
CA3128093A1 (en) | 2019-01-31 | 2020-08-06 | Ionis Pharmaceuticals, Inc. | Modulators of yap1 expression |
MX2021010152A (es) | 2019-02-27 | 2021-09-14 | Ionis Pharmaceuticals Inc | Moduladores de la expresion de malat1. |
KR20220010471A (ko) * | 2019-03-01 | 2022-01-25 | 메소 스케일 테크놀러지즈, 엘엘시 | 면역검정 방법에서 사용을 위한 전기화학발광성 표지화된 프로브, 이의 사용 방법 및 이를 포함하는 키트 |
US11013530B2 (en) | 2019-03-08 | 2021-05-25 | Medos International Sarl | Surface features for device retention |
CA3133241A1 (en) * | 2019-03-15 | 2020-09-24 | University Of Massachusetts | Oligonucleotides for tissue specific apoe modulation |
JP2022525193A (ja) * | 2019-03-15 | 2022-05-11 | ユニヴァーシティ オブ ワシントン | Prpf31遺伝子発現ノックダウンによる、インビトロで分化したヒト細胞の生存の改善 |
US11241252B2 (en) | 2019-03-22 | 2022-02-08 | Medos International Sarl | Skin foundation access portal |
MX2021011916A (es) | 2019-03-29 | 2021-10-26 | Ionis Pharmaceuticals Inc | Compuestos y metodos para modular ube3a-ats. |
US11129727B2 (en) | 2019-03-29 | 2021-09-28 | Medos International Sari | Inflatable non-distracting intervertebral implants and related methods |
US11813026B2 (en) | 2019-04-05 | 2023-11-14 | Medos International Sarl | Systems, devices, and methods for providing surgical trajectory guidance |
EP3969032A1 (de) | 2019-05-15 | 2022-03-23 | University Of Miami | Behandlung von herzkrankheiten durch zerstörung der verankerung von pp2a |
JP2022533722A (ja) * | 2019-05-22 | 2022-07-25 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
US20220235359A1 (en) * | 2019-05-24 | 2022-07-28 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
EP3976059A2 (de) * | 2019-05-24 | 2022-04-06 | Empirico Inc. | Behandlung von mit angiopoietin-like 7 (angptl7) assoziierten krankheiten |
US20220315929A1 (en) * | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
EP3956450A4 (de) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | Verbindungen und verfahren zur modulation von gfap |
WO2021020412A1 (ja) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Murf1を標的とする核酸医薬 |
WO2021030358A1 (en) | 2019-08-12 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
WO2021041846A1 (en) * | 2019-08-30 | 2021-03-04 | Inari Agriculture, Inc. | Rna-guided nucleases and dna binding proteins |
EP4021448A4 (de) * | 2019-08-30 | 2023-12-20 | Agency for Science, Technology and Research | Verfahren zur förderung des überlebens und/oder der funktion eines motoneurons und zugehörige mittel, anwendungen und verfahren |
KR102100163B1 (ko) * | 2019-09-24 | 2020-04-13 | 테고사이언스 (주) | 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물 |
US20230304012A1 (en) * | 2019-10-16 | 2023-09-28 | Brown University | Muscle regeneration and growth |
JP2023501352A (ja) * | 2019-11-08 | 2023-01-18 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Spdef発現を低減するための化合物及び方法 |
WO2021092459A1 (en) * | 2019-11-08 | 2021-05-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing spdef expression |
CN110859960B (zh) * | 2019-11-26 | 2022-03-04 | 深圳先进技术研究院 | 靶向AMPK的抑制剂/siRNA与蛋白酶体抑制剂组合在制备抗肿瘤药物中的应用 |
WO2021119019A1 (en) * | 2019-12-09 | 2021-06-17 | Empirico Inc. | Oligonucleotides for treatment of angiopoietin like 4 (angptl4) related diseases |
CN114829603A (zh) * | 2019-12-20 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于抑制scn9a表达的增强寡核苷酸 |
CA3162845A1 (en) * | 2019-12-23 | 2021-07-01 | Anastasia Khvorova | Oligonucleotides for tissue specific gene expression modulation |
WO2021160937A1 (en) | 2020-02-11 | 2021-08-19 | Turun Yliopisto | Therapy of ras-dependent cancers |
EP4106768A1 (de) * | 2020-02-21 | 2022-12-28 | Replicor Inc. | Verfahren und zusammensetzungen zur hemmung von hepatitis-b-virus-infektionen |
CA3173034A1 (en) | 2020-02-28 | 2021-09-02 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating smn2 |
WO2021173984A2 (en) * | 2020-02-28 | 2021-09-02 | University Of Massachusetts | Oligonucleotides for prnp modulation |
CN115485383A (zh) * | 2020-03-06 | 2022-12-16 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
US11426286B2 (en) | 2020-03-06 | 2022-08-30 | Eit Emerging Implant Technologies Gmbh | Expandable intervertebral implant |
US20230124616A1 (en) * | 2020-03-06 | 2023-04-20 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating kcnq2 |
CA3172111A1 (en) | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
CA3177180A1 (en) | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
CN113444723A (zh) * | 2020-03-27 | 2021-09-28 | 北京键凯科技股份有限公司 | 一种抑制血管内皮生长因子受体2基因表达的干扰rna及其应用 |
JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのkif18a阻害剤 |
CN116096380A (zh) | 2020-05-01 | 2023-05-09 | Ionis制药公司 | 调节atxn1的化合物和方法 |
KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
JP2023526267A (ja) * | 2020-05-13 | 2023-06-21 | エフ. ホフマン-ラ ロシュ アーゲー | プログラニュリン標的オリゴヌクレオチドアゴニスト |
CN116113421A (zh) | 2020-05-14 | 2023-05-12 | 阿莱兹精准医疗公司 | 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗 |
CN111714510B (zh) * | 2020-05-18 | 2021-07-06 | 北京航空航天大学 | 长链非编码rna snhg12抑制剂在制备对抗骨质疏松药物中的应用 |
EP4165185A2 (de) * | 2020-06-11 | 2023-04-19 | Genetic Intelligence, Inc, New York, NY | Zusammensetzungen zur fn-genmodulation und verfahren dafür |
US11459567B2 (en) | 2020-06-24 | 2022-10-04 | Patricia Virginia Elizalde | Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer |
WO2022006134A2 (en) | 2020-06-29 | 2022-01-06 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating plp1 |
US20220090069A1 (en) * | 2020-08-03 | 2022-03-24 | University Of Massachusetts | Oligonucleotides for htt-1a modulation |
UY39417A (es) | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
CN116249538A (zh) * | 2020-09-30 | 2023-06-09 | 富士胶片株式会社 | 抑制乙型肝炎病毒蛋白质的产生的双链rna及药物组合物 |
WO2022089486A1 (zh) * | 2020-10-28 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 抑制PCSK9基因表达的siRNA及其修饰物与应用 |
CA3201661A1 (en) | 2020-11-18 | 2022-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
EP4257686A1 (de) * | 2020-12-07 | 2023-10-11 | OliX Pharmaceuticals, Inc. | Nukleinsäuremolekül zur induktion von asymmetrischer rnai zur hemmung der expression von ror-beta |
MX2023007257A (es) | 2020-12-18 | 2023-07-03 | Ionis Pharmaceuticals Inc | Compuestos y metodos para modular el factor xii. |
WO2022187435A1 (en) | 2021-03-04 | 2022-09-09 | Alnylam Pharmaceuticals, Inc. | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
US11771517B2 (en) | 2021-03-12 | 2023-10-03 | Medos International Sarl | Camera position indication systems and methods |
US20220411802A1 (en) * | 2021-03-17 | 2022-12-29 | Sirnaomics, Inc. | METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST NSD3 |
US11850160B2 (en) | 2021-03-26 | 2023-12-26 | Medos International Sarl | Expandable lordotic intervertebral fusion cage |
WO2022212208A1 (en) * | 2021-03-29 | 2022-10-06 | University Of Massachusetts | Oligonucleotides for syngr-3 modulation |
US11752009B2 (en) | 2021-04-06 | 2023-09-12 | Medos International Sarl | Expandable intervertebral fusion cage |
PE20240766A1 (es) * | 2021-04-08 | 2024-04-17 | Arrowhead Pharmaceuticals Inc | AGENTES DE RNAi PARA INHIBIR LA EXPRESION DEL RECEPTOR PARA PRODUCTOS FINALES DE GLICACION AVANZADA, COMPOSICIONES DE ESTOS Y METODOS DE USO |
EP4323063A1 (de) * | 2021-04-16 | 2024-02-21 | The Children's Hospital Of Philadelphia | Zusammensetzungen und verfahren zur behandlung von h-abc-leukodystrophie |
TW202305136A (zh) | 2021-04-19 | 2023-02-01 | 美商戴瑟納製藥股份有限公司 | 用於抑制核受體次家族1組別h成員3(nr1h3)表現之組成物與方法 |
JP2024517686A (ja) | 2021-04-26 | 2024-04-23 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 膜貫通プロテアーゼ、セリン6(TMPRSS6)iRNA組成物およびその使用方法 |
KR20240014067A (ko) * | 2021-05-28 | 2024-01-31 | 애로우헤드 파마슈티컬스 인코포레이티드 | 뮤신 5AC (MUC5AC)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법 |
US11655473B2 (en) | 2021-05-28 | 2023-05-23 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression |
CN117500815A (zh) | 2021-06-18 | 2024-02-02 | Ionis制药公司 | 用于降低ifnar1表达的化合物和方法 |
CN113416776B (zh) * | 2021-06-21 | 2022-04-01 | 深圳市儿童医院 | 一种用于检测室间隔缺损的生物标记物及其应用 |
US11549112B1 (en) | 2021-06-21 | 2023-01-10 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use |
CN115572725A (zh) * | 2021-06-21 | 2023-01-06 | 上海君实生物医药科技股份有限公司 | 一种抑制ANGPTL3基因表达的siRNA及其用途 |
CA3174095A1 (en) | 2021-06-23 | 2022-12-29 | Vignesh Narayan HARIHARAN | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
WO2022269016A1 (en) * | 2021-06-25 | 2022-12-29 | Stichting Radboud Universitair Medisch Centrum | Allele-specific silencing therapy for dfna21 using antisense oligonucleotides |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
AU2022325715A1 (en) * | 2021-07-17 | 2024-02-01 | Sirnaomics, Inc. | Products and compositions |
CN117795074A (zh) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | 转甲状腺素蛋白(TTR)iRNA组合物和其使用方法 |
IL310407A (en) * | 2021-08-13 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Factor XII (F12) IRNA compositions and methods of using them |
CA3230404A1 (en) * | 2021-08-31 | 2023-03-09 | Alnylam Pharmaceuticals, Inc. | Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof |
US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
US20230079754A1 (en) * | 2021-09-16 | 2023-03-16 | Washington University | Methods and compositions for reducing pathogenic isoforms |
CA3231330A1 (en) | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
TW202334418A (zh) * | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓(HTT)iRNA劑組成物及其使用方法 |
CA3234636A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
US20230167447A1 (en) * | 2021-11-30 | 2023-06-01 | Genetic Intelligence, Inc | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof |
WO2023108020A2 (en) * | 2021-12-07 | 2023-06-15 | Alnylam Pharmaceuticals, Inc. | iRNA COMPOSITIONS AND METHODS FOR SILENCING MYLIP |
WO2023122805A1 (en) | 2021-12-20 | 2023-06-29 | Vestaron Corporation | Sorbitol driven selection pressure method |
WO2023129496A2 (en) * | 2021-12-27 | 2023-07-06 | Apellis Pharmaceuticals, Inc. | Rnas for complement inhibition |
US20230377140A1 (en) * | 2022-02-01 | 2023-11-23 | 4D Path Inc. | Systems and Methods for Image-Based Disease Characterization |
US11879125B2 (en) | 2022-03-16 | 2024-01-23 | Empirico Inc. | GalNAc compositions for improving siRNA bioavailability |
WO2023220566A1 (en) * | 2022-05-09 | 2023-11-16 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
US20240102017A1 (en) * | 2022-05-10 | 2024-03-28 | Amylyx Pharmaceuticals, Inc. | Oligonucleotide compositions and methods thereof |
WO2023250368A2 (en) * | 2022-06-24 | 2023-12-28 | Eli Lilly And Company | Atxn2 rna interference agents |
WO2024026258A2 (en) * | 2022-07-25 | 2024-02-01 | Amgen Inc. | Rnai constructs and methods for inhibiting fam13a expression |
WO2024104663A1 (en) | 2022-11-16 | 2024-05-23 | Unilever Ip Holdings B.V. | Method of reducing malodour |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004142A2 (en) * | 1993-07-27 | 1995-02-09 | Hybridon, Inc. | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
WO1996023065A2 (en) * | 1995-01-26 | 1996-08-01 | Hybridon, Inc. | Inhibition of neovascularization using vegf-specific oligonucleotides |
WO1996027006A2 (en) * | 1995-03-02 | 1996-09-06 | Hybridon, Inc. | Human vegf-specific antisense oligonucleotides |
WO1997020925A1 (en) * | 1995-12-08 | 1997-06-12 | Hybridon, Inc. | Modified vegf antisense oligonucleotides for treatment of skin disorders |
WO1997021808A1 (en) * | 1995-12-08 | 1997-06-19 | Hybridon, Inc. | Modified vegf antisense oligonucleotides |
WO1997039120A2 (en) * | 1996-04-17 | 1997-10-23 | Aronex Pharmaceuticals, Inc. | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression |
WO1998027425A1 (en) * | 1996-12-19 | 1998-06-25 | Isis Pharmaceuticals, Inc. | Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
WO1999063975A2 (en) * | 1998-06-10 | 1999-12-16 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | A method for stimulating the immune system |
US6057437A (en) * | 1997-07-25 | 2000-05-02 | Taogosei Co. Ltd. | Antisense nucleic acid compounds inhibiting vascular endothelial growth factor |
WO2000027414A2 (en) * | 1998-11-06 | 2000-05-18 | Basf Aktiengesellschaft | Inhibition of the formation of vascular hyperpermeability |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
WO2002031141A2 (en) * | 2000-10-13 | 2002-04-18 | Institut De Cardiologie De Montreal | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
WO2002085309A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent |
WO2002085308A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
WO2002096927A2 (en) * | 2001-05-29 | 2002-12-05 | Ribozyme Pharmaceuticals, Incorporated | Ribozyme based treatment of female reproductive diseases |
WO2003040366A2 (fr) * | 2001-11-09 | 2003-05-15 | Centre National De La Recherche Scientifique -Cnrs- | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
FR2835837A1 (fr) * | 2003-02-06 | 2003-08-15 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance |
FR2835838A1 (fr) * | 2003-02-06 | 2003-08-15 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription |
WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003072704A2 (en) * | 2002-02-20 | 2003-09-04 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2004009769A2 (en) * | 2002-07-24 | 2004-01-29 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
Family Cites Families (320)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US647526A (en) * | 1899-06-26 | 1900-04-17 | William Allen Runyan | Freight-car door. |
US1541453A (en) * | 1922-12-20 | 1925-06-09 | Watkins Clayton Stuart | Demountable rim and wheell for automobiles and other vehicles |
US3260656A (en) * | 1962-09-27 | 1966-07-12 | Corning Glass Works | Method and apparatus for electrolytically determining a species in a fluid |
EG10142A (en) * | 1968-01-29 | 1976-06-30 | Bayer Ag | N-tritylimidazolium salts |
US3653841A (en) * | 1969-12-19 | 1972-04-04 | Hoffmann La Roche | Methods and compositions for determining glucose in blood |
US3719564A (en) * | 1971-05-10 | 1973-03-06 | Philip Morris Inc | Method of determining a reducible gas concentration and sensor therefor |
US3837339A (en) * | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
US4184429A (en) * | 1972-02-09 | 1980-01-22 | Max Datwyler & Co. | Constant bevel doctor blade and method and apparatus using same |
US3811449A (en) * | 1972-03-08 | 1974-05-21 | Becton Dickinson Co | Dilating apparatus and method |
US3908657A (en) * | 1973-01-15 | 1975-09-30 | Univ Johns Hopkins | System for continuous withdrawal of blood |
US4100048A (en) * | 1973-09-20 | 1978-07-11 | U.S. Philips Corporation | Polarographic cell |
US3911901A (en) * | 1974-07-24 | 1975-10-14 | Gen Electric | In vivo hydrogen ion sensor |
US3972320A (en) * | 1974-08-12 | 1976-08-03 | Gabor Ujhelyi Kalman | Patient monitoring system |
US3979274A (en) * | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
US4016866A (en) * | 1975-12-18 | 1977-04-12 | General Electric Company | Implantable electrochemical sensor |
US4055175A (en) * | 1976-05-07 | 1977-10-25 | Miles Laboratories, Inc. | Blood glucose control apparatus |
DE2625834B2 (de) * | 1976-06-09 | 1978-10-12 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur Bestimmung von Substraten oder Enzymaktivitäten |
US4076596A (en) * | 1976-10-07 | 1978-02-28 | Leeds & Northrup Company | Apparatus for electrolytically determining a species in a fluid and method of use |
FR2387659A1 (fr) * | 1977-04-21 | 1978-11-17 | Armines | Dispositif de controle et regulation de la glycemie |
US4098574A (en) * | 1977-08-01 | 1978-07-04 | Eastman Kodak Company | Glucose detection system free from fluoride-ion interference |
JPS5912135B2 (ja) * | 1977-09-28 | 1984-03-21 | 松下電器産業株式会社 | 酵素電極 |
US4151845A (en) * | 1977-11-25 | 1979-05-01 | Miles Laboratories, Inc. | Blood glucose control apparatus |
DK151000C (da) * | 1978-02-17 | 1988-06-13 | Radiometer As | Fremgangsmaade og apparat til bestemmelse af en patients in vivo plasma-ph-vaerdi |
US4172770A (en) * | 1978-03-27 | 1979-10-30 | Technicon Instruments Corporation | Flow-through electrochemical system analytical method |
HU177369B (en) * | 1978-09-08 | 1981-09-28 | Radelkis Electrokemiai | Industrial molecule-selective sensing device and method for producing same |
US4247297A (en) * | 1979-02-23 | 1981-01-27 | Miles Laboratories, Inc. | Test means and method for interference resistant determination of oxidizing substances |
US4573994A (en) * | 1979-04-27 | 1986-03-04 | The Johns Hopkins University | Refillable medication infusion apparatus |
US4401122A (en) * | 1979-08-02 | 1983-08-30 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4458686A (en) * | 1979-08-02 | 1984-07-10 | Children's Hospital Medical Center | Cutaneous methods of measuring body substances |
US4450842A (en) * | 1980-04-25 | 1984-05-29 | Cordis Corporation | Solid state reference electrode |
US4340458A (en) * | 1980-06-02 | 1982-07-20 | Joslin Diabetes Center, Inc. | Glucose sensor |
US4401433A (en) * | 1980-06-13 | 1983-08-30 | Luther Ronald B | Apparatus for advancing oversized catheter through cannula, and the like |
DE3025785C2 (de) * | 1980-07-08 | 1984-08-16 | Storz, Karl, 7200 Tuttlingen | Dilatator, Verfahren zu seiner Verwendung und Vorrichtung zur Durchführung des Verfahrens |
US4356074A (en) * | 1980-08-25 | 1982-10-26 | The Yellow Springs Instrument Company, Inc. | Substrate specific galactose oxidase enzyme electrodes |
US4404066A (en) * | 1980-08-25 | 1983-09-13 | The Yellow Springs Instrument Company | Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme |
US4352960A (en) * | 1980-09-30 | 1982-10-05 | Baptist Medical Center Of Oklahoma, Inc. | Magnetic transcutaneous mount for external device of an associated implant |
US4390621A (en) * | 1980-12-15 | 1983-06-28 | Miles Laboratories, Inc. | Method and device for detecting glucose concentration |
US4369790A (en) * | 1981-03-05 | 1983-01-25 | Mccarthy John M | Catheter |
US4436094A (en) * | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
US4350151A (en) * | 1981-03-12 | 1982-09-21 | Lone Star Medical Products, Inc. | Expanding dilator |
DE3117802A1 (de) * | 1981-05-06 | 1982-11-25 | Max Dr. 8520 Erlangen Hubmann | Katheterbesteck |
AT369254B (de) * | 1981-05-07 | 1982-12-27 | Otto Dipl Ing Dr Tech Prohaska | Medizinische sonde |
FR2508305B1 (fr) * | 1981-06-25 | 1986-04-11 | Slama Gerard | Dispositif pour provoquer une petite piqure en vue de recueillir une goutte de sang |
US4440175A (en) * | 1981-08-10 | 1984-04-03 | University Patents, Inc. | Membrane electrode for non-ionic species |
DE3278334D1 (en) * | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
JPS58153154A (ja) * | 1982-03-09 | 1983-09-12 | Ajinomoto Co Inc | 修飾電極 |
US4581336A (en) * | 1982-04-26 | 1986-04-08 | Uop Inc. | Surface-modified electrodes |
DE3221339A1 (de) * | 1982-06-05 | 1983-12-08 | Basf Ag, 6700 Ludwigshafen | Verfahren zur elektrochemischen hydrierung von nicotinamidadenin-dinucleotid |
US4427770A (en) * | 1982-06-14 | 1984-01-24 | Miles Laboratories, Inc. | High glucose-determining analytical element |
US4534356A (en) * | 1982-07-30 | 1985-08-13 | Diamond Shamrock Chemicals Company | Solid state transcutaneous blood gas sensors |
DE3228551A1 (de) * | 1982-07-30 | 1984-02-02 | Siemens AG, 1000 Berlin und 8000 München | Verfahren zur bestimmung der zuckerkonzentration |
US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
US4461691A (en) * | 1983-02-10 | 1984-07-24 | The United States Of America As Represented By The United States Department Of Energy | Organic conductive films for semiconductor electrodes |
US4679562A (en) * | 1983-02-16 | 1987-07-14 | Cardiac Pacemakers, Inc. | Glucose sensor |
IT1170375B (it) * | 1983-04-19 | 1987-06-03 | Giuseppe Bombardieri | Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente |
CA1218704A (en) * | 1983-05-05 | 1987-03-03 | Graham Davis | Assay systems using more than one enzyme |
US4650547A (en) * | 1983-05-19 | 1987-03-17 | The Regents Of The University Of California | Method and membrane applicable to implantable sensor |
US4524114A (en) * | 1983-07-05 | 1985-06-18 | Allied Corporation | Bifunctional air electrode |
US4538616A (en) * | 1983-07-25 | 1985-09-03 | Robert Rogoff | Blood sugar level sensing and monitoring transducer |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US4543955A (en) * | 1983-08-01 | 1985-10-01 | Cordis Corporation | System for controlling body implantable action device |
US4601710B1 (en) * | 1983-08-24 | 1998-05-05 | United States Surgical Corp | Trocar assembly |
US4573448A (en) * | 1983-10-05 | 1986-03-04 | Pilling Co. | Method for decompressing herniated intervertebral discs |
US4522690A (en) * | 1983-12-01 | 1985-06-11 | Honeywell Inc. | Electrochemical sensing of carbon monoxide |
US4840893A (en) * | 1983-12-16 | 1989-06-20 | Medisense, Inc. | Electrochemical assay for nucleic acids and nucleic acid probes |
JPS60135756A (ja) * | 1983-12-24 | 1985-07-19 | Ngk Insulators Ltd | 電気化学的セルの製造方法 |
DE8407894U1 (de) * | 1984-03-15 | 1984-09-06 | Richard Wolf Gmbh, 7134 Knittlingen | Dilatator zum aufweiten von einstichkanaelen der niere |
WO1985005119A1 (fr) * | 1984-04-30 | 1985-11-21 | Stiftung, R., E. | Procede de sensibilisation d'un photo-catalyseur d'oxydo-reduction et photo-catalyseur ainsi obtenu |
DK8601218A (de) * | 1984-07-18 | 1986-03-17 | ||
US4820399A (en) * | 1984-08-31 | 1989-04-11 | Shimadzu Corporation | Enzyme electrodes |
CA1254091A (en) * | 1984-09-28 | 1989-05-16 | Vladimir Feingold | Implantable medication infusion system |
US4721601A (en) * | 1984-11-23 | 1988-01-26 | Massachusetts Institute Of Technology | Molecule-based microelectronic devices |
US4717673A (en) * | 1984-11-23 | 1988-01-05 | Massachusetts Institute Of Technology | Microelectrochemical devices |
JPH0617889B2 (ja) * | 1984-11-27 | 1994-03-09 | 株式会社日立製作所 | 生物化学センサ |
GB8500729D0 (en) * | 1985-01-11 | 1985-02-13 | Hill H A O | Surface-modified electrode |
US4627445A (en) * | 1985-04-08 | 1986-12-09 | Garid, Inc. | Glucose medical monitoring system |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4897173A (en) * | 1985-06-21 | 1990-01-30 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for making the same |
US4796634A (en) * | 1985-08-09 | 1989-01-10 | Lawrence Medical Systems, Inc. | Methods and apparatus for monitoring cardiac output |
US4805624A (en) * | 1985-09-09 | 1989-02-21 | The Montefiore Hospital Association Of Western Pa | Low-potential electrochemical redox sensors |
US4680268A (en) * | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US4890620A (en) * | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4830959A (en) * | 1985-11-11 | 1989-05-16 | Medisense, Inc. | Electrochemical enzymic assay procedures |
GB8529300D0 (en) * | 1985-11-28 | 1986-01-02 | Ici Plc | Membrane |
US4776944A (en) * | 1986-03-20 | 1988-10-11 | Jiri Janata | Chemical selective sensors utilizing admittance modulated membranes |
US4685463A (en) * | 1986-04-03 | 1987-08-11 | Williams R Bruce | Device for continuous in vivo measurement of blood glucose concentrations |
US4726378A (en) * | 1986-04-11 | 1988-02-23 | Minnesota Mining And Manufacturing Company | Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus |
US4757022A (en) * | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4909908A (en) * | 1986-04-24 | 1990-03-20 | Pepi Ross | Electrochemical cncentration detector method |
US4795542A (en) * | 1986-04-24 | 1989-01-03 | St. Jude Medical, Inc. | Electrochemical concentration detector device |
DE3614821A1 (de) * | 1986-05-02 | 1987-11-05 | Siemens Ag | Implantierbare, eichbare messvorrichtung fuer eine koerpersubstanz sowie eichverfahren |
AU598820B2 (en) * | 1986-06-20 | 1990-07-05 | Molecular Devices Corporation | Zero volume electrochemical cell |
US4764416A (en) * | 1986-07-01 | 1988-08-16 | Mitsubishi Denki Kabushiki Kaisha | Electric element circuit using oxidation-reduction substances |
US4917800A (en) * | 1986-07-07 | 1990-04-17 | Bend Research, Inc. | Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers |
US4726716A (en) * | 1986-07-21 | 1988-02-23 | Mcguire Thomas V | Fastener for catheter |
US4894137A (en) * | 1986-09-12 | 1990-01-16 | Omron Tateisi Electronics Co. | Enzyme electrode |
US4802479A (en) * | 1986-10-31 | 1989-02-07 | C. R. Bard, Inc. | Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane |
DE3700119A1 (de) * | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | Implantierbarer elektrochemischer sensor |
US4848351A (en) * | 1987-03-04 | 1989-07-18 | Sentry Medical Products, Inc. | Medical electrode assembly |
US4759828A (en) * | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US4822337A (en) * | 1987-06-22 | 1989-04-18 | Stanley Newhouse | Insulin delivery method and apparatus |
JPH07122624B2 (ja) * | 1987-07-06 | 1995-12-25 | ダイキン工業株式会社 | バイオセンサ |
US4874500A (en) * | 1987-07-15 | 1989-10-17 | Sri International | Microelectrochemical sensor and sensor array |
GB8718430D0 (en) * | 1987-08-04 | 1987-09-09 | Ici Plc | Sensor |
JPS6431701U (de) * | 1987-08-20 | 1989-02-27 | ||
US4815469A (en) * | 1987-10-08 | 1989-03-28 | Siemens-Pacesetter, Inc. | Implantable blood oxygen sensor and method of use |
US4813424A (en) * | 1987-12-23 | 1989-03-21 | University Of New Mexico | Long-life membrane electrode for non-ionic species |
US4862891A (en) * | 1988-03-14 | 1989-09-05 | Canyon Medical Products | Device for sequential percutaneous dilation |
US4923442A (en) * | 1988-05-02 | 1990-05-08 | Cryomedical Sciences Inc. | Blood substitute |
US4994027A (en) * | 1988-06-08 | 1991-02-19 | Farrell Edward M | Percutaneous femoral bypass system |
US5224952A (en) * | 1988-07-06 | 1993-07-06 | Ethicon, Inc. | Safety trocar |
US5613950A (en) * | 1988-07-22 | 1997-03-25 | Yoon; Inbae | Multifunctional manipulating instrument for various surgical procedures |
US5514091A (en) * | 1988-07-22 | 1996-05-07 | Yoon; Inbae | Expandable multifunctional manipulating instruments for various medical procedures |
US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5176697A (en) * | 1989-04-06 | 1993-01-05 | Hasson Harrith M | Laparoscopic cannula |
US5002557A (en) * | 1989-04-06 | 1991-03-26 | Hasson Harrith M | Laparoscopic cannula |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US5114407A (en) * | 1990-08-30 | 1992-05-19 | Ethicon, Inc. | Safety mechanism for trocar |
US5188118A (en) * | 1990-11-07 | 1993-02-23 | Terwilliger Richard A | Automatic biopsy instrument with independently actuated stylet and cannula |
US5324261A (en) * | 1991-01-04 | 1994-06-28 | Medtronic, Inc. | Drug delivery balloon catheter with line of weakness |
AU648135B2 (en) * | 1991-01-15 | 1994-04-14 | Ethicon Inc. | Knife for surgical trocar |
US5176651A (en) * | 1991-04-01 | 1993-01-05 | Dexide, Inc. | Combination surgical trocar housing and selective reducer sleeve assembly |
US5295993A (en) * | 1991-04-30 | 1994-03-22 | United States Surgical Corporation | Safety trocar |
US5241972A (en) * | 1991-05-03 | 1993-09-07 | Meditron Devices, Inc. | Method for debulking tissue to remove pressure on a nerve |
US5183464A (en) * | 1991-05-17 | 1993-02-02 | Interventional Thermodynamics, Inc. | Radially expandable dilator |
CA2069060C (en) * | 1991-06-26 | 2003-07-29 | Daniel Shichman | Powered trocar |
US5195506A (en) * | 1991-10-18 | 1993-03-23 | Life Medical Products, Inc. | Surgical retractor for puncture operation |
GB9123947D0 (en) * | 1991-11-12 | 1992-01-02 | Imp Cancer Res Tech | Therapeutic compounds |
US5267554A (en) * | 1991-11-15 | 1993-12-07 | Wilk Peter J | Spreadable laparoscopic retractor and associated method of use |
WO1993010836A1 (en) * | 1991-11-27 | 1993-06-10 | Inbae Yoon | Retractable safety penetrating instrument for portal sleeve introduction |
US5713870A (en) * | 1991-11-27 | 1998-02-03 | Yoon; Inbae | Retractable safety penetrating instrument with laterally extendable spring strip |
US5171279A (en) * | 1992-03-17 | 1992-12-15 | Danek Medical | Method for subcutaneous suprafascial pedicular internal fixation |
US5290243A (en) * | 1992-07-16 | 1994-03-01 | Technalytics, Inc. | Trocar system |
EP0786522A2 (de) * | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen |
US5312417A (en) * | 1992-07-29 | 1994-05-17 | Wilk Peter J | Laparoscopic cannula assembly and associated method |
US7060077B2 (en) * | 1992-09-04 | 2006-06-13 | Boston Scientific Scimed, Inc. | Suturing instruments and methods of use |
US20040204380A1 (en) * | 1999-01-07 | 2004-10-14 | Ackermann Elizabeth J | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
US6001992A (en) * | 1999-01-07 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of novel anti-apoptotic bcl-2-related proteins |
US20020086321A1 (en) * | 1993-02-02 | 2002-07-04 | Craig Ruth W. | Myeloid cell leukemia associated gene MCL-1 |
US5814073A (en) * | 1996-12-13 | 1998-09-29 | Bonutti; Peter M. | Method and apparatus for positioning a suture anchor |
FR2706309B1 (fr) * | 1993-06-17 | 1995-10-06 | Sofamor | Instrument de traitement chirurgical d'un disque intervertébral par voie antérieure. |
DK0745124T3 (da) * | 1994-02-14 | 1999-02-01 | Amgen Inc | Pattedyr-cellecyklusprotein |
US5407430A (en) * | 1994-03-21 | 1995-04-18 | Peters; Michael J. | Intravenous catheter |
US5512037A (en) * | 1994-05-12 | 1996-04-30 | United States Surgical Corporation | Percutaneous surgical retractor |
US5505710A (en) * | 1994-08-22 | 1996-04-09 | C. R. Bard, Inc. | Telescoping probe |
US5647857A (en) * | 1995-03-16 | 1997-07-15 | Endotex Interventional Systems, Inc. | Protective intraluminal sheath |
US5624447A (en) * | 1995-03-20 | 1997-04-29 | Othy, Inc. | Surgical tool guide and entry hole positioner |
US6206922B1 (en) * | 1995-03-27 | 2001-03-27 | Sdgi Holdings, Inc. | Methods and instruments for interbody fusion |
US5776156A (en) * | 1995-09-05 | 1998-07-07 | United States Surgical Corporation | Endoscopic cutting instrument |
US5817034A (en) * | 1995-09-08 | 1998-10-06 | United States Surgical Corporation | Apparatus and method for removing tissue |
US5772678A (en) * | 1995-10-20 | 1998-06-30 | Inlet Medical, Inc. | Retractable disposable tip reusable trocar obturator |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US5743881A (en) * | 1995-11-03 | 1998-04-28 | Aptec Medical Corporation | Laparoscopic surgical instrument and method of using same |
US5707359A (en) * | 1995-11-14 | 1998-01-13 | Bufalini; Bruno | Expanding trocar assembly |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US5810721A (en) * | 1996-03-04 | 1998-09-22 | Heartport, Inc. | Soft tissue retractor and method for providing surgical access |
US6048309A (en) * | 1996-03-04 | 2000-04-11 | Heartport, Inc. | Soft tissue retractor and delivery device therefor |
US6679833B2 (en) * | 1996-03-22 | 2004-01-20 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US5792044A (en) * | 1996-03-22 | 1998-08-11 | Danek Medical, Inc. | Devices and methods for percutaneous surgery |
ATE270850T1 (de) * | 1996-03-22 | 2004-07-15 | Sdgi Holdings Inc | Gerät für die perkutane chirurgie |
US20050261485A1 (en) * | 1996-05-23 | 2005-11-24 | Toagosei Co., Ltd., A Japan Corporation | Method of producing antisense oligonucleotide |
WO1998000532A2 (en) | 1996-07-01 | 1998-01-08 | Wright Jim A | Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth |
US6264676B1 (en) * | 1996-11-08 | 2001-07-24 | Scimed Life Systems, Inc. | Protective sheath for transvaginal anchor implantation devices |
US6053935A (en) * | 1996-11-08 | 2000-04-25 | Boston Scientific Corporation | Transvaginal anchor implantation device |
US5893850A (en) * | 1996-11-12 | 1999-04-13 | Cachia; Victor V. | Bone fixation device |
EP0952795B1 (de) * | 1996-11-15 | 2007-01-03 | Cook Incorporated | Stentanbringungsvorrichtung mit einer auftrennbaren hülle |
US6228058B1 (en) * | 1997-04-03 | 2001-05-08 | Core Dynamics, Inc. | Sleeve trocar with penetration indicator |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
US6293952B1 (en) * | 1997-07-31 | 2001-09-25 | Circon Corporation | Medical instrument system for piercing through tissue |
CA2302317A1 (en) * | 1997-08-26 | 1999-03-04 | Gliatech, Inc. | A process for inhibiting complement activation via the alternative pathway |
JP2001518328A (ja) * | 1997-10-01 | 2001-10-16 | ボストン サイエンティフィック リミテッド | 拡張システムおよび関連方法 |
US6030364A (en) * | 1997-10-03 | 2000-02-29 | Boston Scientific Corporation | Apparatus and method for percutaneous placement of gastro-intestinal tubes |
US6046319A (en) * | 1997-10-22 | 2000-04-04 | University Technologies International, Inc. | Antisense oligodeoxynucleotides regulating expression of TNF-α |
US6206826B1 (en) * | 1997-12-18 | 2001-03-27 | Sdgi Holdings, Inc. | Devices and methods for percutaneous surgery |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AU2572499A (en) | 1998-01-29 | 1999-08-16 | Trustees Of Columbia University In The City Of New York, The | Human hairless gene, protein and uses thereof |
US6111086A (en) * | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
WO1999051730A2 (en) * | 1998-04-03 | 1999-10-14 | Wisconsin Alumni Research Foundation | Mammalian gene encoding tolloid-like protein |
US6428541B1 (en) * | 1998-04-09 | 2002-08-06 | Sdgi Holdings, Inc. | Method and instrumentation for vertebral interbody fusion |
US20030228597A1 (en) * | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
US6447527B1 (en) * | 1998-04-23 | 2002-09-10 | Ronald J. Thompson | Apparatus and methods for the penetration of tissue |
US20030096775A1 (en) * | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
JP2000010376A (ja) * | 1998-06-26 | 2000-01-14 | Fujitsu Ltd | 画像形成装置 |
US6007995A (en) * | 1998-06-26 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of TNFR1 expression |
EP1093373A4 (de) * | 1998-07-02 | 2005-04-13 | Univ Columbia | OLIGONUKLEOTIDE INHIBITOREN DES bcl-xl |
US5916145A (en) * | 1998-08-07 | 1999-06-29 | Scimed Life Systems, Inc. | Device and method of using a surgical assembly with mesh sheath |
US6093173A (en) * | 1998-09-09 | 2000-07-25 | Embol-X, Inc. | Introducer/dilator with balloon protection and methods of use |
US6117174A (en) * | 1998-09-16 | 2000-09-12 | Nolan; Wesley A. | Spinal implant device |
US5957902A (en) * | 1998-09-28 | 1999-09-28 | Teves; Leonides Y. | Surgical tool for enlarging puncture opening made by trocar |
US6228642B1 (en) * | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
ATE332969T1 (de) * | 1998-10-26 | 2006-08-15 | Avi Biopharma Inc | Auf morpholin basierendes p53-antisense- oligonucleotid und dessen verwendungen |
US5958773A (en) * | 1998-12-17 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense modulation of AKT-1 expression |
EP1150734B1 (de) * | 1999-02-12 | 2004-10-20 | Karl Storz GmbH & Co. | Vorrichtung zum einführen eines intubationstubus in die trachea |
WO2000048991A1 (en) * | 1999-02-18 | 2000-08-24 | The Regents Of The University Of California | Salicylamide-lanthanide complexes for use as luminescent markers |
AU4077100A (en) | 1999-04-08 | 2000-11-14 | Chiron Corporation | Enhancement of the immune response for vaccine and gene therapy applications |
US6607530B1 (en) * | 1999-05-10 | 2003-08-19 | Highgate Orthopedics, Inc. | Systems and methods for spinal fixation |
JP4638098B2 (ja) | 1999-06-14 | 2011-02-23 | キャンサー・リサーチ・テクノロジー・リミテッド | 癌治療 |
US6607547B1 (en) * | 1999-08-25 | 2003-08-19 | Origin Medsystems, Inc. | Longitudinal dilator and method |
US6200322B1 (en) * | 1999-08-13 | 2001-03-13 | Sdgi Holdings, Inc. | Minimal exposure posterior spinal interbody instrumentation and technique |
WO2001013807A2 (en) * | 1999-08-26 | 2001-03-01 | Sdgi Holdings, Inc. | Devices and methods for implanting fusion cages |
US6770633B1 (en) * | 1999-10-26 | 2004-08-03 | Immusol, Inc. | Ribozyme therapy for the treatment of proliferative skin and eye diseases |
US6287313B1 (en) * | 1999-11-23 | 2001-09-11 | Sdgi Holdings, Inc. | Screw delivery system and method |
US7179796B2 (en) * | 2000-01-18 | 2007-02-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
US6582441B1 (en) * | 2000-02-24 | 2003-06-24 | Advanced Bionics Corporation | Surgical insertion tool |
US6562049B1 (en) * | 2000-03-01 | 2003-05-13 | Cook Vascular Incorporated | Medical introducer apparatus |
AU2001249622B2 (en) * | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
JP2004501637A (ja) * | 2000-06-26 | 2004-01-22 | スージェン・インコーポレーテッド | 新規プロテアーゼ |
US6592553B2 (en) * | 2000-07-05 | 2003-07-15 | Cardiac Pacemakers, Inc. | Introducer assembly and method therefor |
WO2002048168A1 (en) * | 2000-10-24 | 2002-06-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of tnfr1 expression |
CA2427698A1 (en) * | 2000-11-01 | 2002-05-10 | Bki Holding Corporation | Cellulose ethers and method of preparing the same |
HU230458B1 (hu) * | 2000-12-01 | 2016-07-28 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Az RNS interferenciát közvetítő kis RNS molekulák |
WO2002047562A1 (fr) * | 2000-12-12 | 2002-06-20 | Olympus Optical Co., Ltd. | Trocart et systeme de trocart |
US20030143597A1 (en) | 2000-12-28 | 2003-07-31 | Finney Robert E. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
US20020150945A1 (en) * | 2000-12-28 | 2002-10-17 | Cell Therapeutics, Inc. | Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis |
EP1353676A4 (de) * | 2000-12-29 | 2006-05-31 | Alteon Inc | Methode zur behandlung von fibrosen oder anderen indikationen |
US20020087152A1 (en) * | 2001-01-04 | 2002-07-04 | Endocare, Inc. | Systems and methods for delivering a probe into tissue |
WO2003035869A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens |
EP1372690A4 (de) * | 2001-03-01 | 2005-08-24 | Millennium Pharm Inc | 93870, humaner g-protein-gekoppelter rezeptor und seine verwendungen |
US6511481B2 (en) * | 2001-03-30 | 2003-01-28 | Triage Medical, Inc. | Method and apparatus for fixation of proximal femoral fractures |
WO2002085285A2 (en) * | 2001-04-18 | 2002-10-31 | Wyeth | Methods and reagents for regulating bone and cartilage formation |
US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
US20050130181A1 (en) * | 2001-05-18 | 2005-06-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA) |
US20040219671A1 (en) * | 2002-02-20 | 2004-11-04 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA) |
US20050148530A1 (en) * | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050176025A1 (en) * | 2001-05-18 | 2005-08-11 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA) |
US20050227935A1 (en) * | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
US20050239731A1 (en) * | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
WO2003072705A2 (en) | 2002-02-20 | 2003-09-04 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina) |
US6746451B2 (en) * | 2001-06-01 | 2004-06-08 | Lance M. Middleton | Tissue cavitation device and method |
MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
US6589240B2 (en) * | 2001-08-28 | 2003-07-08 | Rex Medical, L.P. | Tissue biopsy apparatus with collapsible cutter |
US6734017B2 (en) * | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
JP4917225B2 (ja) | 2001-09-28 | 2012-04-18 | ローム株式会社 | 半導体装置 |
WO2003035870A1 (de) | 2001-10-26 | 2003-05-01 | Ribopharma Ag | Medikament zur behandlung eines pankreaskarzinoms |
US7008431B2 (en) * | 2001-10-30 | 2006-03-07 | Depuy Spine, Inc. | Configured and sized cannula |
US20040063654A1 (en) * | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
EP2325193A3 (de) * | 2001-11-02 | 2012-05-02 | Insert Therapeutics, Inc. | Verfahren und Zusammensetzungen zur therapeutischen Verwendung von RNA-Interferenz |
US6685706B2 (en) * | 2001-11-19 | 2004-02-03 | Triage Medical, Inc. | Proximal anchors for bone fixation system |
US20030186903A1 (en) * | 2001-11-23 | 2003-10-02 | Isis Pharmaceuticals Inc. | Antisense modulation of MyD88 expression |
EP1451214A2 (de) | 2001-11-26 | 2004-09-01 | Hybrigenics | Protein-protein-wechselwirkungen beim human immunodeficiency virus |
US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
EP1458437B1 (de) * | 2001-12-26 | 2010-03-03 | Yale University | Gefäss-shuntvorrichtung |
KR100441894B1 (ko) * | 2002-01-26 | 2004-07-27 | 한국전자통신연구원 | 마이크로 집적형 근접장 광기록 헤드 및 이를 이용한광기록 장치 |
WO2003064625A2 (en) * | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Oligonucleotide compositions with enhanced efficiency |
JP2005517433A (ja) * | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸(siNA)を用いるTNFおよびTNFレセプタースーパーファミリー遺伝子発現のRNA干渉媒介性阻害 |
JP2005517452A (ja) * | 2002-02-20 | 2005-06-16 | サーナ・セラピューティクス・インコーポレイテッド | 短干渉核酸(siNA)を用いるBCL2遺伝子発現のRNA干渉媒介性阻害 |
CA2479530A1 (en) * | 2002-03-20 | 2003-10-02 | Massachusetts Institute Of Technology | Hiv therapeutic |
JP2005521418A (ja) * | 2002-03-29 | 2005-07-21 | イェン、ユン | ヒト・リボヌクレオチド還元酵素m2サブユニット |
US20030224512A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of beta-site APP-cleaving enzyme expression |
WO2003094790A2 (en) * | 2002-05-13 | 2003-11-20 | Salviac Limited | Catheter system with procedural catheter and embolic proctection system |
US20040101857A1 (en) * | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of cytokine-inducible kinase expression |
US7399586B2 (en) * | 2002-05-23 | 2008-07-15 | Ceptyr, Inc. | Modulation of biological signal transduction by RNA interference |
US20040102391A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Gankyrin expression |
CA2489726A1 (en) * | 2002-06-18 | 2003-12-24 | Irm Llc | Diagnosis and treatment of chemoresistant tumors |
US7993351B2 (en) * | 2002-07-24 | 2011-08-09 | Pressure Products Medical Supplies, Inc. | Telescopic introducer with a compound curvature for inducing alignment and method of using the same |
US6906186B1 (en) * | 2002-07-30 | 2005-06-14 | Isis Pharmaceuticals, Inc. | Antisense modulation of polo-like kinase expression |
US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
WO2004027030A2 (en) * | 2002-09-18 | 2004-04-01 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds |
US7074226B2 (en) * | 2002-09-19 | 2006-07-11 | Sdgi Holdings, Inc. | Oval dilator and retractor set and method |
JP2006517783A (ja) | 2002-09-30 | 2006-08-03 | オンコセラピー・サイエンス株式会社 | ヒト骨髄性白血病に関連する遺伝子およびポリペプチド |
AU2003304386A1 (en) * | 2002-10-30 | 2005-02-25 | The Center For Blood Research, Inc. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
EP1562970A4 (de) * | 2002-11-01 | 2006-04-12 | Univ Pennsylvania | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON HIF-1 ALPHA |
ATE443764T1 (de) * | 2002-11-04 | 2009-10-15 | Univ Massachusetts | Allelspezifische rna-interferenz |
US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
US7781575B2 (en) | 2002-11-14 | 2010-08-24 | Dharmacon, Inc. | siRNA targeting tumor protein 53 (p53) |
US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
US7612196B2 (en) | 2002-11-14 | 2009-11-03 | Dharmacon, Inc. | siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
US7691998B2 (en) | 2002-11-14 | 2010-04-06 | Dharmacon, Inc. | siRNA targeting nucleoporin 62kDa (Nup62) |
US7619081B2 (en) | 2002-11-14 | 2009-11-17 | Dharmacon, Inc. | siRNA targeting coatomer protein complex, subunit beta 2 (COPB2) |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US7592442B2 (en) * | 2002-11-14 | 2009-09-22 | Dharmacon, Inc. | siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2) |
US7951935B2 (en) | 2002-11-14 | 2011-05-31 | Dharmacon, Inc. | siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC) |
JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
US7582747B2 (en) * | 2002-11-14 | 2009-09-01 | Dharmacon, Inc. | siRNA targeting inner centromere protein antigens (INCENP) |
US7977471B2 (en) | 2002-11-14 | 2011-07-12 | Dharmacon, Inc. | siRNA targeting TNFα |
WO2004046324A2 (en) | 2002-11-15 | 2004-06-03 | University Of Massachusetts | Allele-targeted rna interference |
US7790867B2 (en) | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
US6994979B2 (en) * | 2002-12-12 | 2006-02-07 | The Burnham Institute | Conversion of apoptotic proteins |
US20040248299A1 (en) * | 2002-12-27 | 2004-12-09 | Sumedha Jayasena | RNA interference |
US7166088B2 (en) * | 2003-01-27 | 2007-01-23 | Heuser Richard R | Catheter introducer system |
WO2004070062A2 (en) * | 2003-02-04 | 2004-08-19 | Wyeth | Compositions and methods for diagnosing and treating cancers |
US7090680B2 (en) * | 2003-02-12 | 2006-08-15 | Bonati Alfred O | Method for removing orthopaedic hardware |
WO2004076639A2 (en) * | 2003-02-26 | 2004-09-10 | Wyeth | Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
WO2004090105A2 (en) | 2003-04-02 | 2004-10-21 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
US7399853B2 (en) * | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
WO2004105774A1 (ja) * | 2003-05-30 | 2004-12-09 | Nippon Shinyaku Co., Ltd. | オリゴ核酸担持複合体、当該複合体を含有する医薬組成物 |
US20080020990A1 (en) | 2003-05-30 | 2008-01-24 | Nippon Shinyaku Co., Ltd. | Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same |
DK1633767T3 (en) * | 2003-06-02 | 2019-03-25 | Univ Massachusetts | METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING |
US7750144B2 (en) * | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
US8309704B2 (en) * | 2003-06-02 | 2012-11-13 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNAi |
DK3604537T3 (da) * | 2003-06-13 | 2022-02-28 | Alnylam Europe Ag | Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme |
US7825235B2 (en) * | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
DE10341333B4 (de) * | 2003-09-08 | 2006-06-08 | Siemens Ag | Piezoaktor und Verfahren zum Herstellen eines Piezoaktors |
KR100568246B1 (ko) * | 2003-11-19 | 2006-04-05 | 삼성전자주식회사 | 컴퓨터 시스템 및 그 제어방법 |
US20050176045A1 (en) | 2004-02-06 | 2005-08-11 | Dharmacon, Inc. | SNP discriminatory siRNA |
ES2423060T3 (es) | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
WO2005105157A2 (en) * | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Ofnew York | INHIBITION OF HAIRLESS PROTEIN mRNA |
WO2005117991A2 (en) | 2004-05-04 | 2005-12-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
EP1752536A4 (de) * | 2004-05-11 | 2008-04-16 | Alphagen Co Ltd | Rna-störung verursachendes polynukleotid sowie verfahren zur regulation der genexpression unter verwendung davon |
US7605250B2 (en) | 2004-05-12 | 2009-10-20 | Dharmacon, Inc. | siRNA targeting cAMP-specific phosphodiesterase 4D |
JP2006013252A (ja) * | 2004-06-28 | 2006-01-12 | Hitachi Cable Ltd | レーザダイオードの制御方法、制御回路、および光送信器 |
JP4991547B2 (ja) * | 2004-09-28 | 2012-08-01 | クアーク・ファーマスーティカルス、インコーポレイテッド | 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法 |
AU2005306533B2 (en) * | 2004-11-17 | 2012-05-31 | Arbutus Biopharma Corporation | siRNA silencing of apolipoprotein B |
JP2008537752A (ja) | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのRNAi治療用の組成物および方法 |
US20060286575A1 (en) * | 2005-04-16 | 2006-12-21 | Cylene Pharmaceuticals, Inc. | MCL-1 quadruplex nucleic acids and uses thereof |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
CN101448943B (zh) | 2006-05-19 | 2013-07-17 | 爱尔康研究有限公司 | 肿瘤坏死因子α相关状况的RNAi介导的抑制 |
US8523707B2 (en) * | 2006-05-31 | 2013-09-03 | Bridgestone Sports Co., Ltd. | Multi-piece solid golf ball |
US8138160B2 (en) * | 2006-08-03 | 2012-03-20 | Warsaw Orthopedic, Inc. | Reagents, methods and systems to suppress pro-inflammatory cytokines |
CN101640467B (zh) | 2008-07-28 | 2012-05-30 | 鸿富锦精密工业(深圳)有限公司 | 弹片及音圈马达 |
-
2003
- 2003-11-14 JP JP2004570430A patent/JP2006507841A/ja active Pending
- 2003-11-14 ES ES10012132.6T patent/ES2440284T3/es not_active Expired - Lifetime
- 2003-11-14 PT PT100121326T patent/PT2284266E/pt unknown
- 2003-11-14 AU AU2003295600A patent/AU2003295600A1/en not_active Abandoned
- 2003-11-14 EP EP10013099A patent/EP2305812A3/de not_active Withdrawn
- 2003-11-14 AT AT03786798T patent/ATE517992T1/de not_active IP Right Cessation
- 2003-11-14 EP EP10013098A patent/EP2314691A3/de not_active Withdrawn
- 2003-11-14 EP EP10003382A patent/EP2213738B1/de not_active Expired - Lifetime
- 2003-11-14 US US10/714,333 patent/US8090542B2/en not_active Expired - Fee Related
- 2003-11-14 EP EP10012132.6A patent/EP2284266B1/de not_active Expired - Lifetime
- 2003-11-14 EP EP03786798A patent/EP1560931B1/de not_active Expired - Lifetime
- 2003-11-14 DK DK10012132.6T patent/DK2284266T3/da active
- 2003-11-14 EP EP10013100A patent/EP2305813A3/de not_active Withdrawn
- 2003-11-14 WO PCT/US2003/036787 patent/WO2004045543A2/en active Search and Examination
- 2003-11-14 EP EP10013081A patent/EP2278005A3/de not_active Withdrawn
-
2004
- 2004-09-14 US US10/940,892 patent/US20120052487A9/en not_active Abandoned
-
2005
- 2005-01-19 US US11/038,784 patent/US20050256525A1/en not_active Abandoned
- 2005-03-18 US US11/083,784 patent/US7820809B2/en not_active Expired - Fee Related
- 2005-03-29 US US11/093,832 patent/US20070039072A1/en not_active Abandoned
- 2005-03-30 US US11/095,383 patent/US7834170B2/en active Active
- 2005-04-07 US US11/101,244 patent/US7691997B2/en active Active
-
2006
- 2006-12-04 US US11/633,306 patent/US7507811B2/en not_active Expired - Lifetime
- 2006-12-04 US US11/633,342 patent/US7608707B2/en not_active Expired - Fee Related
- 2006-12-04 US US11/633,383 patent/US7645869B2/en not_active Expired - Lifetime
- 2006-12-04 US US11/633,404 patent/US20070093653A1/en not_active Abandoned
- 2006-12-07 US US11/635,478 patent/US20070088155A1/en not_active Abandoned
- 2006-12-07 US US11/635,329 patent/US7674896B2/en not_active Expired - Fee Related
- 2006-12-07 US US11/635,330 patent/US7696344B2/en not_active Expired - Lifetime
- 2006-12-07 US US11/635,618 patent/US7579457B2/en not_active Expired - Fee Related
-
2007
- 2007-07-23 US US11/880,628 patent/US7595389B2/en not_active Expired - Fee Related
- 2007-07-24 US US11/880,755 patent/US20080293595A1/en not_active Abandoned
- 2007-07-24 US US11/880,855 patent/US20080300395A1/en not_active Abandoned
- 2007-07-24 US US11/880,777 patent/US20080188648A1/en not_active Abandoned
- 2007-07-24 US US11/880,775 patent/US7655788B2/en not_active Expired - Lifetime
- 2007-07-25 US US11/881,385 patent/US20080306015A1/en not_active Abandoned
- 2007-07-25 US US11/881,386 patent/US20080221317A1/en not_active Abandoned
- 2007-09-20 US US11/903,001 patent/US7514550B2/en not_active Expired - Lifetime
- 2007-10-15 US US11/974,610 patent/US20080091001A1/en not_active Abandoned
- 2007-10-16 US US11/974,885 patent/US7511132B2/en not_active Expired - Lifetime
- 2007-10-16 US US11/974,865 patent/US20080091002A1/en not_active Abandoned
- 2007-10-16 US US11/974,880 patent/US20080091003A1/en not_active Abandoned
- 2007-10-16 US US11/974,878 patent/US20080114162A1/en not_active Abandoned
- 2007-10-17 US US11/975,152 patent/US7795420B2/en not_active Expired - Fee Related
- 2007-10-18 US US11/975,331 patent/US20080091004A1/en not_active Abandoned
- 2007-10-19 US US11/975,661 patent/US20080108803A1/en not_active Abandoned
-
2008
- 2008-06-06 US US12/157,137 patent/US7642349B2/en not_active Expired - Lifetime
- 2008-10-14 US US12/287,757 patent/US7576196B2/en not_active Expired - Fee Related
- 2008-12-09 US US12/330,981 patent/US7576197B2/en not_active Expired - Fee Related
-
2009
- 2009-02-10 US US12/322,980 patent/US20090163701A1/en not_active Abandoned
- 2009-02-11 US US12/378,164 patent/US7592444B2/en not_active Expired - Fee Related
- 2009-04-08 US US12/384,768 patent/US8030474B2/en not_active Expired - Lifetime
- 2009-07-01 US US12/459,489 patent/US20090291497A1/en not_active Abandoned
- 2009-07-06 US US12/459,670 patent/US7745611B2/en not_active Expired - Fee Related
- 2009-08-12 US US12/463,000 patent/US20100004142A1/en not_active Abandoned
- 2009-09-10 US US12/584,705 patent/US7807819B2/en not_active Expired - Fee Related
- 2009-11-12 US US12/590,707 patent/US7803933B2/en not_active Expired - Lifetime
- 2009-11-23 US US12/592,335 patent/US7893247B2/en not_active Expired - Lifetime
-
2010
- 2010-01-15 US US12/657,263 patent/US20100152064A1/en not_active Abandoned
- 2010-02-19 JP JP2010035279A patent/JP2010187668A/ja active Pending
- 2010-05-03 US US12/799,844 patent/US8008474B2/en not_active Expired - Fee Related
- 2010-06-11 US US12/802,647 patent/US8000902B2/en not_active Expired - Lifetime
- 2010-08-10 US US12/806,320 patent/US7985854B2/en not_active Expired - Lifetime
- 2010-08-13 US US12/806,513 patent/US20100331214A1/en not_active Abandoned
- 2010-12-06 US US12/928,190 patent/US8093370B2/en not_active Expired - Fee Related
-
2011
- 2011-08-17 US US13/199,001 patent/US20110319474A1/en not_active Abandoned
- 2011-12-06 US US13/373,956 patent/US20120135892A1/en not_active Abandoned
-
2019
- 2019-03-05 US US16/292,513 patent/US20190345573A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004142A2 (en) * | 1993-07-27 | 1995-02-09 | Hybridon, Inc. | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
WO1996023065A2 (en) * | 1995-01-26 | 1996-08-01 | Hybridon, Inc. | Inhibition of neovascularization using vegf-specific oligonucleotides |
WO1996027006A2 (en) * | 1995-03-02 | 1996-09-06 | Hybridon, Inc. | Human vegf-specific antisense oligonucleotides |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
WO1997020925A1 (en) * | 1995-12-08 | 1997-06-12 | Hybridon, Inc. | Modified vegf antisense oligonucleotides for treatment of skin disorders |
WO1997021808A1 (en) * | 1995-12-08 | 1997-06-19 | Hybridon, Inc. | Modified vegf antisense oligonucleotides |
WO1997039120A2 (en) * | 1996-04-17 | 1997-10-23 | Aronex Pharmaceuticals, Inc. | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression |
WO1998027425A1 (en) * | 1996-12-19 | 1998-06-25 | Isis Pharmaceuticals, Inc. | Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction |
US6057437A (en) * | 1997-07-25 | 2000-05-02 | Taogosei Co. Ltd. | Antisense nucleic acid compounds inhibiting vascular endothelial growth factor |
WO1999063975A2 (en) * | 1998-06-10 | 1999-12-16 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | A method for stimulating the immune system |
WO2000027414A2 (en) * | 1998-11-06 | 2000-05-18 | Basf Aktiengesellschaft | Inhibition of the formation of vascular hyperpermeability |
WO2002031141A2 (en) * | 2000-10-13 | 2002-04-18 | Institut De Cardiologie De Montreal | Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof |
WO2002085309A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent |
WO2002085308A2 (en) * | 2001-04-24 | 2002-10-31 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
WO2002096927A2 (en) * | 2001-05-29 | 2002-12-05 | Ribozyme Pharmaceuticals, Incorporated | Ribozyme based treatment of female reproductive diseases |
WO2003040366A2 (fr) * | 2001-11-09 | 2003-05-15 | Centre National De La Recherche Scientifique -Cnrs- | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2003072704A2 (en) * | 2002-02-20 | 2003-09-04 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2004009769A2 (en) * | 2002-07-24 | 2004-01-29 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
FR2835837A1 (fr) * | 2003-02-06 | 2003-08-15 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance |
FR2835838A1 (fr) * | 2003-02-06 | 2003-08-15 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription |
Non-Patent Citations (1)
Title |
---|
KISIELOW MALGORZATA ET AL.: "Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA", BIOCHEMICAL JOURNAL, vol. 363, no. 1, 1 April 2002 (2002-04-01), pages 1 - 5, XP002630760, ISSN: 0264-6021 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2278005A3 (de) | Funktionelle und hyperfunktionelle Sirna | |
WO2006006948A3 (en) | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY | |
EP1229134A3 (de) | Verwendung von post-transkriptioneller Genabschaltung zur Identifizierung von Nukleinsäuresequenzen die die Funktion einer Zelle beeinflussen | |
WO2004058940A3 (en) | Sirna-mediated gene silencing | |
MXPA03004913A (es) | Usos de genes de mamifero y reactivos relacionados. | |
HK1079238A1 (en) | Selection and isolation of living cells using rna-binding probes | |
WO2004099387A3 (en) | siRNA INDUCED SYSTEMIC GENE SILENCING IN MAMMALIAN SYSTEMS | |
WO2006083800A3 (en) | Nucleic acid silencing of huntington's disease gene | |
WO2004065613A3 (en) | Inducible small interfering rna (sirna) expression constructs for targeted gene silencing | |
ATE335852T1 (de) | Happier mapping | |
WO2004022586A3 (de) | Tubulysin-biosynthese-gene | |
HK1056292A1 (en) | Method of culturing zooplankton, apparatus for culturing by the same, and culture obtained by the same. | |
WO2003050240A3 (en) | Expression system | |
WO2001094627A3 (en) | Assay techniques based on growth stage dependent expression in c. elegans | |
AU2003219781A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
MY146647A (en) | Reaction vessel | |
WO2004024863A3 (en) | Adenoviral va1 pol iii expression system for rna expression | |
WO2002010138A3 (en) | Uses of mammalian genes and related reagents | |
TW200623636A (en) | Sequencer and method for sequencing | |
WO2005005634A3 (en) | siRNA EXPRESSION SYSTEM | |
WO2004097042A8 (de) | Sirna-selektionsverfahren | |
EP1541681A4 (de) | VERFAHREN ZUR KONSTRUKTION EINES NICHTMENSCHLICHEN SÄUGERS MIT RNAi-PHENOTYP UNTER VERWENDUNG EINES PAPILLOMAVIRUS-VEKTORS | |
TW200602488A (en) | Method of screening siRNA | |
MXPA05008925A (es) | Ciclooxigenasa-3 humana y usos de la misma. | |
EP1581635A4 (de) | Durch sirna vermitteltes gen-silencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1560931 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/113 20100101AFI20101126BHEP Ipc: A61K 31/713 20060101ALI20110401BHEP Ipc: C12N 15/11 20060101ALI20110401BHEP |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101ALI20111214BHEP Ipc: A61K 31/713 20060101ALI20111214BHEP Ipc: C12N 15/113 20100101AFI20111214BHEP |
|
17P | Request for examination filed |
Effective date: 20120620 |
|
17Q | First examination report despatched |
Effective date: 20120903 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130817 |